PatientID,Age,Sex,Ethnicity,APOL1_Variant,eGFR,Creatinine,Diagnosis,Medications,Eligible_For_Trial,Clinical_Notes,APOL1,NPHS1,NPHS2,WT1,UMOD,COL4A3
bdd640fb-0667-4ad1-9c80-317fa3b1799d,32,M,Hispanic,G0/G1,34.6,3.81,Nephrotic Syndrome,"Insulin, ACE Inhibitors, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,WT,WT,WT
23b8c1e9-3924-46de-beb1-3b9046685257,21,M,Other,G1/G2,34.2,3.15,Diabetic Nephropathy,Calcium Channel Blockers,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,Mut,WT,WT
bd9c66b3-ad3c-4d6d-9a3d-1fa7bc8960a9,31,M,Asian,G0/G0,49.5,2.05,CKD Stage 3,Erythropoietin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,WT,Mut,Mut
972a8469-1641-4f82-8b9d-2434e465e150,26,M,Caucasian,G1/G1,118.4,4.35,Diabetic Nephropathy,Statins,Yes,"History of hypertension and diabetes, currently managed with Statins.",Mut,Mut,Mut,WT,Mut,Mut
17fc695a-07a0-4a6e-8822-e8f36c031199,52,M,Other,G0/G1,68.8,1.6,CKD Stage 4,"Diuretics, Erythropoietin",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, Erythropoietin.",WT,Mut,WT,WT,WT,Mut
9a1de644-815e-46d1-bb8f-aa1837f8a88b,26,M,Other,G1/G1,33.4,2.75,Nephrotic Syndrome,"ARBs, Diuretics",Yes,"History of hypertension and diabetes, currently managed with ARBs, Diuretics.",WT,WT,Mut,Mut,Mut,Mut
b74d0fb1-32e7-4629-8fad-c1a606cb0fb3,83,F,African American,G0/G0,104.7,1.19,CKD Stage 2,"Statins, Insulin, ACE Inhibitors",Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,Mut,Mut,Mut,Mut,WT,WT
6b65a6a4-8b81-48f6-b38a-088ca65ed389,52,F,African American,G1/G1,57.8,2.54,Nephrotic Syndrome,"Diuretics, Insulin, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,WT,Mut,WT
47378190-96da-4dac-b2ff-5d2a386ecbe0,18,F,Asian,G0/G0,22.3,2.13,Diabetic Nephropathy,"ARBs, ACE Inhibitors",Yes,"History of hypertension and diabetes, currently managed with ARBs, ACE Inhibitors.",WT,WT,WT,Mut,WT,WT
c241330b-01a9-471f-9e8a-774bcf36d58b,78,M,Hispanic,G2/G2,106.0,2.4,CKD Stage 2,"Calcium Channel Blockers, Erythropoietin, ARBs",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, Erythropoietin, ARBs.",Mut,Mut,Mut,Mut,Mut,WT
6c307511-b2b9-437a-a8df-6ec4ce4a2bbd,26,F,African American,G2/G2,70.9,3.15,CKD Stage 1,Erythropoietin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,WT,Mut,WT
371ecd7b-27cd-4130-8722-9389571aa876,53,F,Caucasian,G2/G2,24.6,4.71,FSGS,"Statins, ARBs, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: Statins, ARBs, Calcium Channel Blockers.",Mut,WT,WT,WT,Mut,Mut
1a2a73ed-562b-4f79-8374-59eef50bea63,77,M,African American,G0/G0,54.3,2.03,Diabetic Nephropathy,ARBs,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,WT,Mut,WT
5be6128e-18c2-4797-a142-ea7d17be3111,49,M,Asian,G2/G2,20.8,3.43,FSGS,ACE Inhibitors,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,Mut,Mut,WT
43b7a3a6-9a8d-4a03-980d-7b71d8f56413,25,M,Asian,G0/G0,118.4,1.69,Diabetic Nephropathy,"Diuretics, Statins",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,Mut,WT,WT
759cde66-bacf-43d0-8b1f-9163ce9ff57f,87,M,Hispanic,G0/G0,15.5,2.65,Diabetic Nephropathy,"ARBs, ACE Inhibitors, Insulin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, ACE Inhibitors, Insulin.",WT,WT,WT,WT,WT,Mut
ec1b8ca1-f91e-4d4c-9ff4-9b7889463e85,49,M,Other,G0/G0,56.1,3.13,FSGS,"Diuretics, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, ARBs.",Mut,WT,Mut,Mut,WT,Mut
4b0dbb41-8d52-48f1-942c-3fe860e7a113,27,M,Asian,G2/G2,119.8,4.98,CKD Stage 1,"ARBs, Insulin, Diuretics",Yes,"History of hypertension and diabetes, currently managed with ARBs, Insulin, Diuretics.",WT,Mut,WT,WT,Mut,Mut
e2acf72f-9e57-4f7a-a0ee-89aed453dd32,87,F,Other,G2/G2,10.9,4.18,CKD Stage 3,"ACE Inhibitors, ARBs, Diuretics",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,WT,WT,WT,Mut,Mut,WT
3139d32c-93cd-49bf-9c94-1cf0dc98d2c1,44,F,Other,G1/G2,37.6,4.59,CKD Stage 1,Erythropoietin,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,Mut,WT,WT,Mut,WT
a9488d99-0bbb-4599-91ce-5dd2b45ed1f0,38,F,Other,G1/G2,71.7,1.0,Nephrotic Syndrome,Insulin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,WT,WT
fc377a4c-4a15-444d-85e7-ce8a3a578a8e,23,F,Caucasian,G0/G1,83.4,2.09,FSGS,"Insulin, Erythropoietin",Yes,"History of hypertension and diabetes, currently managed with Insulin, Erythropoietin.",WT,WT,WT,WT,Mut,WT
ddd1dfb2-3b98-4ef8-9af6-1a26146d3f31,60,F,Caucasian,G1/G1,27.5,3.66,CKD Stage 4,Calcium Channel Blockers,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,Mut,Mut,Mut
7412b293-4729-4739-a14f-f3d719db3ad0,46,M,Caucasian,G1/G2,46.1,4.39,Diabetic Nephropathy,"Diuretics, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,WT,Mut,WT
29a3b2e9-5d65-4441-9588-42dea2bc372f,22,M,Other,G1/G2,48.0,4.04,CKD Stage 4,"Insulin, ACE Inhibitors, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,WT,WT
ab9099a4-35a2-40ae-9af3-05535ec42e08,26,F,Other,G1/G1,83.0,1.06,CKD Stage 3,"Diuretics, Erythropoietin, Statins",Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,Mut,Mut,WT,WT,Mut
aefcfad8-efc8-4849-b3aa-7efe4458a885,40,F,Asian,G2/G2,101.7,1.87,CKD Stage 2,"Calcium Channel Blockers, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,Mut,WT,Mut
a28defe3-9bf0-4273-9247-6f57a5e5a5ab,39,M,Hispanic,G2/G2,83.0,3.29,CKD Stage 1,Erythropoietin,Yes,"History of hypertension and diabetes, currently managed with Erythropoietin.",Mut,WT,WT,WT,WT,WT
3eabedcb-baa8-4dd4-88bd-64072bcfbe01,27,F,Asian,G2/G2,31.4,3.63,CKD Stage 4,"ARBs, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, Calcium Channel Blockers.",WT,WT,Mut,WT,WT,Mut
451b4cf3-6123-4df7-b656-af7229d4beef,49,M,Asian,G0/G1,98.2,3.5,FSGS,"Diuretics, Statins, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,Mut,Mut,Mut
b02b61c4-a3d7-4628-ace6-6fa2fd5166e6,53,F,Caucasian,G1/G1,58.4,3.71,CKD Stage 2,"Diuretics, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,WT,WT,WT,WT,Mut,WT
5304317f-af42-412f-b838-b3268e944239,26,F,Asian,G1/G1,69.7,2.37,CKD Stage 2,"Statins, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,WT,Mut,Mut
0e51f30d-c6a7-4e39-84b0-32ccd7c524a5,71,M,Asian,G0/G1,40.0,2.69,CKD Stage 4,"Erythropoietin, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,WT,WT,Mut
ce177b4e-0837-48a3-9261-a7ab3aa2e4f9,21,M,Asian,G0/G1,105.4,1.32,CKD Stage 3,"Diuretics, ARBs",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,Mut,Mut,Mut
10f1bc81-448a-4a9e-a6b2-bc5b50c187fc,78,M,Other,G0/G0,120.0,2.07,Nephrotic Syndrome,Calcium Channel Blockers,No,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers.",WT,WT,WT,WT,WT,WT
9132b63e-f162-47e4-a9c3-49e03602f8ac,78,M,Other,G0/G1,61.2,1.65,CKD Stage 3,Insulin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,WT,WT,Mut
366eb16f-508e-4ad7-b7c9-3acfe059a0ee,66,F,Caucasian,G0/G0,75.1,4.24,CKD Stage 2,Erythropoietin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin.",Mut,WT,WT,Mut,Mut,Mut
e27a984d-6548-41d0-bfcd-9eb1a7cad415,61,M,Asian,G1/G2,21.6,4.82,Nephrotic Syndrome,"Erythropoietin, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,Mut,Mut,Mut
24933b83-7577-40a9-a491-f0b2ea1fca65,52,F,Caucasian,G0/G0,40.7,2.53,Diabetic Nephropathy,"Insulin, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: Insulin, Calcium Channel Blockers.",Mut,Mut,WT,Mut,Mut,WT
beb79919-3f22-4af8-a3be-d01d43cf2fde,63,F,Hispanic,G1/G1,106.8,3.66,CKD Stage 3,"ACE Inhibitors, Insulin, ARBs",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,WT,Mut,Mut,WT,Mut
bf3c4c06-4343-48bc-89fa-6a688fb5d27b,80,F,African American,G0/G0,42.4,2.32,CKD Stage 2,"Erythropoietin, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,Mut,Mut,Mut,Mut,Mut
956269f0-e5d7-4875-adad-d6c795a76d79,52,F,Hispanic,G0/G1,23.3,1.37,CKD Stage 1,"Insulin, Erythropoietin, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,Mut,Mut,WT
ff50bde4-3825-47b8-9cab-cc97663f1c97,55,M,Hispanic,G0/G1,43.2,3.69,CKD Stage 2,"ACE Inhibitors, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, Calcium Channel Blockers.",Mut,WT,Mut,WT,WT,Mut
7e570ddf-8270-40a8-a369-b584ff5e9ff0,74,F,Caucasian,G0/G0,37.8,4.38,CKD Stage 1,Statins,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins.",Mut,WT,WT,WT,WT,Mut
dc713d96-0c0f-4195-817a-f08a1745d6d8,33,F,Other,G2/G2,97.0,1.52,FSGS,"Statins, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,Mut,Mut,WT,WT,WT
28f49481-a0a0-4dc4-a720-9bdf1c11f735,51,M,Caucasian,G0/G1,29.1,0.84,CKD Stage 1,"Statins, Erythropoietin",Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,Mut,WT,WT,Mut,Mut
98ae4334-6c12-4ce8-ae34-0454cac5b68c,27,M,Hispanic,G2/G2,82.7,4.7,CKD Stage 4,Insulin,Yes,"History of hypertension and diabetes, currently managed with Insulin.",WT,WT,Mut,WT,WT,WT
988c24c9-61b1-4d22-a280-1c4510435a10,90,F,Asian,G0/G0,61.6,1.87,CKD Stage 4,"Insulin, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,WT,Mut,Mut
405cacec-8774-49a9-b7d2-1e02ff01cf99,21,M,Caucasian,G2/G2,74.6,0.59,Diabetic Nephropathy,"Calcium Channel Blockers, Diuretics, Insulin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,Mut,Mut,WT
f143262f-dc5c-4eed-8da0-365bf89897b9,80,M,Asian,G1/G1,54.9,1.94,CKD Stage 1,Diuretics,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics.",Mut,Mut,Mut,Mut,WT,Mut
1d53434b-b881-49b9-ae27-0da702f06b90,50,F,African American,G1/G2,105.1,4.21,CKD Stage 1,"Calcium Channel Blockers, Insulin, Statins",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,Mut,Mut,Mut
c0398710-8976-4334-a281-7efdae849217,44,F,Other,G0/G1,112.0,2.47,Nephrotic Syndrome,"ACE Inhibitors, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Calcium Channel Blockers.",WT,WT,Mut,WT,Mut,WT
5715bd6f-a416-4293-84c2-e2e3444ea7c8,77,M,Caucasian,G1/G2,112.6,1.81,Nephrotic Syndrome,"Statins, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,WT,Mut,WT
287d06ca-6f4c-469a-8b22-d3081c8eaee9,35,M,Hispanic,G1/G2,47.4,4.04,CKD Stage 3,Diuretics,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,Mut,Mut,Mut
b8db0672-f42d-47cc-80d4-af5974273ca3,87,F,Asian,G1/G1,105.7,4.91,CKD Stage 2,"Statins, ARBs, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: Statins, ARBs, Calcium Channel Blockers.",WT,Mut,Mut,Mut,Mut,WT
f8cda88b-436d-46e2-b83c-fe0be037e5ed,34,F,African American,G1/G2,21.0,4.6,CKD Stage 1,"ARBs, Statins, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,Mut,Mut,WT
81f76d1c-2dbc-4134-830f-f46e8026695f,86,F,Hispanic,G1/G2,106.0,0.66,CKD Stage 1,Erythropoietin,Yes,No significant change in eGFR. Continuing current treatment: Erythropoietin.,Mut,WT,WT,Mut,WT,WT
a013ac6e-deda-4e16-9b3d-bd5ce9a1fa6f,56,M,African American,G1/G1,97.6,1.82,CKD Stage 3,"ARBs, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,WT,WT,Mut
81f631d4-a392-41a7-9777-a4774c66e0a8,48,F,Other,G0/G1,35.5,3.37,CKD Stage 4,"Erythropoietin, ACE Inhibitors",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,WT,Mut,Mut
5fb8d16c-2720-497d-b2eb-d6899be578c7,72,F,Asian,G1/G1,31.9,2.23,CKD Stage 4,ARBs,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,Mut,WT,Mut
f4188f3f-8a14-4e62-a95b-4715c333e861,90,M,Other,G1/G2,101.6,4.56,Diabetic Nephropathy,Insulin,Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,Mut,WT,WT,Mut,WT,WT
eb2263dd-87c5-421e-ac24-a3c5c754108f,23,F,Asian,G0/G0,73.8,3.8,CKD Stage 1,"Diuretics, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,WT,Mut,Mut
7d154385-52fb-443b-9954-6eb400257ad1,50,F,Hispanic,G1/G1,98.5,2.61,CKD Stage 1,Calcium Channel Blockers,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,WT,Mut,WT
5cec4eb5-edd9-4831-9ca3-5cfb04fc6d82,33,F,Hispanic,G1/G1,74.3,4.2,CKD Stage 3,Erythropoietin,Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,WT,Mut,WT,Mut,WT,WT
ce88cb2d-d4e8-4839-bc3e-058be0f3eab0,56,F,African American,G0/G1,15.0,0.67,CKD Stage 4,ACE Inhibitors,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,Mut,Mut,Mut
3da9c2a9-0ed4-4f1a-bd4c-bf374eb93eff,37,F,African American,G1/G2,77.7,4.73,CKD Stage 3,Erythropoietin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin.",Mut,WT,Mut,Mut,WT,Mut
14296c07-f26b-4776-913e-4de2e0c53cb8,65,F,African American,G1/G2,40.3,4.86,Diabetic Nephropathy,"ACE Inhibitors, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,Mut,WT,WT
d0e6e660-7c69-4ee1-bb5e-4bcf15ed6269,44,M,Other,G0/G1,74.5,4.16,CKD Stage 2,"Calcium Channel Blockers, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, ARBs.",WT,Mut,WT,WT,Mut,WT
885f6e66-c2b6-42c5-ba5d-310011b7e948,21,M,African American,G1/G1,96.9,1.57,CKD Stage 3,ARBs,Yes,No significant change in eGFR. Continuing current treatment: ARBs.,Mut,WT,WT,Mut,WT,WT
a8e56e0c-20de-435d-a031-d750c40db9b4,64,M,Asian,G2/G2,34.4,3.27,Nephrotic Syndrome,"Insulin, Diuretics, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Insulin, Diuretics, Statins.",WT,WT,Mut,Mut,Mut,WT
2a45c2ab-8cbf-4db0-b264-accc79ac1b1e,74,M,African American,G1/G1,76.9,0.8,CKD Stage 3,"Erythropoietin, Insulin, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,Mut,Mut,WT
9b49bd26-df57-459a-8715-a10343dac043,32,M,Asian,G1/G2,107.7,2.36,Diabetic Nephropathy,"Statins, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with Statins, Calcium Channel Blockers.",WT,Mut,Mut,Mut,Mut,Mut
edcd465e-3638-4821-b6e0-7cc06c52c49f,78,M,African American,G0/G0,20.3,0.93,Nephrotic Syndrome,"Calcium Channel Blockers, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,Mut,Mut,Mut
b09b2a5c-badc-432a-8159-0f538a0f4efb,24,F,Other,G1/G1,48.7,3.1,CKD Stage 2,Erythropoietin,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,Mut,Mut,WT
66245bfa-4fcc-439a-b683-d2e6337ea2df,46,F,Other,G2/G2,77.5,3.39,CKD Stage 1,"Erythropoietin, Calcium Channel Blockers, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin, Calcium Channel Blockers, Diuretics.",WT,WT,Mut,Mut,Mut,Mut
5f987c71-a65e-488e-abf3-ad39fec21bbe,36,F,African American,G0/G1,91.5,4.87,CKD Stage 1,"Insulin, ARBs, Statins",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,Mut,Mut,WT,Mut,Mut
7394988f-847f-49b4-a64d-1bcb702753a1,90,M,African American,G0/G1,27.3,3.28,Nephrotic Syndrome,Diuretics,Yes,"History of hypertension and diabetes, currently managed with Diuretics.",Mut,Mut,Mut,Mut,Mut,Mut
1064005c-3985-43cf-bf76-be1d1efa2197,32,F,Asian,G0/G0,41.2,3.55,CKD Stage 4,"Erythropoietin, Diuretics, ACE Inhibitors",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, Diuretics, ACE Inhibitors.",WT,Mut,WT,WT,WT,Mut
8dcdcd03-969b-4662-8562-8059568cc69b,50,F,Hispanic,G0/G0,10.9,3.86,CKD Stage 2,Statins,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins.",WT,Mut,WT,Mut,WT,Mut
01d74256-3860-4ab6-96a4-02f23ae8cc93,27,F,Other,G1/G2,73.1,3.69,CKD Stage 4,"ACE Inhibitors, Statins",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, Statins.",WT,Mut,WT,Mut,Mut,WT
0f1259e0-a18f-46b6-b535-106e122c9a56,49,F,Other,G1/G2,67.6,2.28,CKD Stage 3,"Diuretics, ARBs, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,WT,WT,WT,Mut,Mut
080aadfb-e7c9-4b26-9141-25c63a9bedd4,36,M,African American,G0/G1,38.2,1.28,CKD Stage 2,"ACE Inhibitors, ARBs, Statins",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors, ARBs, Statins.",Mut,Mut,Mut,Mut,WT,Mut
839fbc50-1223-4513-9496-f63cdc1110c1,74,F,Hispanic,G2/G2,16.2,2.78,CKD Stage 3,"Statins, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Statins, ACE Inhibitors.",WT,Mut,Mut,WT,WT,Mut
7c441fe7-ab42-40a7-874a-493b3ceddf2d,88,M,Asian,G2/G2,81.7,1.95,CKD Stage 4,"ARBs, ACE Inhibitors, Statins",Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,WT,Mut,WT,WT,WT,WT
b92da22b-21df-406f-8a0b-3c3336d8393a,74,M,Hispanic,G1/G1,111.0,2.24,Diabetic Nephropathy,"Erythropoietin, Insulin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,WT,Mut
93829b43-922f-415a-a1e3-db63ef7ddc76,37,F,African American,G2/G2,83.0,4.63,CKD Stage 3,"Erythropoietin, Calcium Channel Blockers, Statins",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,WT,Mut,Mut,Mut,WT
7914c120-c8dc-419f-be35-11287900f7f9,85,M,Asian,G2/G2,49.8,2.13,CKD Stage 2,Diuretics,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,WT,WT,WT
1825bc54-30be-445f-a835-14f2ceb81f9d,82,M,Hispanic,G2/G2,24.4,2.2,CKD Stage 2,Calcium Channel Blockers,Yes,No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers.,WT,Mut,WT,Mut,Mut,WT
5ab33edf-6e59-4ed3-a8b3-17fa18d0752b,54,F,Caucasian,G2/G2,36.3,4.85,Diabetic Nephropathy,"Calcium Channel Blockers, ARBs",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, ARBs.",Mut,Mut,Mut,Mut,Mut,Mut
dd2467ac-778e-4db3-a93d-ffbc6c6fa611,35,F,African American,G1/G2,106.2,3.0,CKD Stage 1,"Calcium Channel Blockers, Insulin, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,Mut,Mut,WT
a748dbcf-ac61-4e63-8dde-29a6baa4b71a,29,M,Asian,G1/G1,112.4,2.37,CKD Stage 4,"Diuretics, ARBs, Statins",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,WT,Mut,WT
0f844fef-1931-49ee-a56c-0941fbf24050,60,M,Caucasian,G0/G0,41.6,4.23,Nephrotic Syndrome,Calcium Channel Blockers,Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers.",Mut,Mut,WT,WT,WT,Mut
ccf3a171-56dc-4907-ba6c-34ab6712303a,88,F,African American,G1/G1,36.1,1.05,CKD Stage 2,"Erythropoietin, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,WT,WT,Mut,WT,WT
310c0c00-3fa7-4104-9bf9-0e27dc96925e,55,F,African American,G2/G2,48.8,3.07,CKD Stage 2,"Erythropoietin, ACE Inhibitors, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,WT,WT,Mut,Mut,WT
23e2fcb4-72d8-467d-894a-05e430b187ef,65,F,African American,G1/G1,96.7,2.05,Nephrotic Syndrome,"Erythropoietin, ACE Inhibitors, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,Mut,Mut,WT
766ecb15-474e-4c19-aef9-12766c006f61,77,F,Caucasian,G0/G1,16.9,3.99,CKD Stage 4,Diuretics,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,WT,Mut,Mut
134c6c92-ec5b-427c-9fde-4fbf3ff350bf,87,F,Hispanic,G0/G0,92.9,1.36,CKD Stage 3,Calcium Channel Blockers,Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,Mut,WT,Mut,Mut,Mut
db20a56e-dc81-4fe7-8eda-8bbb71710434,67,F,Caucasian,G1/G2,86.1,2.15,Diabetic Nephropathy,"Diuretics, ACE Inhibitors, Statins",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics, ACE Inhibitors, Statins.",WT,Mut,WT,Mut,Mut,WT
a6f2f7b8-0cf3-4b58-9910-8be58ce21ea3,55,F,Asian,G2/G2,88.9,1.25,CKD Stage 4,"Statins, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,WT,WT,Mut
03c72ba8-d605-4770-8a63-f881ffd0f9d5,38,M,Caucasian,G2/G2,84.6,2.47,CKD Stage 2,ARBs,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,WT,WT,Mut
c0e9ab30-ed26-42e9-97e0-11b7f8102383,74,M,Other,G0/G1,68.2,2.29,Nephrotic Syndrome,"ARBs, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,Mut,WT,Mut
680ac07a-2a93-4d62-bc83-5dc0d9441fa5,75,M,Other,G1/G1,86.3,4.99,CKD Stage 2,ARBs,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,WT,Mut,WT,Mut,WT,Mut
dd59ba71-36b8-4481-bb3a-4e3e7c52fa17,26,F,Hispanic,G0/G1,88.3,4.67,Nephrotic Syndrome,Calcium Channel Blockers,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,WT,WT,WT
2a25a888-0f02-4ad0-a706-7ef466aa9385,21,F,Other,G2/G2,50.6,4.12,FSGS,Insulin,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,Mut,Mut,Mut
63f2ae24-fc3d-4348-808d-4127610461e3,27,M,Hispanic,G0/G0,59.5,3.56,CKD Stage 3,Calcium Channel Blockers,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,WT,WT,WT
c8fe3ccd-c8b8-49c6-ad30-49cf43e458fc,38,F,Caucasian,G1/G1,114.2,2.84,CKD Stage 3,Diuretics,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,Mut,WT,WT
b253d218-6c4a-47ea-8906-17f2747b6dba,37,M,Other,G2/G2,47.1,4.66,CKD Stage 1,ACE Inhibitors,Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,WT,Mut,WT,Mut,WT,Mut
c88a618e-fed4-457d-bb02-6576f512c4c3,55,F,Asian,G0/G1,98.5,3.58,CKD Stage 3,"ACE Inhibitors, Erythropoietin",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Erythropoietin.",WT,WT,Mut,Mut,Mut,Mut
7c967f79-b7e9-4aca-a970-65e18e46d534,36,F,Hispanic,G1/G1,117.3,1.09,CKD Stage 3,"Insulin, ACE Inhibitors, Diuretics",Yes,"History of hypertension and diabetes, currently managed with Insulin, ACE Inhibitors, Diuretics.",WT,Mut,WT,Mut,Mut,WT
37bb3eec-4bf5-4b52-b09d-258c27a0c3d7,24,F,Asian,G2/G2,56.0,4.83,CKD Stage 2,"Insulin, Erythropoietin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,Mut,Mut,Mut
bc594585-9445-48c0-8ef8-c2d6f7fd5646,20,M,Asian,G2/G2,60.3,1.58,FSGS,"ACE Inhibitors, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, Calcium Channel Blockers.",Mut,Mut,Mut,Mut,WT,WT
504867ba-bf7b-439b-8f9a-ea4b8acd4e10,51,F,Asian,G1/G1,15.0,0.73,FSGS,Diuretics,Yes,"History of hypertension and diabetes, currently managed with Diuretics.",Mut,WT,Mut,Mut,Mut,WT
7a0ecfea-958c-49ba-8cd6-20c20ea2622b,68,F,Hispanic,G2/G2,113.3,3.9,CKD Stage 2,"Insulin, Statins, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,WT,Mut,Mut
87f7e1fb-da4b-49ca-ab5c-f46780bacd64,37,M,Hispanic,G2/G2,45.0,2.27,FSGS,"Calcium Channel Blockers, Diuretics, Insulin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,Mut,WT,Mut
82010c62-f5f5-4b22-8e8f-a8e0284d82e5,32,F,Other,G1/G1,97.6,3.76,Nephrotic Syndrome,"ACE Inhibitors, Insulin, Statins",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Insulin, Statins.",Mut,WT,WT,Mut,WT,Mut
118a9d29-2f92-4996-99f1-95d014822f53,49,M,Other,G0/G0,31.0,2.48,CKD Stage 4,Statins,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,WT,WT,WT
dca02eec-acda-4acc-9165-e21098543881,79,F,Hispanic,G0/G1,60.6,2.9,FSGS,"Erythropoietin, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, Calcium Channel Blockers.",Mut,Mut,WT,WT,Mut,Mut
f10c718b-1eb0-438a-a75d-d5af3c365296,54,M,Asian,G1/G1,62.8,3.02,Diabetic Nephropathy,"Diuretics, Calcium Channel Blockers, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,WT,Mut,WT
94340a03-3f07-4814-91d6-3f78e3e9de99,28,F,Asian,G1/G1,92.2,1.46,Diabetic Nephropathy,"Diuretics, Insulin, Calcium Channel Blockers",No,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,WT,WT,WT,WT,WT,WT
14fcdd54-9e8f-4965-8a2c-827e98326856,24,M,Asian,G1/G1,88.9,0.95,Diabetic Nephropathy,ACE Inhibitors,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,Mut,WT,Mut
90b2b633-956b-4c0c-a849-9b926b5252e3,25,M,Other,G0/G1,68.9,3.75,CKD Stage 1,Statins,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins.",WT,WT,Mut,Mut,WT,Mut
42c18a62-ef48-48d5-90fd-9d3f85d51695,56,M,Hispanic,G1/G1,60.0,3.39,FSGS,"ARBs, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,Mut,WT,WT,Mut,WT
506e5a9a-b758-488d-ab73-295b344a54b8,50,M,African American,G1/G1,97.0,3.06,Diabetic Nephropathy,ARBs,Yes,"History of hypertension and diabetes, currently managed with ARBs.",Mut,Mut,Mut,WT,Mut,WT
21813d25-6552-48a6-83ff-50113d1a85dd,79,F,Caucasian,G0/G0,38.7,1.56,Diabetic Nephropathy,"Diuretics, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, Calcium Channel Blockers.",WT,Mut,Mut,WT,WT,WT
750cab75-4ccc-4bc2-a53f-8a28abf3e3fc,38,F,Other,G1/G1,85.9,3.37,CKD Stage 3,"Insulin, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Insulin, ARBs.",WT,WT,Mut,WT,Mut,Mut
ef8c485b-c07a-40f2-add4-253b50f0fd0a,88,F,Other,G0/G1,93.8,3.56,FSGS,Insulin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,WT,WT,WT
9f044aed-7552-4327-8262-7f7312922f83,37,M,Hispanic,G2/G2,58.6,3.56,Nephrotic Syndrome,"Statins, ACE Inhibitors, Insulin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,WT,Mut,Mut
19985f15-ff00-4d4d-9020-59e4ff9ab5c2,89,F,Hispanic,G0/G0,53.6,4.17,Nephrotic Syndrome,Insulin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin.",WT,WT,Mut,Mut,WT,WT
8181a8cc-3691-47eb-89a2-688b12c136e0,22,F,Asian,G0/G1,94.6,3.95,Nephrotic Syndrome,"Statins, Diuretics, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, Diuretics, Calcium Channel Blockers.",Mut,Mut,Mut,WT,WT,Mut
5958a499-eeea-463e-a1e8-ac6843e42caf,86,F,Other,G0/G1,90.1,1.5,CKD Stage 1,Diuretics,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,WT,WT,Mut
3e896c64-e117-4ac3-919c-4ea3e1805081,53,M,African American,G0/G0,99.0,2.39,Diabetic Nephropathy,ARBs,Yes,"History of hypertension and diabetes, currently managed with ARBs.",WT,WT,WT,WT,Mut,WT
702cdd20-2862-48b8-88f4-ef125e9953d2,23,F,Asian,G0/G1,69.4,3.89,Diabetic Nephropathy,ARBs,Yes,"History of hypertension and diabetes, currently managed with ARBs.",Mut,WT,Mut,Mut,WT,Mut
4d71c366-b41b-4143-8b10-550cd5704f32,84,M,Asian,G1/G1,40.3,3.01,FSGS,"ARBs, Erythropoietin, Statins",Yes,"No significant change in eGFR. Continuing current treatment: ARBs, Erythropoietin, Statins.",Mut,WT,Mut,Mut,Mut,Mut
ce9e1a11-fcbb-4e59-bbdd-cf7c9c96e9ec,56,F,Caucasian,G2/G2,62.1,4.32,CKD Stage 3,"ARBs, Statins, ACE Inhibitors",Yes,"History of hypertension and diabetes, currently managed with ARBs, Statins, ACE Inhibitors.",Mut,Mut,WT,Mut,WT,Mut
aaf91531-0200-41f0-8768-a84fa76afde6,28,F,Hispanic,G0/G0,68.9,4.23,CKD Stage 1,"Statins, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,WT,Mut,WT
ee87905e-4ca4-45ea-8dfa-6a56d12dbc9a,56,M,Caucasian,G0/G1,115.8,1.03,Diabetic Nephropathy,"ARBs, Erythropoietin",Yes,"No significant change in eGFR. Continuing current treatment: ARBs, Erythropoietin.",WT,Mut,WT,Mut,Mut,Mut
e0ccedc5-f05d-476e-9a84-a51aa9d3d7c7,63,F,Hispanic,G1/G1,66.4,2.74,CKD Stage 1,"Statins, Diuretics, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, Diuretics, ARBs.",Mut,Mut,Mut,WT,WT,WT
e3c43657-1d8c-4bac-83b4-09ef2260e70f,88,F,Hispanic,G0/G1,31.6,1.54,FSGS,Statins,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,Mut,Mut,Mut,Mut,WT
27cb6f2a-8da0-4097-be0f-051b1b66b5a9,39,M,Other,G1/G2,30.2,4.5,Nephrotic Syndrome,Insulin,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,WT,Mut,WT
35ebd32d-9ad6-40ab-8821-2ddb45b89cd9,47,M,Caucasian,G0/G0,34.1,2.55,CKD Stage 1,"Erythropoietin, Calcium Channel Blockers, Insulin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin, Calcium Channel Blockers, Insulin.",Mut,Mut,WT,WT,Mut,WT
afffcfd2-341e-440b-97c7-00aab7b56ea7,53,F,African American,G2/G2,99.4,3.53,Diabetic Nephropathy,ACE Inhibitors,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,WT,Mut,Mut
81627cf1-4394-42e6-9a58-7e8aa25d6b29,28,F,Asian,G1/G2,72.2,4.96,CKD Stage 2,"Erythropoietin, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin, ACE Inhibitors.",WT,WT,Mut,Mut,Mut,Mut
e87d1c78-e7c4-41c7-8049-7b717d106c60,19,M,African American,G1/G2,103.0,3.4,CKD Stage 3,"Calcium Channel Blockers, ACE Inhibitors, Insulin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, ACE Inhibitors, Insulin.",WT,WT,WT,Mut,Mut,WT
a2607723-17a0-4f49-8d01-280fd89a40c0,53,M,Caucasian,G1/G1,11.7,1.43,CKD Stage 2,"Calcium Channel Blockers, Statins, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,Mut,Mut,Mut
0b49452d-46d4-43f3-9450-281c6c6f7633,35,M,Other,G1/G1,15.9,2.47,Diabetic Nephropathy,Diuretics,Yes,"History of hypertension and diabetes, currently managed with Diuretics.",Mut,Mut,WT,Mut,Mut,Mut
217d65a0-c568-41cd-9563-f61600e85ece,88,F,Asian,G0/G1,84.8,3.47,CKD Stage 1,"Diuretics, ARBs, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,WT,Mut
295d6fbf-430f-401d-bad4-09e2a319dcb4,31,M,African American,G1/G1,58.9,3.93,CKD Stage 1,ACE Inhibitors,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors.",WT,Mut,Mut,Mut,WT,WT
b4a69f3c-8d3a-4d99-b11c-21c9bdc14f1f,88,M,Other,G2/G2,96.3,4.39,CKD Stage 1,"Statins, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,Mut,WT,WT
1ca3c448-0279-46a6-8f97-97b06d7ce3c9,52,F,Caucasian,G0/G0,28.4,1.74,CKD Stage 3,"Calcium Channel Blockers, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, ACE Inhibitors.",Mut,Mut,WT,Mut,WT,Mut
b0e6a969-e213-42b0-b1ee-dba313432e61,56,M,Asian,G1/G1,102.6,2.21,Diabetic Nephropathy,"Statins, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,Mut,WT,Mut
093923de-8bab-4e3b-a628-6bfbe767dcea,68,F,Hispanic,G1/G2,116.5,4.02,CKD Stage 3,"Diuretics, Statins",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,WT,WT,WT,WT,Mut
8d7248e2-951f-48d0-9e84-f058d5a804eb,74,F,African American,G1/G2,84.0,1.13,CKD Stage 3,Diuretics,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,WT,Mut,Mut
0ab54bde-20a0-4502-ae06-809725e97977,86,F,Other,G0/G0,97.0,2.12,Diabetic Nephropathy,"Insulin, Erythropoietin, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,WT,WT,Mut
eededb07-e623-4689-9d59-cd2a4eea04e7,73,M,African American,G0/G0,38.5,2.8,FSGS,"Insulin, Erythropoietin, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,Mut,Mut,WT
0a368ce7-dc57-4131-b8e1-daa7cbceabde,79,M,Hispanic,G1/G2,111.3,0.89,Diabetic Nephropathy,"ARBs, Diuretics, Erythropoietin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, Diuretics, Erythropoietin.",Mut,Mut,WT,Mut,Mut,Mut
ae9bec36-35c7-436c-9b99-62c6e61fecc0,75,F,African American,G1/G1,14.9,3.7,CKD Stage 1,"Erythropoietin, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, ACE Inhibitors.",WT,WT,WT,WT,Mut,Mut
5a8aaeca-1a50-4ec3-aabc-25fa3fe12e47,69,M,Caucasian,G1/G2,53.5,3.82,CKD Stage 2,"Insulin, Statins",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,WT,Mut,WT
dfed2c43-e256-46dc-8f54-86b7c7b5b2bc,86,M,Hispanic,G1/G1,31.7,1.01,Nephrotic Syndrome,"Insulin, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,WT,Mut,Mut
bfddc3d9-9ee3-4c2a-b94d-62046808593f,40,F,Other,G2/G2,19.3,1.1,CKD Stage 1,Diuretics,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,WT,Mut,Mut
3c9ad14c-ee0c-4eb5-acfe-db992790cebd,67,F,Caucasian,G1/G2,79.9,3.62,Nephrotic Syndrome,Insulin,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,WT,WT,Mut
ccc56569-f9e8-4369-a999-b735dd56cc94,24,F,African American,G1/G2,25.0,4.17,FSGS,"Erythropoietin, Statins, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,Mut,WT,WT
698c206f-e1a4-4e10-ad53-4dd0cf8ebc5a,46,F,African American,G1/G1,34.7,1.8,Diabetic Nephropathy,"Insulin, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,Mut,Mut,WT
ecab3301-bc8f-4d29-adea-94930658663a,74,M,Asian,G0/G0,91.0,3.44,CKD Stage 2,"Calcium Channel Blockers, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,WT,Mut,WT
696608aa-ee49-4329-884a-7b28550a1b46,44,F,Other,G1/G2,28.3,1.13,CKD Stage 2,Calcium Channel Blockers,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,WT,Mut,Mut
bc2cbb0d-dd33-4cc7-ab7f-089acd5f4822,52,M,Caucasian,G1/G2,111.1,4.97,Diabetic Nephropathy,"ARBs, Erythropoietin, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with ARBs, Erythropoietin, Calcium Channel Blockers.",WT,WT,Mut,WT,Mut,Mut
28c13091-444d-410b-bf87-e362cf8d446a,52,F,Asian,G1/G2,18.3,4.08,Diabetic Nephropathy,Statins,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,Mut,Mut,WT
61ee411a-1bac-47a7-b386-f7a4c991603f,29,F,Hispanic,G0/G0,97.5,2.29,CKD Stage 4,Statins,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,Mut,WT,Mut
787f2425-dbcc-4477-89e9-db0adf465290,24,M,African American,G1/G2,11.8,4.68,CKD Stage 2,"Statins, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, ACE Inhibitors.",Mut,WT,WT,Mut,WT,Mut
eb1fa9f2-d10b-41d0-b317-347038f16a81,64,F,African American,G1/G1,83.1,3.42,CKD Stage 1,"Erythropoietin, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, Diuretics.",WT,Mut,WT,WT,WT,WT
d20eac17-4e20-4d1a-9983-36e375d66ed4,34,M,Other,G1/G2,11.0,3.63,Diabetic Nephropathy,Calcium Channel Blockers,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers.",Mut,WT,Mut,WT,WT,Mut
39118497-3a43-42ba-9f0f-06cbcb9bc326,31,M,Hispanic,G1/G1,106.9,1.12,Diabetic Nephropathy,Erythropoietin,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,WT,WT,WT,WT,Mut,Mut
6601ddd0-3170-4437-a8f7-ef5a060edf5b,37,F,Other,G1/G2,104.6,0.89,CKD Stage 1,Calcium Channel Blockers,Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers.",WT,Mut,Mut,Mut,Mut,WT
11c58ef0-dd46-4c09-8752-87aa5408f9ac,28,M,Other,G2/G2,76.0,3.23,Diabetic Nephropathy,"ACE Inhibitors, Erythropoietin, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, Erythropoietin, Diuretics.",WT,WT,Mut,Mut,WT,WT
59e4b671-4774-4c58-85f8-bc16f7860b50,32,M,Asian,G2/G2,17.8,4.5,CKD Stage 1,"Diuretics, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics, ARBs.",Mut,Mut,Mut,WT,Mut,WT
adf4e62d-6651-429e-8268-690ba43825b5,26,M,Hispanic,G0/G1,14.4,0.77,Diabetic Nephropathy,"Insulin, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin, Diuretics.",Mut,Mut,Mut,WT,WT,Mut
54c63cd8-8945-4f27-97fa-2d8dfb2ca025,28,M,Caucasian,G2/G2,45.9,3.14,Diabetic Nephropathy,"Erythropoietin, Calcium Channel Blockers, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, Calcium Channel Blockers, ACE Inhibitors.",Mut,Mut,WT,WT,WT,WT
e08596db-1d87-4966-8710-d430f071d879,76,M,Hispanic,G0/G1,23.1,3.69,Nephrotic Syndrome,ARBs,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,Mut,Mut,WT,Mut,WT
94a1875d-2db6-4edb-82de-ffccf86c2ca2,33,M,Hispanic,G1/G2,39.9,0.79,Nephrotic Syndrome,"Erythropoietin, ACE Inhibitors, Statins",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, ACE Inhibitors, Statins.",Mut,Mut,WT,Mut,WT,Mut
09cb3942-43f5-4a85-bbc9-f87af668a617,31,M,Caucasian,G2/G2,10.3,4.36,CKD Stage 1,ACE Inhibitors,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,WT,WT,WT
587ef344-6f3f-420c-98b8-e4cc1bc044fc,71,M,Hispanic,G0/G1,55.8,3.74,CKD Stage 3,Insulin,Yes,No significant change in eGFR. Continuing current treatment: Insulin.,Mut,WT,WT,WT,WT,WT
6fb78271-504d-481f-8953-5b63ba81edd9,77,F,Hispanic,G1/G1,19.5,2.56,CKD Stage 3,Diuretics,Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,Mut,WT,Mut,Mut,Mut,WT
1d9af659-82ec-4f2d-bbf6-e16f9b3080d5,49,M,African American,G1/G2,12.6,2.94,Nephrotic Syndrome,"ACE Inhibitors, Diuretics, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, Diuretics, Calcium Channel Blockers.",Mut,Mut,WT,WT,WT,Mut
30a900ad-939b-462d-a645-f129629c2ae3,36,F,African American,G0/G0,111.3,4.54,FSGS,"Erythropoietin, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,WT,Mut,WT
6fa17735-b572-43d0-8b5c-ea6a41357e8c,25,F,Caucasian,G0/G1,42.1,4.33,Diabetic Nephropathy,"Erythropoietin, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, Calcium Channel Blockers.",Mut,Mut,Mut,Mut,WT,WT
ce777f00-ecf2-4e76-8519-7ff4006ed6e3,31,M,African American,G0/G1,59.5,1.91,CKD Stage 1,"Diuretics, ARBs, Statins",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,WT,WT,WT
f0b5156b-b82c-4074-afd5-dea589d7fd6c,56,M,Caucasian,G1/G1,26.3,3.7,CKD Stage 3,"Insulin, ACE Inhibitors",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,WT,Mut,Mut
3270e4fa-abae-4f43-bcae-8081bdf070aa,88,M,African American,G1/G2,21.2,4.07,CKD Stage 1,ACE Inhibitors,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,Mut,Mut,WT
f2e9702d-11e9-4daa-ae69-81a35d3d9e56,51,M,African American,G0/G0,31.8,3.41,Diabetic Nephropathy,ACE Inhibitors,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,Mut,WT,WT
9f871ce7-5487-4d4f-abb7-a385aa0b7b14,68,F,African American,G1/G2,85.2,1.28,CKD Stage 2,Diuretics,Yes,No significant change in eGFR. Continuing current treatment: Diuretics.,Mut,Mut,WT,WT,WT,Mut
1fe771d6-d917-4793-a9d3-c2e6505cc686,88,F,African American,G0/G0,40.8,1.12,CKD Stage 2,"Calcium Channel Blockers, Insulin, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,Mut,Mut,Mut
81d2c7de-4ce1-4b90-a669-7833b841d0a0,59,F,Hispanic,G0/G1,12.9,3.19,CKD Stage 1,"ACE Inhibitors, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,WT,WT,WT
5380b904-688c-4015-aab9-7e494f2d4796,25,M,Other,G1/G2,49.0,4.28,Diabetic Nephropathy,ARBs,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,WT,Mut,WT
8dedf9fb-4bb0-4f20-b27c-40266703b636,81,F,Caucasian,G1/G2,14.2,0.75,FSGS,ACE Inhibitors,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,WT,Mut,WT,WT,Mut
aa38d0a1-6ba2-4efe-b11c-6eb62095eef6,59,M,African American,G0/G1,74.5,4.63,Diabetic Nephropathy,Calcium Channel Blockers,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,Mut,WT,Mut
bf85bf0e-ad64-456c-a10f-aa3ff0bbac67,35,M,Asian,G1/G2,81.4,1.28,FSGS,"Insulin, Diuretics, ARBs",Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,WT,Mut,Mut,Mut,WT,WT
91b0e1d9-9d92-42af-ac8d-0e44e71e43a6,68,M,Caucasian,G2/G2,45.0,4.14,FSGS,Erythropoietin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,WT,WT
d56f0350-8c45-4ce2-a7f4-8ad54d0b0d1a,39,M,Hispanic,G1/G2,11.3,1.44,Nephrotic Syndrome,Diuretics,Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,WT,WT,WT,Mut,Mut
35ce8841-4973-4d6c-8dca-bfb7001a9a8b,39,F,Asian,G1/G2,48.6,2.19,Diabetic Nephropathy,"Calcium Channel Blockers, Insulin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Insulin.",WT,WT,Mut,WT,WT,Mut
9b4e2c24-9479-41e6-8927-7d9b6e0d2648,51,M,African American,G1/G1,28.7,2.19,Nephrotic Syndrome,Insulin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,WT,Mut,WT
7118e364-7709-4749-927e-ecfaa79ac9aa,38,M,African American,G1/G1,32.6,1.35,Nephrotic Syndrome,"Erythropoietin, Calcium Channel Blockers, Insulin",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, Calcium Channel Blockers, Insulin.",Mut,Mut,Mut,WT,WT,WT
82dc4c8e-36b5-429a-acf5-e81e71316269,88,F,Caucasian,G0/G0,49.7,2.42,CKD Stage 3,"Erythropoietin, Insulin, Statins",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin, Insulin, Statins.",WT,WT,WT,WT,WT,Mut
f5b78cc7-e6b3-4944-8b32-3e357922bac2,32,F,Asian,G1/G2,63.8,3.47,CKD Stage 1,"Insulin, Statins, ARBs",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,WT,Mut,WT
a8aa7158-2b70-4525-bc67-f831cbc84759,77,F,Caucasian,G1/G1,72.1,1.18,Nephrotic Syndrome,"ACE Inhibitors, Calcium Channel Blockers, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,Mut,Mut,Mut
a9f25336-83f4-49a9-88a6-39d015b52908,78,F,African American,G1/G2,109.3,3.71,FSGS,"Insulin, Calcium Channel Blockers, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,WT,WT,WT
17e8392a-55ce-45db-9e87-e04ca2086977,34,M,Asian,G0/G0,118.7,2.46,Diabetic Nephropathy,"ARBs, Insulin, Diuretics",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,Mut,Mut,Mut
3c20592f-c04a-46c4-b3b6-3fe1d1843324,84,F,African American,G2/G2,74.6,4.02,CKD Stage 1,"ARBs, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,Mut,Mut,Mut
ce7ae7f6-3982-4cff-8f77-a665ac3c5640,80,F,African American,G0/G1,40.3,1.15,FSGS,"Erythropoietin, Statins, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,WT,Mut,Mut
0bd4a990-0640-4e0f-a5b8-fd4b32fa2de8,61,F,Hispanic,G1/G1,102.7,4.36,Nephrotic Syndrome,Calcium Channel Blockers,Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,WT,WT,Mut,Mut,Mut,Mut
9c7c7377-79a2-4903-bbe3-3b243eae0032,29,M,Asian,G0/G1,110.5,2.33,CKD Stage 4,"Calcium Channel Blockers, Diuretics, ACE Inhibitors",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, Diuretics, ACE Inhibitors.",WT,WT,Mut,Mut,WT,WT
74962764-12a4-4ef0-84bb-b7a9d98868dd,43,M,Caucasian,G0/G0,60.2,4.63,Nephrotic Syndrome,Diuretics,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,WT,WT,WT
935f2b0a-a138-4ddc-a2d9-de5d6a18ce4c,75,M,Asian,G2/G2,70.6,2.05,Diabetic Nephropathy,"Erythropoietin, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,Mut,WT,WT
624c69b6-b244-45a7-b7e5-848131c681ec,45,M,Caucasian,G0/G1,39.6,2.34,CKD Stage 1,"ACE Inhibitors, Statins, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, Statins, ARBs.",WT,WT,WT,Mut,Mut,Mut
25c73c44-3e75-43b4-a64f-a6637e8f8095,62,F,Hispanic,G0/G1,61.3,3.55,Diabetic Nephropathy,"Statins, Insulin, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, Insulin, ACE Inhibitors.",WT,Mut,Mut,Mut,WT,Mut
e4855aa1-016b-4287-b008-05cca7f36ae9,53,F,Hispanic,G1/G1,82.2,4.78,Nephrotic Syndrome,"ARBs, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,WT,WT,Mut,Mut,WT,WT
e2add909-c521-4f2d-9c45-d539c03f3538,55,F,Asian,G1/G2,52.7,0.66,Nephrotic Syndrome,"Calcium Channel Blockers, ARBs, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,Mut,WT,WT
3805f907-6cd6-4193-8746-8f591b494e15,78,M,Hispanic,G2/G2,93.9,1.32,Nephrotic Syndrome,"Erythropoietin, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,Mut,Mut
b227462c-f53d-4330-8dda-24ba2d06e8cf,55,F,African American,G1/G2,15.9,3.35,FSGS,"ACE Inhibitors, Statins, ARBs",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Statins, ARBs.",WT,Mut,Mut,Mut,WT,WT
8eb22579-0cdb-4ca4-b6ec-bdd68498e113,61,F,Other,G1/G2,25.8,4.38,CKD Stage 2,Statins,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,WT,WT,Mut
1f115b76-d92c-4227-aadf-50853fcb7546,39,M,Asian,G0/G0,24.2,2.45,CKD Stage 4,"Statins, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,WT,Mut,WT
76f2dbfe-cd29-436f-a222-82e174daaebf,42,M,African American,G0/G1,34.9,4.45,CKD Stage 3,ACE Inhibitors,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,WT,WT,Mut
8f15ba58-fce6-4504-87f8-424daae65fc1,84,F,Asian,G0/G1,47.7,4.56,CKD Stage 3,ARBs,Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,Mut,WT,WT,WT,WT,WT
c1581092-f335-4ba3-913a-7052986f9025,82,M,African American,G1/G1,88.2,4.06,CKD Stage 4,"Diuretics, Insulin, Erythropoietin",No,"No significant change in eGFR. Continuing current treatment: Diuretics, Insulin, Erythropoietin.",WT,WT,WT,WT,WT,WT
d0a44432-9cd6-4852-b14c-7df4e4347d51,66,M,Other,G1/G1,62.2,1.19,Nephrotic Syndrome,"Erythropoietin, ACE Inhibitors, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,WT,Mut,WT
6d3ee1dc-8139-4443-a45b-712eb8225688,33,F,African American,G0/G0,64.8,3.24,Diabetic Nephropathy,"Calcium Channel Blockers, Insulin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,Mut,WT,WT
722764e6-8c41-461b-a827-a1b9d4a02e53,44,F,Hispanic,G0/G1,10.3,3.52,CKD Stage 1,"Erythropoietin, Statins, ARBs",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,Mut,WT,Mut
dc8aee30-be60-43f7-a8be-9288e5af6e39,77,M,African American,G0/G1,106.2,4.34,CKD Stage 3,"Diuretics, Statins, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,WT,WT,Mut
c074718e-425a-409f-b337-c59979844388,52,M,Hispanic,G1/G1,30.1,2.3,CKD Stage 4,"Calcium Channel Blockers, Statins",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,WT,WT,WT
46fde062-a33d-47af-9701-410d3f4b1a70,31,F,Other,G1/G2,98.2,3.55,CKD Stage 2,"Statins, Diuretics, Insulin",Yes,"No significant change in eGFR. Continuing current treatment: Statins, Diuretics, Insulin.",WT,WT,Mut,Mut,WT,Mut
7c0e8cd8-8573-4793-8715-b2b9c40c5d91,26,F,Hispanic,G0/G0,87.5,3.55,Diabetic Nephropathy,"Insulin, Erythropoietin, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,WT,Mut
709b7d97-464c-44af-bd3f-3799a07295e9,67,M,Other,G2/G2,16.0,3.4,CKD Stage 2,"Calcium Channel Blockers, Statins, Erythropoietin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,Mut,WT,Mut
3c07c574-4925-4af1-b6aa-e05b13d5f2f7,82,M,Other,G1/G2,54.4,1.56,CKD Stage 4,"Calcium Channel Blockers, Insulin",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, Insulin.",Mut,WT,Mut,Mut,Mut,WT
e49d681d-51d8-4c64-95fa-1ab8458f1f19,20,M,Asian,G1/G2,13.9,2.97,Diabetic Nephropathy,Calcium Channel Blockers,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,Mut,Mut,WT
269cd696-236c-4b87-94a0-bccb8a476a87,76,F,Other,G2/G2,76.0,3.72,CKD Stage 3,"Statins, ACE Inhibitors, Erythropoietin",Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,WT,WT,Mut,Mut,Mut,Mut
271e3ee2-b1a6-41f1-a20e-99d33b33f3d8,23,M,Asian,G0/G1,100.4,3.84,CKD Stage 4,Diuretics,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,Mut,WT,Mut
6a34c854-1071-4d51-b6c5-9dacb4d7e28e,61,M,Asian,G0/G0,111.9,4.27,FSGS,Calcium Channel Blockers,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,Mut,WT,WT
7746d0ba-8ae8-405b-94b4-a48268586eba,79,M,Other,G0/G1,90.4,1.08,CKD Stage 4,"Insulin, Calcium Channel Blockers, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,Mut,Mut,Mut
d5385b0e-34f3-493c-8ff0-a55c6a702e2f,35,M,Asian,G2/G2,87.0,3.87,CKD Stage 3,"Insulin, Diuretics, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,WT,WT,Mut,Mut,WT
c51155ff-e7a3-4e81-a3b4-c08b6b8e869f,40,F,African American,G1/G1,71.9,3.12,Nephrotic Syndrome,"Statins, Erythropoietin, Insulin",Yes,"History of hypertension and diabetes, currently managed with Statins, Erythropoietin, Insulin.",Mut,Mut,WT,WT,WT,Mut
05000bc6-b20d-4b6e-b231-1f1795863a76,25,M,Hispanic,G0/G1,118.2,3.58,CKD Stage 2,Erythropoietin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,Mut,Mut,WT
9360715f-c3fe-4183-a172-b725db52ca58,89,M,Other,G1/G2,36.1,4.03,Diabetic Nephropathy,"Diuretics, Erythropoietin, ACE Inhibitors",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,Mut,Mut,Mut,WT,WT
f1578470-0182-47c4-ba1b-58066160a6b4,43,F,Caucasian,G1/G1,93.1,2.96,FSGS,Calcium Channel Blockers,Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers.",WT,Mut,Mut,WT,WT,WT
63d62a39-c0e3-4efd-8c71-e0fe5a0cdd7c,83,M,Asian,G0/G0,57.1,3.0,CKD Stage 2,Insulin,Yes,"History of hypertension and diabetes, currently managed with Insulin.",Mut,WT,Mut,Mut,WT,WT
d5f25073-f414-42b1-a442-9ebbda7b9095,24,F,Asian,G2/G2,70.5,0.83,Nephrotic Syndrome,"Insulin, ARBs",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,Mut,Mut,WT
bc10fa52-bf5d-4fdf-89c8-d2ab6b44fa8d,45,F,Hispanic,G1/G1,42.3,4.78,FSGS,"Statins, Insulin, ACE Inhibitors",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,WT,Mut,Mut,WT,WT,WT
e5d6f6e6-9a6e-42f5-8cc4-29038bcf53a1,66,M,Asian,G1/G1,69.4,1.77,FSGS,"Insulin, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,Mut,WT,Mut
45df16b6-382c-443f-bcfc-9b793875394c,30,M,Other,G2/G2,10.8,0.79,Nephrotic Syndrome,"Calcium Channel Blockers, ARBs, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, ARBs, Statins.",WT,WT,Mut,WT,WT,WT
638c254c-076e-4bba-bc53-08bf6f92f25e,60,M,African American,G0/G0,16.0,4.07,FSGS,Insulin,Yes,No significant change in eGFR. Continuing current treatment: Insulin.,WT,Mut,Mut,Mut,Mut,Mut
cc530e36-addc-4e13-ab3b-4d37560c95ee,20,F,African American,G2/G2,10.6,3.74,CKD Stage 1,"Insulin, ACE Inhibitors, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,Mut,WT,Mut
d72b6108-2a40-4f12-b963-f37f67814c1f,66,F,African American,G1/G2,27.2,1.49,Nephrotic Syndrome,"Calcium Channel Blockers, Insulin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Insulin.",Mut,WT,Mut,Mut,WT,WT
fb10987f-20ac-4703-ab67-146a77a6e17c,18,F,Other,G2/G2,114.2,1.87,Nephrotic Syndrome,"Erythropoietin, Diuretics, ARBs",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, Diuretics, ARBs.",Mut,WT,WT,WT,WT,Mut
e82c7d7b-06e7-45f9-88bc-539c9f4c3b79,41,M,Other,G1/G2,80.9,0.83,Nephrotic Syndrome,Diuretics,Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,WT,Mut,Mut,Mut,WT
a9ba5a27-907b-4e36-9786-48f864de82e6,48,M,Hispanic,G2/G2,17.7,1.37,CKD Stage 4,"Diuretics, Insulin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics, Insulin.",Mut,WT,Mut,Mut,Mut,WT
6db99102-a48b-4dbe-957d-94a106f028ff,49,M,Asian,G1/G1,102.4,1.1,Nephrotic Syndrome,"Statins, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,Mut,Mut,Mut,Mut,WT,WT
2e85cb21-7631-4e9d-9de9-f86322bd3388,28,F,Caucasian,G2/G2,31.6,3.8,Nephrotic Syndrome,Erythropoietin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,Mut,WT,WT
53cd6268-610c-4373-8299-9aa40cdf742b,87,F,Caucasian,G1/G1,53.2,4.51,FSGS,"Calcium Channel Blockers, Diuretics, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,Mut,WT,WT
56666f9f-53ac-4ab9-b467-2cd9362f5e5c,39,M,Asian,G0/G1,29.7,4.77,Nephrotic Syndrome,Erythropoietin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin.",Mut,Mut,WT,WT,Mut,WT
473bd358-610e-4a64-a130-1617c2dff335,65,M,African American,G0/G1,67.0,4.06,CKD Stage 4,"Statins, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Statins, ACE Inhibitors.",WT,Mut,WT,Mut,Mut,WT
6bebac31-d4f8-4d72-b382-1cfdc083b73a,66,F,Other,G0/G0,66.8,2.19,CKD Stage 2,"Statins, Diuretics, Erythropoietin",Yes,"History of hypertension and diabetes, currently managed with Statins, Diuretics, Erythropoietin.",Mut,Mut,WT,WT,Mut,WT
78660765-14f7-4e8d-95bc-b8d04094dded,83,F,Caucasian,G0/G1,30.6,2.13,Nephrotic Syndrome,Erythropoietin,Yes,No significant change in eGFR. Continuing current treatment: Erythropoietin.,WT,Mut,Mut,WT,Mut,Mut
0d557b61-8a17-4dfe-bfc0-0dc804f64d86,38,F,African American,G0/G1,14.7,3.08,CKD Stage 2,Erythropoietin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,WT,Mut,WT
39669fa7-5997-4043-b3b1-025bfff9f585,90,M,Hispanic,G0/G0,33.8,3.23,CKD Stage 4,"ARBs, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: ARBs, Calcium Channel Blockers.",Mut,WT,WT,Mut,WT,Mut
f510ab53-c7fe-439f-9190-f938a66fd7f7,26,M,Asian,G1/G2,24.5,0.57,FSGS,"Erythropoietin, Statins, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, Statins, ARBs.",WT,WT,Mut,WT,WT,WT
07f194f9-c115-4d6d-8a4e-5b70a6d964a3,34,M,Asian,G2/G2,56.3,4.44,Nephrotic Syndrome,"Statins, ARBs, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: Statins, ARBs, Calcium Channel Blockers.",Mut,Mut,WT,Mut,WT,Mut
d6d7b3b8-3309-4d35-bf4d-f561f319c125,28,F,Other,G2/G2,55.0,1.35,Nephrotic Syndrome,"Calcium Channel Blockers, ACE Inhibitors, Insulin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,WT,Mut,Mut
3d114802-2702-478b-9f0f-da8d05379ff6,37,F,Other,G1/G1,38.7,2.91,FSGS,"Insulin, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,Mut,WT,Mut
1d48a071-ab61-47b1-b93b-4c3220500494,79,F,Hispanic,G2/G2,47.9,3.67,Nephrotic Syndrome,Calcium Channel Blockers,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,WT,WT,WT
770c7798-37cc-463b-b2a0-345990604f62,61,M,Caucasian,G1/G2,116.1,0.52,CKD Stage 1,Statins,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins.",Mut,WT,WT,Mut,WT,Mut
5e6fea07-c453-4f1d-8199-2fdfb31022f0,22,F,Asian,G2/G2,82.2,1.79,FSGS,Calcium Channel Blockers,Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers.",WT,Mut,Mut,WT,WT,Mut
f6b751f7-9b74-4245-9b1b-c8952af43ab7,83,M,Other,G0/G1,84.1,2.12,Nephrotic Syndrome,ARBs,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,Mut,Mut,Mut
c71d5e60-1d52-46ab-b7e6-427cbf780e3f,84,M,African American,G0/G0,70.5,3.77,FSGS,"Diuretics, Calcium Channel Blockers, Erythropoietin",Yes,"History of hypertension and diabetes, currently managed with Diuretics, Calcium Channel Blockers, Erythropoietin.",WT,WT,Mut,Mut,WT,Mut
4fa03f26-f6f7-40cc-a9ec-8e49d1bdb8c0,82,M,Other,G0/G0,65.3,2.03,CKD Stage 1,"Diuretics, Insulin, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,Mut,WT,Mut
edcb8cb6-0692-4c63-9424-aed51bac5c15,76,M,Asian,G0/G0,38.4,2.22,Diabetic Nephropathy,Erythropoietin,Yes,"History of hypertension and diabetes, currently managed with Erythropoietin.",WT,Mut,Mut,Mut,WT,Mut
e87466d7-ad66-41bd-9367-6a024fdc6e1b,29,F,Hispanic,G0/G0,71.0,1.3,CKD Stage 3,"ARBs, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,WT,WT,Mut,WT,WT
f1043785-658b-4523-a014-1de9f54ad0a2,51,M,Caucasian,G0/G1,101.8,4.26,CKD Stage 3,Calcium Channel Blockers,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,Mut,WT,WT
9793b9b4-1374-4146-b2c5-bd89b70b3420,65,F,Asian,G2/G2,105.6,2.71,Diabetic Nephropathy,"Diuretics, Statins, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, Statins, ARBs.",WT,WT,Mut,Mut,WT,Mut
3e2b6091-a092-452a-94a0-57a7b0cc1b3b,40,F,African American,G2/G2,60.6,3.6,CKD Stage 1,"ARBs, Statins, Insulin",Yes,"History of hypertension and diabetes, currently managed with ARBs, Statins, Insulin.",WT,Mut,Mut,Mut,WT,Mut
4d3485c5-c5c1-4eb4-b27b-3d901a16342c,78,F,Hispanic,G0/G1,64.9,1.45,Nephrotic Syndrome,"Diuretics, Statins",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,Mut,WT,WT,WT,WT
ce3714af-99b4-4350-af2b-99b4d9acd158,48,F,Asian,G0/G1,26.0,4.82,CKD Stage 2,"Calcium Channel Blockers, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,WT,Mut,Mut
90e0f4a0-fbdd-4933-8bd5-8bf61efd76e9,89,M,Asian,G0/G0,86.0,0.77,Diabetic Nephropathy,"Statins, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,Mut,Mut,Mut
8861fe18-58e2-4888-8a83-81bec85aca46,50,F,African American,G1/G2,23.3,4.4,FSGS,Insulin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin.",WT,Mut,Mut,Mut,Mut,Mut
11a72609-5edd-4bbf-a959-76636daa2e68,54,F,Caucasian,G0/G1,80.5,4.68,CKD Stage 4,"Insulin, Calcium Channel Blockers, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,Mut,WT,Mut
033d2bce-575a-4d2c-a5c5-650c8186a576,55,F,Other,G1/G2,39.8,2.5,Diabetic Nephropathy,"Erythropoietin, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,Mut,WT,WT,WT,WT
7d7ddbed-d284-476c-ab88-f83dd97dc9cd,50,M,Caucasian,G0/G1,53.7,0.93,CKD Stage 4,"ACE Inhibitors, Calcium Channel Blockers, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,WT,WT,Mut
5cb85aed-f5f6-4c97-aefb-63b11b049863,49,F,Asian,G0/G1,24.4,4.27,CKD Stage 1,Erythropoietin,Yes,"History of hypertension and diabetes, currently managed with Erythropoietin.",Mut,Mut,Mut,Mut,Mut,Mut
75b17a55-d426-4982-a43e-4288a2b5b498,87,M,Other,G2/G2,60.2,3.87,FSGS,"Insulin, Erythropoietin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,WT,WT,Mut
2d174fc9-6f7c-45ea-a72a-6d8eb5122df8,70,F,Caucasian,G1/G1,11.2,2.85,Diabetic Nephropathy,Diuretics,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics.",Mut,Mut,WT,Mut,Mut,Mut
a6846099-f729-4951-8591-31d2bbda0242,55,M,African American,G2/G2,51.1,2.35,FSGS,"Statins, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Statins, ARBs.",WT,Mut,Mut,WT,Mut,WT
eb6c1016-cee6-44d0-9dac-6e8345241ea6,48,F,Hispanic,G2/G2,99.0,2.36,Diabetic Nephropathy,ARBs,Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,WT,Mut,WT,Mut,Mut,Mut
7701f7bb-7bc6-4e1f-864e-e6e389c5b31a,80,M,Hispanic,G0/G0,26.7,4.86,CKD Stage 1,ACE Inhibitors,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors.",Mut,Mut,WT,Mut,WT,WT
97ac6aa8-bb24-48a3-9363-57b66f81cf4f,19,F,Caucasian,G1/G1,56.2,4.04,CKD Stage 4,"Statins, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,WT,WT,Mut
3ed8c56c-da09-4fa0-9282-8d8044b591f7,27,F,Caucasian,G0/G1,108.5,1.63,CKD Stage 4,ACE Inhibitors,Yes,No significant change in eGFR. Continuing current treatment: ACE Inhibitors.,WT,Mut,Mut,WT,WT,WT
4767d76c-162f-4a24-af43-613cd4aac9a3,30,M,Asian,G1/G2,85.0,1.9,CKD Stage 3,Erythropoietin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,Mut,Mut,WT
c01f36bf-3e6d-458b-b367-c28de1b294de,45,M,Caucasian,G1/G2,45.7,1.25,CKD Stage 3,"ACE Inhibitors, Statins, ARBs",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Statins, ARBs.",WT,WT,Mut,WT,Mut,WT
ab0e664e-9c3e-42d5-91e1-aa9676f72255,81,M,Other,G1/G1,112.4,4.99,Nephrotic Syndrome,ACE Inhibitors,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,WT,Mut,WT
7e8adee7-0758-4201-961e-16d16105716b,62,F,Caucasian,G0/G0,85.8,2.11,CKD Stage 2,"ACE Inhibitors, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,WT,WT,Mut
7cd0129d-2e8d-4e87-9334-20e6d9d80b8d,77,F,Other,G2/G2,27.6,2.89,CKD Stage 4,"Calcium Channel Blockers, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,Mut,WT,WT
4223623b-cc3e-4dde-9ad5-cf06364d7c87,48,F,African American,G2/G2,100.1,1.35,Nephrotic Syndrome,"Calcium Channel Blockers, Insulin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Insulin.",WT,Mut,Mut,Mut,Mut,WT
989d9d4a-e15c-4666-8797-b2c957207246,26,M,Caucasian,G0/G1,106.1,1.41,CKD Stage 4,ACE Inhibitors,Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors.",WT,Mut,Mut,Mut,WT,Mut
8e485223-46b9-4991-a14e-b70db380c73a,27,M,Caucasian,G1/G2,112.1,4.24,CKD Stage 4,"ACE Inhibitors, Diuretics, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,Mut,WT,WT
30e912f2-f2b4-4abf-8441-aefd0299436a,27,M,Other,G0/G0,21.1,1.54,CKD Stage 4,ARBs,Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,WT,Mut,WT,Mut,Mut
680bac63-b856-4035-bdc9-829015eabb27,72,M,Caucasian,G0/G1,70.5,2.77,Nephrotic Syndrome,Insulin,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,Mut,Mut,Mut
3d85de89-c217-4429-8e20-07247d137018,73,F,Other,G0/G1,71.9,1.46,Diabetic Nephropathy,"Erythropoietin, Diuretics, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,WT,WT,Mut
b63b4dc3-a559-4463-b9e1-3ceab0cbc61f,84,M,Hispanic,G0/G0,43.0,1.5,Diabetic Nephropathy,"ACE Inhibitors, Erythropoietin",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Erythropoietin.",Mut,WT,WT,WT,Mut,Mut
046a0df5-cafd-4613-b2bb-912d7da67785,51,F,Other,G0/G1,35.6,4.15,CKD Stage 1,"Statins, Insulin, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,WT,Mut,WT
6786d506-38ba-4abc-8b53-05e517d2582e,56,M,Other,G1/G2,18.6,0.75,Diabetic Nephropathy,"Diuretics, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,WT,Mut,WT
a9f948b2-4e63-44bb-be49-3f43b118f68d,23,F,Other,G2/G2,26.5,2.76,CKD Stage 2,ACE Inhibitors,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,WT,Mut,Mut
8db06746-7927-4973-9e78-1fd794e0d3ba,36,M,Hispanic,G0/G0,62.3,3.85,FSGS,"Diuretics, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, ACE Inhibitors.",Mut,Mut,WT,WT,Mut,WT
ff233d5f-6ced-415d-9800-7c0287ea7ff5,43,M,Caucasian,G0/G0,39.3,2.44,Nephrotic Syndrome,"ACE Inhibitors, Calcium Channel Blockers, Statins",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,WT,Mut,Mut
5a104129-54ae-4d1b-8ce6-424dbef59fe6,21,F,Caucasian,G1/G1,77.8,4.96,CKD Stage 4,"ARBs, Statins, ACE Inhibitors",Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,WT,WT,Mut,WT,WT,WT
4e7ed827-455a-4762-b428-a656b3ee4d3b,49,M,Hispanic,G0/G0,47.8,4.12,CKD Stage 3,"Statins, ACE Inhibitors",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,WT,Mut,Mut
b8a6171f-1ee3-4dc4-bb04-8a8b405bfdc9,36,M,Asian,G2/G2,109.7,2.87,CKD Stage 3,ACE Inhibitors,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors.",Mut,WT,Mut,WT,Mut,WT
be2d740a-1e9b-43bc-90c7-c006314d3441,52,F,African American,G0/G0,42.2,4.48,CKD Stage 4,Statins,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,WT,WT,WT
b0ae8f08-c31e-4bbc-b36c-b62b892e6161,89,M,African American,G0/G1,111.4,1.87,CKD Stage 4,"Erythropoietin, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,Mut,Mut,WT
bd1531c8-3764-4bda-b108-d4482f65fafa,25,F,Asian,G0/G0,113.9,4.77,CKD Stage 2,Diuretics,Yes,"History of hypertension and diabetes, currently managed with Diuretics.",Mut,WT,WT,Mut,WT,Mut
96ef2ad6-b97e-4703-86c8-adfe7bf47042,37,F,Hispanic,G2/G2,46.2,2.94,CKD Stage 2,"ARBs, Insulin, Erythropoietin",Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,WT,WT,Mut,WT,Mut,WT
98c7472a-864e-4a13-829c-fc0cfa02eaec,38,F,African American,G2/G2,68.6,3.74,CKD Stage 2,"Calcium Channel Blockers, ARBs",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,Mut,Mut,Mut,Mut,Mut
d52721e7-19bc-443e-bb02-bebb48729a4d,53,M,Caucasian,G0/G0,24.5,0.62,FSGS,"Diuretics, Insulin, Erythropoietin",Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,WT,WT,WT,WT,Mut,WT
5c62b3a2-3a3c-463e-8bd6-cee631b1b099,35,F,Hispanic,G0/G1,103.7,2.71,CKD Stage 2,ARBs,Yes,"History of hypertension and diabetes, currently managed with ARBs.",WT,WT,Mut,WT,Mut,Mut
b540b30e-039f-4a25-8d61-68bd2defe193,43,M,African American,G0/G1,112.0,4.94,Diabetic Nephropathy,"Statins, Erythropoietin, Diuretics",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,WT,Mut,Mut,WT,Mut
0ba6eab9-4639-447b-a067-bdac88bd13d1,68,M,Other,G0/G0,59.7,4.22,CKD Stage 1,Insulin,Yes,No significant change in eGFR. Continuing current treatment: Insulin.,Mut,WT,Mut,WT,WT,Mut
4ac9778d-8da8-4ee4-8df5-6ac6f96b648a,56,F,Asian,G0/G1,56.5,3.26,CKD Stage 1,"Insulin, ARBs, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Insulin, ARBs, Statins.",Mut,WT,WT,WT,WT,Mut
a34b6cf6-2053-4a42-b1af-db65b289f224,75,M,Caucasian,G1/G2,74.9,3.71,CKD Stage 2,"ACE Inhibitors, Diuretics",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,WT,WT,WT,WT,Mut
1a432f0a-7daa-49f0-80b6-fce2de53790a,28,F,Other,G2/G2,114.5,2.2,CKD Stage 4,Calcium Channel Blockers,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,WT,WT,WT
48ca7651-92f5-4f7b-8323-d342df6a8f93,24,F,Hispanic,G1/G1,90.3,4.82,CKD Stage 3,"ARBs, ACE Inhibitors, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,WT,Mut,Mut
5738811d-70c2-403f-ba8d-03aa782a65e0,87,M,Other,G1/G2,36.2,3.15,CKD Stage 4,"Statins, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with Statins, Calcium Channel Blockers.",WT,WT,WT,Mut,WT,WT
40a26c60-0d27-4659-b72a-da9b2f32751e,25,F,African American,G0/G1,103.9,3.5,Diabetic Nephropathy,"Diuretics, Calcium Channel Blockers, ACE Inhibitors",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,WT,WT,Mut
1d34d08e-7a4c-45d4-9c99-e04cf0e98b3b,89,M,Asian,G2/G2,49.6,0.66,Diabetic Nephropathy,"Diuretics, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with Diuretics, Calcium Channel Blockers.",Mut,WT,Mut,WT,Mut,Mut
7de31a51-6694-4343-90ba-58e3d2762bdc,53,F,Other,G1/G2,67.7,3.63,FSGS,ACE Inhibitors,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,Mut,Mut,Mut
afbb411a-a123-4a8c-93b7-a88612f70c97,63,M,Other,G2/G2,64.6,3.78,CKD Stage 4,"Calcium Channel Blockers, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, ARBs.",WT,Mut,WT,WT,WT,WT
cfa701cd-2631-400b-a6d7-94d30db95301,33,M,Other,G1/G2,55.5,2.0,FSGS,"ARBs, ACE Inhibitors, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,Mut,Mut,Mut
15ce6a66-4dc8-4a1e-b2f9-e5fa90164161,32,F,Hispanic,G1/G2,89.7,3.27,CKD Stage 1,ARBs,Yes,No significant change in eGFR. Continuing current treatment: ARBs.,Mut,Mut,Mut,Mut,WT,WT
8edddfcd-1e52-4770-bf89-7142fe716b14,76,F,Asian,G1/G2,112.1,0.75,FSGS,"Insulin, Erythropoietin",Yes,"History of hypertension and diabetes, currently managed with Insulin, Erythropoietin.",Mut,WT,WT,Mut,Mut,WT
989bc4da-9b37-422b-aa8a-616fc3b290d0,21,F,Asian,G2/G2,102.7,3.07,CKD Stage 4,Insulin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin.",WT,Mut,Mut,WT,Mut,Mut
c693da11-39c6-41ca-9e50-aa42ca6dfda1,48,F,Asian,G1/G1,33.8,1.86,CKD Stage 1,"Calcium Channel Blockers, ACE Inhibitors",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, ACE Inhibitors.",WT,WT,Mut,WT,Mut,WT
e893be3d-7354-4a6f-a160-745985c7504b,79,F,Hispanic,G0/G1,94.6,0.94,FSGS,"ARBs, Calcium Channel Blockers, ACE Inhibitors",Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,Mut,Mut,WT,WT,Mut,WT
96a9954f-dc33-41f9-8c1f-55ab715629ee,29,F,Asian,G0/G0,21.3,3.95,Nephrotic Syndrome,"ACE Inhibitors, Insulin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,WT,WT,Mut
9191b363-4e2d-4645-adc7-cac7fd72b050,58,F,African American,G1/G1,26.4,1.73,CKD Stage 1,"Insulin, Calcium Channel Blockers, ACE Inhibitors",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,Mut,WT,Mut
f5c9b047-9c10-4572-8f6b-40d09efba58b,39,M,Hispanic,G2/G2,108.1,2.93,CKD Stage 1,ACE Inhibitors,Yes,No significant change in eGFR. Continuing current treatment: ACE Inhibitors.,Mut,WT,WT,Mut,WT,WT
c342bd2b-f295-456e-9967-5f06bd767e35,40,F,Other,G1/G1,44.4,4.18,Nephrotic Syndrome,"Calcium Channel Blockers, Insulin, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,Mut,WT,Mut
43bfd931-3605-4f54-a021-c0ca3531968d,77,F,Caucasian,G0/G1,25.8,4.53,CKD Stage 3,"Statins, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Statins, ARBs.",Mut,Mut,Mut,Mut,WT,WT
3d67cde9-2834-44c0-94c8-b3b4a911d192,62,F,Asian,G0/G1,41.0,2.07,FSGS,Insulin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,Mut,WT,Mut
2812859a-1337-439e-8d4f-5d272c7f0b79,69,F,Caucasian,G2/G2,36.8,1.22,CKD Stage 4,"ACE Inhibitors, Diuretics",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,Mut,Mut,Mut,WT,WT
b07aa066-7354-45ea-a894-9b8d00af5b3a,27,F,African American,G2/G2,75.6,1.96,CKD Stage 1,"ARBs, Diuretics",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,Mut,WT,WT,Mut,Mut,Mut
085b15fb-4a8f-4810-b84c-2f29980402a2,25,M,Caucasian,G0/G1,107.6,4.56,Nephrotic Syndrome,Calcium Channel Blockers,Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers.",WT,WT,Mut,Mut,Mut,Mut
48603b32-b4fb-4eb9-89c1-3de73b4206c5,58,F,Other,G1/G1,111.0,4.72,Nephrotic Syndrome,"ACE Inhibitors, Insulin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,Mut,WT,Mut
1238d630-743b-45a2-9c0f-2fcfb3f6fe0d,18,F,African American,G1/G1,105.2,1.56,Nephrotic Syndrome,"Statins, Erythropoietin, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: Statins, Erythropoietin, Diuretics.",Mut,Mut,Mut,Mut,WT,WT
43b9da13-ec85-4f37-bbc1-a987aff8754d,42,F,Hispanic,G1/G2,27.0,4.99,Nephrotic Syndrome,ARBs,Yes,"History of hypertension and diabetes, currently managed with ARBs.",WT,WT,WT,WT,Mut,Mut
96fc734d-a003-4d28-8a8f-3653c9af18f8,35,F,Asian,G2/G2,112.3,3.3,CKD Stage 4,"Statins, Insulin, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,WT,Mut,WT
32a447b2-ef04-457d-8dcc-c33aa9434aa0,48,F,Asian,G2/G2,73.4,0.65,CKD Stage 1,"Statins, Erythropoietin, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,WT,Mut,Mut
398d1ca6-8b68-40b5-9d61-fac36cd5e859,84,M,Caucasian,G1/G2,79.4,3.49,Nephrotic Syndrome,Erythropoietin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,WT,Mut,Mut
44007d5a-e88d-4719-a624-2b40a5cb63a2,60,F,Hispanic,G1/G1,41.8,0.66,FSGS,"Diuretics, Erythropoietin, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,WT,WT,Mut
0f44704f-1247-4a4e-a469-98e8d39e198b,21,F,Asian,G0/G0,24.0,0.85,Diabetic Nephropathy,"Diuretics, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,WT,WT,WT
9854ce4e-4ebf-45c3-8ae9-b4a72a79ea68,37,F,Hispanic,G0/G1,38.7,3.65,CKD Stage 4,Calcium Channel Blockers,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,WT,WT,Mut
ebd34616-91b7-4d8e-9301-6989bfbbb17f,67,M,Asian,G0/G1,33.2,3.8,CKD Stage 3,Erythropoietin,Yes,No significant change in eGFR. Continuing current treatment: Erythropoietin.,Mut,WT,WT,WT,Mut,Mut
77fc9703-1fd5-4423-b06c-5c5649e2623d,78,M,Asian,G1/G2,62.2,1.15,Diabetic Nephropathy,"ACE Inhibitors, Diuretics",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,WT,WT,Mut
670acc5c-b321-4f21-8dd8-eb85b04d3376,52,F,Hispanic,G1/G1,98.3,1.65,FSGS,"Statins, Erythropoietin",Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,WT,WT,Mut,WT,Mut,WT
8a3c3b5e-801e-41da-85b1-ed25f1533ae8,26,M,Asian,G0/G0,67.8,3.58,CKD Stage 3,Erythropoietin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin.",Mut,Mut,WT,WT,WT,WT
9918ee46-1497-4658-b010-f7197e695d0d,45,M,African American,G0/G0,104.2,1.08,Nephrotic Syndrome,"Insulin, ARBs, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,Mut,WT,Mut
bc0a6a5d-6e99-4e3e-a3b1-37fc0a3450fc,59,F,Caucasian,G0/G0,40.5,0.78,CKD Stage 4,"ACE Inhibitors, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,WT,Mut,WT
069f14f1-4018-4c6e-9a8c-fa3c5283aac7,40,F,African American,G0/G1,69.5,2.44,FSGS,"ACE Inhibitors, Statins, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors, Statins, Diuretics.",WT,WT,WT,WT,Mut,Mut
ac9ed156-f63f-4e41-ba9a-ca5e176132ed,37,M,African American,G1/G2,39.3,3.65,CKD Stage 4,"ACE Inhibitors, Insulin, Statins",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, Insulin, Statins.",Mut,Mut,Mut,WT,WT,WT
964db03f-9340-4fad-9c4a-d56bd6016237,79,M,Other,G2/G2,112.9,2.12,Nephrotic Syndrome,"Statins, ACE Inhibitors",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,WT,Mut,Mut,WT,Mut,Mut
c3c75611-ffe3-4a49-854f-92fff366bad4,40,M,Asian,G0/G1,42.9,2.26,CKD Stage 1,"Erythropoietin, Diuretics, Statins",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin, Diuretics, Statins.",WT,Mut,WT,WT,WT,WT
9384ec2b-44fe-4cae-9248-a9a7ac1aa554,48,F,Asian,G0/G0,97.2,3.4,CKD Stage 4,"Calcium Channel Blockers, Statins, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Statins, ACE Inhibitors.",WT,Mut,WT,Mut,WT,Mut
2cd94cbb-c19a-458c-835b-1c8c0a4c9f7f,84,F,Other,G0/G1,91.5,1.55,CKD Stage 1,Erythropoietin,Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,Mut,WT,Mut,WT,WT
7135f221-a6c9-437f-84da-d06a7872bdeb,34,M,Caucasian,G0/G0,109.5,4.19,CKD Stage 1,"Insulin, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,Mut,WT,WT
ff37d19c-2e76-428b-8735-44f9ea83bf00,72,F,Asian,G1/G1,23.3,3.58,FSGS,Diuretics,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,Mut,WT,WT
d0725b5c-a281-4044-af96-288295d82980,71,M,Hispanic,G2/G2,28.2,1.6,FSGS,ARBs,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs.",WT,Mut,WT,WT,Mut,WT
785299f4-175b-498d-b814-01027de1bdfe,40,M,Other,G1/G1,55.8,4.13,Diabetic Nephropathy,"Erythropoietin, ARBs",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, ARBs.",WT,WT,Mut,Mut,Mut,WT
5230dfbd-5553-42fe-a889-803e5913f9d3,22,M,Asian,G2/G2,114.5,3.32,Diabetic Nephropathy,"Diuretics, Statins",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,WT,WT,Mut
292bd156-db94-4570-9ac7-0ec0ab8ddeb4,82,M,Asian,G0/G1,40.4,1.37,Diabetic Nephropathy,Erythropoietin,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,Mut,WT,WT,WT,WT
7ed70ed7-b194-490b-a961-929e546e035a,54,M,Asian,G1/G1,46.8,4.12,Diabetic Nephropathy,"ACE Inhibitors, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors, Calcium Channel Blockers.",WT,WT,WT,WT,Mut,WT
668409e3-f1f8-443e-a99f-131849c8a43f,74,F,Asian,G0/G1,92.2,4.54,CKD Stage 2,Diuretics,Yes,"History of hypertension and diabetes, currently managed with Diuretics.",WT,WT,WT,Mut,WT,Mut
0964fbbf-8cd3-41b0-82b0-1cfdd045dd1c,78,F,African American,G1/G2,25.9,4.68,CKD Stage 4,Statins,Yes,"History of hypertension and diabetes, currently managed with Statins.",Mut,WT,Mut,WT,Mut,Mut
409d3602-5084-4242-968b-1625746f7891,34,M,Other,G0/G0,40.9,1.0,CKD Stage 4,"Statins, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, ARBs.",Mut,WT,Mut,WT,WT,WT
c5c5b37a-f85e-46a1-9dad-09b252c21221,84,F,Caucasian,G2/G2,62.1,2.58,CKD Stage 1,"Statins, Erythropoietin, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Statins, Erythropoietin, ARBs.",WT,Mut,Mut,WT,WT,WT
d32e6dcd-83bc-4478-9d6a-c7b86778043b,23,F,Other,G0/G0,56.8,2.27,Diabetic Nephropathy,"Calcium Channel Blockers, ACE Inhibitors, Statins",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, ACE Inhibitors, Statins.",Mut,WT,WT,WT,Mut,WT
de8ede0b-a85c-4e4a-804b-6fabfcf56188,55,M,African American,G0/G0,62.8,1.87,Nephrotic Syndrome,"Calcium Channel Blockers, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,WT,Mut,WT
0de051a6-69ca-47d2-b644-14fd8ae769ed,77,M,African American,G1/G2,108.3,2.0,CKD Stage 1,"Statins, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, Diuretics.",WT,WT,Mut,WT,Mut,WT
9f64eeed-5c9d-427d-84b8-71bb300568d2,64,F,Other,G0/G0,50.2,1.29,FSGS,"ACE Inhibitors, Insulin, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,WT,Mut,WT
71299889-a01a-4992-bf9d-3e64c1a6423b,46,F,Hispanic,G1/G1,65.4,2.4,CKD Stage 1,Diuretics,Yes,No significant change in eGFR. Continuing current treatment: Diuretics.,Mut,Mut,Mut,WT,Mut,Mut
445dcc38-341c-4494-8d36-6dfcc28ebd70,65,M,Caucasian,G1/G2,19.6,2.26,CKD Stage 2,"ACE Inhibitors, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,WT,Mut,WT
49bc473f-ed7b-4656-a18a-15368c99a894,84,M,Hispanic,G1/G2,116.7,2.94,CKD Stage 2,"Diuretics, Statins",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,WT,WT,WT
7c16128d-b2c0-4394-a17f-29e170286046,84,F,Asian,G2/G2,47.7,3.41,CKD Stage 3,"Insulin, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,WT,Mut,WT
a14923c2-f920-464c-8763-fcd01f15c7b6,47,F,Hispanic,G1/G1,94.7,0.71,CKD Stage 3,"Statins, ARBs",Yes,"History of hypertension and diabetes, currently managed with Statins, ARBs.",WT,Mut,WT,WT,WT,WT
b5b453ca-3d42-493c-8c9f-d3349bdf0377,23,F,Other,G0/G1,58.5,2.16,CKD Stage 2,"Erythropoietin, ACE Inhibitors, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin, ACE Inhibitors, Diuretics.",Mut,WT,Mut,Mut,WT,Mut
03802b70-8d03-491e-8f8d-5238288b78b5,69,F,Caucasian,G1/G2,112.1,1.2,Nephrotic Syndrome,"Insulin, Diuretics, Erythropoietin",Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,Mut,WT,Mut,Mut,WT
3985fb62-17dc-4eff-a872-13f98d605936,23,M,Other,G0/G0,43.9,2.31,Diabetic Nephropathy,Statins,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,WT,WT,WT
1d0bc9bd-e9b5-45cf-9766-5cdafe049059,43,M,African American,G2/G2,103.4,3.55,CKD Stage 1,"Statins, ARBs, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,Mut,WT,Mut
a5d04d53-1e12-42e3-b272-92b6762172ed,65,M,Hispanic,G1/G1,48.6,4.9,Diabetic Nephropathy,"ACE Inhibitors, ARBs, Statins",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, ARBs, Statins.",Mut,Mut,Mut,WT,Mut,Mut
eec259dc-7f95-497c-a76a-a6ced50755d9,29,M,Caucasian,G1/G1,62.2,4.4,CKD Stage 3,Insulin,Yes,"History of hypertension and diabetes, currently managed with Insulin.",Mut,WT,WT,Mut,Mut,Mut
b495db4e-8245-4fb4-8ab7-706eb77350ca,77,M,Caucasian,G0/G1,101.6,1.8,CKD Stage 4,Calcium Channel Blockers,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,Mut,WT,WT
7b85179a-d5b0-47e0-aa5d-932b45ff2c83,37,F,Hispanic,G1/G2,23.7,3.5,CKD Stage 3,"ARBs, Statins",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,Mut,Mut,WT
74eff545-3e65-4603-b8e3-654bfaf14ff0,64,F,Other,G1/G2,105.5,3.33,CKD Stage 4,"Calcium Channel Blockers, ACE Inhibitors, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, ACE Inhibitors, Diuretics.",WT,Mut,WT,WT,WT,Mut
30cbd755-6232-417a-a507-41818d1fb540,35,F,Caucasian,G0/G0,40.0,2.39,CKD Stage 3,Diuretics,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,WT,WT,WT
bf0d073d-821c-4336-9970-cf60ebff8d15,58,F,Hispanic,G1/G1,20.5,3.11,Diabetic Nephropathy,ACE Inhibitors,Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors.",WT,Mut,Mut,Mut,Mut,Mut
11df12d7-dd30-4e89-a2f2-35f2e11b868d,45,M,Other,G0/G1,101.5,4.08,FSGS,"Erythropoietin, Insulin, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin, Insulin, Calcium Channel Blockers.",WT,Mut,Mut,WT,WT,WT
dabac50d-ca3d-4859-85ce-099c46b82659,62,F,Hispanic,G0/G1,99.9,4.5,FSGS,"Calcium Channel Blockers, Diuretics, ARBs",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,WT,WT,WT,WT,WT
c9a7d91f-ef2a-4713-9702-10496a39aaa6,57,M,Caucasian,G0/G1,117.9,2.41,Diabetic Nephropathy,ACE Inhibitors,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors.",WT,Mut,Mut,WT,WT,WT
00a81de9-d20f-47d0-8465-6d6b81fb18b3,83,M,Asian,G0/G0,109.9,0.69,CKD Stage 3,"ACE Inhibitors, Calcium Channel Blockers, Erythropoietin",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Calcium Channel Blockers, Erythropoietin.",WT,WT,WT,Mut,WT,WT
d664d264-4c6e-47ff-b9de-7a3a486822b9,53,F,Hispanic,G0/G1,104.1,4.01,FSGS,Insulin,Yes,"History of hypertension and diabetes, currently managed with Insulin.",WT,WT,WT,WT,WT,Mut
a8f1e091-ffb8-402d-9475-dbc996418ced,18,M,Caucasian,G2/G2,103.6,2.64,Nephrotic Syndrome,"ARBs, Statins, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: ARBs, Statins, ACE Inhibitors.",WT,Mut,Mut,Mut,WT,WT
7250ee18-260a-4962-9d81-b7f57d5911c6,58,M,Asian,G0/G0,67.2,2.73,CKD Stage 3,"Diuretics, Insulin, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, Insulin, ACE Inhibitors.",WT,Mut,Mut,WT,Mut,Mut
551ac8ea-585a-4afa-bbfd-cc1289e06ab3,57,F,Caucasian,G2/G2,54.8,4.93,CKD Stage 4,Calcium Channel Blockers,Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,WT,Mut,Mut,WT,WT,Mut
6090d697-8b1e-4b9d-834b-9fbb8d4a75b8,68,F,Other,G0/G0,23.1,2.28,Nephrotic Syndrome,"ACE Inhibitors, Erythropoietin, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors, Erythropoietin, ARBs.",WT,Mut,WT,Mut,WT,Mut
de9e3757-5260-401e-aecf-67d2749176f4,72,F,Hispanic,G2/G2,75.3,3.9,Diabetic Nephropathy,"Statins, Diuretics, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, Diuretics, Calcium Channel Blockers.",Mut,Mut,Mut,WT,Mut,WT
3d225c30-b28f-41de-bb14-0bc3304b8590,80,F,Caucasian,G0/G1,13.3,3.82,Diabetic Nephropathy,Statins,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,Mut,WT,Mut
db23aa8c-3bca-4f85-a20a-60ac9261549d,30,M,Other,G1/G2,97.2,1.41,Nephrotic Syndrome,"Statins, Insulin",Yes,"No significant change in eGFR. Continuing current treatment: Statins, Insulin.",Mut,Mut,WT,WT,Mut,WT
517400f8-0b2c-482a-a928-8e92c68a152f,58,F,Asian,G1/G2,14.0,1.3,Nephrotic Syndrome,"Erythropoietin, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,Mut,Mut,Mut
e9d68f23-b489-4070-b914-f8a8bea4ff31,90,F,Other,G2/G2,72.9,2.64,Diabetic Nephropathy,Insulin,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,Mut,Mut,Mut
fd08b32c-62d6-4e93-a198-5d54cfb87e6f,59,M,African American,G2/G2,15.0,4.27,CKD Stage 3,"Insulin, ACE Inhibitors, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,Mut,Mut,Mut
a6eab79e-d21c-42f8-8ada-4f80a9e782d4,49,M,Caucasian,G1/G1,75.2,4.6,CKD Stage 1,"ACE Inhibitors, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,WT,Mut,Mut
f6febc0e-7ecd-4baf-a6f0-5fcffb16e5db,71,F,African American,G1/G2,74.7,4.94,CKD Stage 4,"Statins, Diuretics, Insulin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,WT,Mut,Mut
f72169bb-8096-4718-a051-acef097a1e10,61,M,Other,G1/G1,50.0,2.46,CKD Stage 4,"Calcium Channel Blockers, ACE Inhibitors, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,WT,Mut,Mut
19b17e80-dea4-4e17-94fd-9ad39716108e,29,M,Other,G1/G1,40.1,3.05,FSGS,"Statins, ARBs",Yes,"History of hypertension and diabetes, currently managed with Statins, ARBs.",Mut,WT,Mut,Mut,Mut,Mut
1986b4b2-70b7-4868-9854-80f0dfcaf0b7,69,F,Other,G2/G2,59.9,3.94,CKD Stage 2,Erythropoietin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,Mut,Mut,Mut
03edd1f8-74f9-4d17-a912-b4bf86a4bae4,25,M,Hispanic,G1/G2,26.3,1.18,Nephrotic Syndrome,"Calcium Channel Blockers, Statins",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,WT,Mut,Mut
def57689-68f4-4bce-a4e7-5e8eb8f21423,38,F,Other,G0/G1,54.6,1.01,CKD Stage 2,ARBs,Yes,"History of hypertension and diabetes, currently managed with ARBs.",Mut,Mut,Mut,Mut,Mut,WT
1327f1bc-2784-478f-b84f-16b3a79fbfaf,52,M,African American,G1/G1,96.9,1.75,FSGS,Erythropoietin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,WT,WT,Mut
43d88870-f81d-4aa1-8812-0a8e78308930,26,F,Hispanic,G0/G0,53.7,4.28,Diabetic Nephropathy,ARBs,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,Mut,WT,WT
65c17795-b155-46bc-9f8d-ed9756abf2f1,58,F,Other,G1/G2,98.6,3.85,CKD Stage 4,ARBs,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,Mut,Mut,Mut
541cdfcd-da0d-4a5f-948f-8b74a65bb1f2,25,F,Other,G1/G1,87.0,1.01,FSGS,"Statins, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,Mut,Mut,Mut
889b78d5-dbfd-497e-aca2-b148da330aa1,20,M,African American,G0/G1,37.8,2.23,Nephrotic Syndrome,"Diuretics, Erythropoietin, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,WT,Mut,Mut
a075e927-5110-4492-b442-7e0b61484bb3,48,F,Caucasian,G0/G1,110.7,3.34,Diabetic Nephropathy,"Statins, ACE Inhibitors, Diuretics",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,Mut,Mut,Mut
7cea2045-c268-483e-a32f-2e63b7fddd71,38,F,Other,G0/G0,48.7,3.21,Diabetic Nephropathy,"Erythropoietin, Diuretics, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, Diuretics, Statins.",WT,WT,WT,Mut,WT,WT
9e11d2cd-0930-4ef6-8a80-068ddf547e50,57,F,Other,G0/G0,22.2,1.62,Nephrotic Syndrome,"Calcium Channel Blockers, ARBs, Insulin",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, ARBs, Insulin.",Mut,Mut,Mut,Mut,WT,Mut
af34cf65-a193-44b2-bc19-e71d118405ad,59,F,Caucasian,G0/G0,55.6,1.32,CKD Stage 4,"ARBs, ACE Inhibitors, Erythropoietin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, ACE Inhibitors, Erythropoietin.",WT,WT,Mut,WT,Mut,WT
3a3c8a71-ff57-4e2b-8991-ab9bebc2026f,72,F,Caucasian,G0/G0,115.4,1.27,FSGS,ACE Inhibitors,Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors.",Mut,Mut,Mut,WT,WT,WT
fa745761-6f18-4108-9723-199dbf2c14a0,54,F,Asian,G0/G1,57.4,1.43,CKD Stage 2,"Erythropoietin, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,WT,WT
b4323070-a23d-4c2f-82a7-96891933918c,48,F,Caucasian,G1/G1,74.1,3.41,CKD Stage 1,Statins,Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,WT,Mut,Mut,WT,Mut,Mut
2a96e1e2-7194-4ae2-99ba-d7aedf615a5c,50,M,African American,G2/G2,16.5,2.0,CKD Stage 2,"Diuretics, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,WT,WT,Mut,Mut,Mut,Mut
0769165f-e746-4cb9-8ca9-cf07b1aa0f6a,34,M,Other,G0/G1,38.6,2.77,CKD Stage 3,"ARBs, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, ACE Inhibitors.",Mut,Mut,WT,Mut,WT,Mut
0e5dd462-cbd0-4ef2-930a-37df0bc61066,81,F,Hispanic,G1/G2,41.1,4.45,FSGS,"Insulin, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin, Diuretics.",Mut,WT,Mut,Mut,WT,Mut
6e417d47-5ff5-45ea-9bc4-40f14b1a269b,37,M,Caucasian,G0/G1,13.9,1.67,Nephrotic Syndrome,"Statins, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Statins, ACE Inhibitors.",Mut,WT,Mut,Mut,Mut,Mut
697c3923-87fa-441a-be83-b91f25440fe0,36,M,Hispanic,G0/G0,32.4,1.78,Diabetic Nephropathy,Erythropoietin,Yes,"History of hypertension and diabetes, currently managed with Erythropoietin.",Mut,WT,WT,WT,Mut,WT
2e183554-cae2-4e66-ae8a-781390e0a95b,30,F,African American,G1/G1,84.9,3.56,CKD Stage 4,"Insulin, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Insulin, ACE Inhibitors.",Mut,WT,WT,WT,Mut,Mut
9c07a751-1437-4509-acd1-586a2b840c67,52,M,Hispanic,G0/G0,82.2,4.78,CKD Stage 3,"Erythropoietin, Insulin, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,Mut,WT,WT
aee1e86b-9ea5-46aa-a1ee-6c5bdeef580f,66,M,Asian,G1/G1,29.6,4.84,Diabetic Nephropathy,"ACE Inhibitors, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors, Calcium Channel Blockers.",WT,WT,Mut,Mut,Mut,WT
9549c931-e9af-499d-bf67-1eec3da70577,80,F,Hispanic,G2/G2,24.4,3.49,Diabetic Nephropathy,"Insulin, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin, ARBs.",Mut,Mut,Mut,Mut,Mut,Mut
a34db7c5-760d-4bbb-bb70-b3a124a35cf2,65,M,Asian,G1/G2,20.2,2.81,CKD Stage 4,"ARBs, Erythropoietin, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,Mut,Mut,WT
aab612c9-415d-474a-b5a6-69814104a8b5,56,M,Caucasian,G1/G1,102.6,2.85,CKD Stage 3,"ACE Inhibitors, Insulin, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,WT,Mut,Mut,WT,Mut
771ad655-cdfc-4ee0-a61e-de900267deb3,90,F,Hispanic,G1/G1,74.4,3.96,CKD Stage 1,Erythropoietin,Yes,No significant change in eGFR. Continuing current treatment: Erythropoietin.,Mut,WT,WT,Mut,WT,WT
8beddb12-ad77-482f-89a2-3a89e6b5a92c,56,F,Other,G1/G2,93.3,2.52,Diabetic Nephropathy,"Diuretics, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,Mut,WT,Mut
f1faf665-7115-43f3-92e8-9d1028711733,18,F,African American,G0/G0,28.9,2.65,Nephrotic Syndrome,"Calcium Channel Blockers, Erythropoietin",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, Erythropoietin.",Mut,Mut,Mut,Mut,Mut,WT
4c955f6a-966b-4964-bcd6-bdca5876fd09,19,M,African American,G0/G0,86.6,1.35,CKD Stage 1,Statins,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,WT,WT,Mut
b0b862ef-6c9f-42b9-b647-8986a3917c99,36,F,Asian,G0/G0,22.8,4.56,Nephrotic Syndrome,"Statins, Calcium Channel Blockers, Erythropoietin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, Calcium Channel Blockers, Erythropoietin.",WT,Mut,WT,WT,Mut,Mut
4d57d880-d865-469a-b4f3-310340066ff2,19,M,Asian,G1/G2,103.3,3.82,FSGS,"Insulin, Diuretics, ACE Inhibitors",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,Mut,WT,WT
da743152-627b-41a1-bfd6-f23232ffe294,72,F,Other,G0/G0,39.5,3.42,CKD Stage 4,Statins,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,Mut,Mut,WT,WT,Mut
61a11729-3cb9-4350-9b4d-a0fe7bb38605,78,F,Asian,G0/G1,65.8,3.14,Nephrotic Syndrome,"Insulin, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,Mut,Mut,Mut
4bbe4aff-9326-4ffd-9be4-bf5192698698,38,M,Hispanic,G0/G0,83.4,1.08,CKD Stage 2,Insulin,Yes,"History of hypertension and diabetes, currently managed with Insulin.",Mut,WT,Mut,Mut,Mut,WT
059dd55d-4b94-4e30-b303-f438fe2110d0,24,M,Hispanic,G1/G1,49.3,1.21,Diabetic Nephropathy,"ACE Inhibitors, Calcium Channel Blockers, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,WT,WT,Mut
6553867d-a881-4fd3-947d-577bfa5a91ca,63,M,Other,G1/G1,108.6,4.34,Diabetic Nephropathy,"Insulin, Erythropoietin, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,WT,WT,WT
dd750e98-90e0-495f-8212-b554464458b4,23,M,Caucasian,G0/G0,105.8,4.6,CKD Stage 2,"Diuretics, Erythropoietin, Statins",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics, Erythropoietin, Statins.",Mut,WT,WT,Mut,Mut,WT
f93e08d5-bea2-4dfe-873f-6e1baf908e3c,74,F,African American,G0/G1,101.8,2.63,CKD Stage 3,"ARBs, ACE Inhibitors, Diuretics",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,WT,WT,Mut
bec39a37-9b3d-44bd-a91e-314e0c8e29e3,35,F,Asian,G1/G2,108.8,4.78,FSGS,"Diuretics, ACE Inhibitors, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, ACE Inhibitors, Statins.",WT,WT,WT,WT,Mut,Mut
e726be23-e776-4886-9534-ee1d7f2984f5,73,M,Asian,G0/G0,82.6,3.39,FSGS,Erythropoietin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin.",Mut,Mut,Mut,Mut,Mut,Mut
3ae909fe-cc82-48da-8696-f5e64944051b,85,M,Asian,G1/G2,80.8,4.49,FSGS,"Erythropoietin, Statins, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, Statins, Diuretics.",Mut,WT,Mut,WT,WT,Mut
3810ae66-5a31-44cc-8d4b-69a99b689c88,34,F,Caucasian,G0/G0,66.3,1.91,CKD Stage 3,"ARBs, ACE Inhibitors, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,Mut,WT,WT
402913ec-9ef2-493e-b0ac-7d7ba2f963a3,51,F,African American,G0/G0,93.2,4.74,CKD Stage 4,"Insulin, Erythropoietin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,WT,WT,Mut
c478f6f1-b88e-4318-816d-83edad81f8bd,35,F,Other,G0/G1,21.6,2.82,CKD Stage 2,"Statins, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Statins, ACE Inhibitors.",WT,Mut,Mut,WT,WT,WT
2303f6c6-d69d-42f1-ae4c-84ffa8c01f05,78,M,Asian,G0/G0,50.6,2.87,FSGS,"Insulin, Statins, Diuretics",Yes,"History of hypertension and diabetes, currently managed with Insulin, Statins, Diuretics.",Mut,Mut,Mut,Mut,Mut,WT
a0a11839-e745-4704-98df-bc3ca0d4de3d,34,F,Asian,G0/G1,116.5,2.81,FSGS,Erythropoietin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin.",WT,Mut,Mut,WT,WT,Mut
c9e26074-4f16-49a0-8a17-991ea5769411,70,M,African American,G1/G1,72.9,0.68,CKD Stage 2,Diuretics,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,Mut,Mut,WT
5d678bb1-945e-42e4-888a-93ec70d9c9f8,36,F,African American,G1/G1,107.8,1.47,Diabetic Nephropathy,"Statins, ACE Inhibitors, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,Mut,Mut,Mut
e8dd5e5a-1712-4b16-a1a4-344fbb7bee03,61,F,Asian,G2/G2,24.6,1.12,Nephrotic Syndrome,"Calcium Channel Blockers, Statins",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, Statins.",Mut,WT,Mut,WT,Mut,Mut
6a5e6920-bf5a-47e6-93a3-dd5a4b8c5bdc,61,M,Asian,G1/G1,81.1,4.4,Nephrotic Syndrome,Insulin,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,WT,WT,WT
c958e75e-21d5-4971-b367-49b52cf6bf75,82,M,African American,G2/G2,29.8,0.59,Diabetic Nephropathy,ARBs,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,Mut,WT,Mut
5da8d6d2-f8b3-4a8b-a05f-b8bc8a16a06c,61,F,Caucasian,G1/G2,12.6,2.88,CKD Stage 4,"ACE Inhibitors, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,WT,WT,Mut
45c45a3e-e9da-484a-8075-9f1f87e5f0fe,37,F,Asian,G0/G1,16.5,4.83,CKD Stage 2,Erythropoietin,Yes,No significant change in eGFR. Continuing current treatment: Erythropoietin.,WT,Mut,Mut,WT,Mut,WT
e9ff1cae-41c8-4a8c-aa1f-955ad499da99,51,F,African American,G0/G0,32.3,3.88,FSGS,Statins,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,WT,Mut,Mut
f7a67b94-7b5a-411a-b1b6-4afed31edf1a,26,F,African American,G1/G2,79.7,4.61,CKD Stage 1,"Insulin, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin, Calcium Channel Blockers.",WT,WT,WT,Mut,Mut,Mut
ded255d0-bf1e-4366-8b8e-63d4ce7607ad,82,M,Caucasian,G1/G1,69.4,1.26,CKD Stage 2,"Statins, Insulin, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, Insulin, Calcium Channel Blockers.",WT,WT,Mut,Mut,WT,WT
77e490c7-1d7b-4313-8de2-2f1c56b60afc,52,F,Asian,G1/G1,102.7,1.46,Diabetic Nephropathy,"Diuretics, ACE Inhibitors, ARBs",Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,WT,Mut,WT,Mut,WT,WT
c1101266-2408-46dc-9346-d1a9f6802cdb,53,F,Caucasian,G2/G2,65.5,4.11,Nephrotic Syndrome,"Erythropoietin, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, Diuretics.",Mut,Mut,WT,Mut,Mut,WT
ad238d36-dc32-4c97-b9c1-e262f76c8ede,60,M,Caucasian,G0/G0,77.0,0.52,CKD Stage 1,"ARBs, Statins, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,Mut,Mut,WT,WT,WT,Mut
65bcc272-fadd-4ea3-aca5-e2fdb966442a,63,F,Other,G1/G1,52.5,4.28,Diabetic Nephropathy,"ACE Inhibitors, Calcium Channel Blockers, Statins",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,WT,WT,WT
8eac0a33-cdf9-44a7-9882-b5c1f79efd70,63,M,African American,G2/G2,78.8,4.14,CKD Stage 2,Statins,Yes,"History of hypertension and diabetes, currently managed with Statins.",Mut,WT,Mut,Mut,WT,WT
6502d6a2-ca6a-4224-971e-16cc5da36f1b,68,M,Hispanic,G2/G2,65.0,1.27,CKD Stage 2,"Erythropoietin, Insulin, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,WT,WT,Mut
1fa382e8-895c-4d99-83b3-8eb403902c5d,84,F,Caucasian,G0/G0,119.1,3.62,FSGS,"Diuretics, Erythropoietin, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,WT,Mut,Mut
bfbf397b-ac3e-4b0d-9e5b-a13d746cdb77,53,M,Other,G1/G2,64.5,2.83,CKD Stage 1,"ARBs, ACE Inhibitors, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,WT,Mut,WT
618ae305-95a5-4afa-831d-029fac1e86d8,21,M,Asian,G0/G0,110.9,1.39,CKD Stage 3,"ACE Inhibitors, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,Mut,WT,Mut
5f18e583-f0b6-483f-a377-f6f1d289f0ab,49,M,Asian,G0/G1,115.5,4.25,Diabetic Nephropathy,"Insulin, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin, ARBs.",WT,Mut,WT,Mut,WT,WT
78b2b549-3bdb-409e-acc2-16a01bbc91f7,66,F,African American,G0/G1,16.8,4.11,CKD Stage 1,"Insulin, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,WT,WT,Mut
f1738856-e25d-46eb-9e9a-9f83066803ee,69,M,Other,G1/G2,35.6,3.2,Nephrotic Syndrome,"ACE Inhibitors, Statins, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,Mut,WT,Mut
9c2e58de-ea4e-4617-93f8-382b8fb864e4,42,M,African American,G0/G0,75.5,0.8,Diabetic Nephropathy,Insulin,Yes,"History of hypertension and diabetes, currently managed with Insulin.",WT,Mut,Mut,Mut,Mut,Mut
a2a9d4d8-102e-4de5-a5cc-8bf738ab854c,35,M,African American,G0/G1,44.3,2.46,Nephrotic Syndrome,"Diuretics, Insulin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,Mut,Mut,Mut
b379cb1e-e8cd-40cc-b6da-3ca0d2e82f38,84,M,African American,G0/G1,65.8,4.26,Diabetic Nephropathy,Statins,Yes,"History of hypertension and diabetes, currently managed with Statins.",Mut,WT,WT,WT,WT,Mut
1dde7969-6886-43db-a634-8e784d5c55c7,78,F,Other,G1/G1,103.7,3.05,CKD Stage 3,"Diuretics, Statins, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics, Statins, Calcium Channel Blockers.",WT,WT,Mut,WT,Mut,WT
0986bbeb-f23e-423d-8b9b-d93423c86d30,46,M,Asian,G2/G2,33.4,2.66,Diabetic Nephropathy,"Calcium Channel Blockers, Erythropoietin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Erythropoietin.",Mut,WT,Mut,WT,WT,Mut
1dba1267-7e1c-45a1-bef5-18a64dead645,63,M,Other,G0/G0,25.7,2.48,Nephrotic Syndrome,"Calcium Channel Blockers, Diuretics, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,Mut,WT,WT
899ca782-e323-4d1a-bc1b-dacc18e19331,40,F,Other,G0/G1,29.6,0.6,Diabetic Nephropathy,"ACE Inhibitors, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, Calcium Channel Blockers.",WT,Mut,WT,Mut,WT,Mut
5efa9c5b-7421-4f46-a37e-4b0122bae10e,65,F,Caucasian,G2/G2,117.5,4.99,CKD Stage 4,"ACE Inhibitors, Calcium Channel Blockers, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,Mut,Mut,Mut
b24cc64f-be3e-4e57-b30a-9e32aba4fc03,49,M,Other,G2/G2,30.8,2.91,Diabetic Nephropathy,Diuretics,Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,WT,WT,Mut,WT,Mut,WT
965befdf-6b4b-4411-8a4a-0e2df22b5b98,78,M,Caucasian,G2/G2,52.7,4.47,Diabetic Nephropathy,"Diuretics, Statins, Insulin",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, Statins, Insulin.",Mut,WT,Mut,Mut,Mut,Mut
e2aa7a5d-278e-400d-ba02-66efbe055787,69,M,Caucasian,G0/G1,108.4,2.53,CKD Stage 2,"ARBs, Diuretics",Yes,"History of hypertension and diabetes, currently managed with ARBs, Diuretics.",Mut,Mut,WT,Mut,Mut,WT
d56ce8ea-1959-4b5a-a7a8-f6366a35df59,55,F,Other,G1/G1,35.3,0.69,FSGS,"Diuretics, Statins, Erythropoietin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,Mut,Mut,Mut
f065c817-687a-4850-9d9b-62317d45d8ef,21,M,Asian,G0/G1,39.2,0.84,CKD Stage 1,"Calcium Channel Blockers, Insulin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,WT,WT,WT
b0b63bcf-0860-4833-879d-0cdaf396ea37,87,M,Hispanic,G0/G1,84.3,1.63,Nephrotic Syndrome,"Calcium Channel Blockers, Diuretics, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,Mut,Mut,Mut
71d79665-7181-4dcf-b79e-fc6e5edb0d3c,69,M,Asian,G2/G2,118.8,4.78,Diabetic Nephropathy,"ARBs, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,Mut,Mut,Mut
5cd8fe1a-dafe-48a9-bc71-e0bef3579560,58,M,Asian,G1/G2,33.1,2.52,FSGS,Diuretics,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,WT,Mut,Mut
5e09a9ee-af88-4dec-bb1e-143b196f4dfa,71,F,Asian,G2/G2,43.0,3.14,FSGS,ARBs,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs.",WT,Mut,Mut,Mut,WT,Mut
a5135ea0-fa53-434d-a6d5-901d8b621d41,67,M,Asian,G0/G0,46.2,4.83,Nephrotic Syndrome,"ACE Inhibitors, ARBs",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, ARBs.",WT,WT,WT,Mut,WT,WT
46a02a9b-65ec-4acd-8f80-35f55bd20c98,67,F,Caucasian,G0/G1,42.0,2.86,CKD Stage 4,Diuretics,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics.",WT,WT,Mut,Mut,Mut,WT
f2f25eef-1f45-4bfd-b7dc-67e030974b2b,86,F,Asian,G0/G0,52.8,4.57,CKD Stage 2,Calcium Channel Blockers,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,Mut,WT,Mut
1777e8cb-7468-4b98-92fe-2fded918b3e5,82,F,Hispanic,G0/G1,10.8,1.14,CKD Stage 1,"Insulin, ARBs",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,Mut,WT,WT
a3b5cece-a446-4e72-b64c-911aa9ab364a,76,F,Hispanic,G1/G2,77.4,4.14,CKD Stage 2,"ARBs, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,Mut,Mut,Mut,WT,WT,Mut
0cf2b69b-0577-4ea9-b899-924698de8ebb,48,M,Hispanic,G2/G2,42.1,4.62,Nephrotic Syndrome,"Erythropoietin, ARBs, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, ARBs, Statins.",Mut,WT,Mut,WT,WT,Mut
fd235def-3e5a-47e3-9560-db22c96b5edb,39,F,Caucasian,G2/G2,14.9,0.62,Nephrotic Syndrome,"Erythropoietin, Calcium Channel Blockers, Statins",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin, Calcium Channel Blockers, Statins.",Mut,Mut,Mut,WT,Mut,WT
34885a46-9088-4eaf-8977-6598203c8c25,32,M,Hispanic,G1/G2,63.3,0.81,FSGS,"ARBs, Erythropoietin, Statins",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,WT,WT,WT
8de08fc2-c3e1-4a85-946e-f10411906f50,40,F,African American,G2/G2,91.6,1.26,Nephrotic Syndrome,Erythropoietin,Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,Mut,WT,Mut,Mut,WT,WT
d0243d72-3748-467f-961d-33ba350843f0,86,M,Asian,G0/G0,102.0,4.15,Nephrotic Syndrome,"Erythropoietin, Calcium Channel Blockers, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,WT,WT,WT
c63d04ee-541c-4a86-bba5-cd2fdea45c19,43,M,Hispanic,G0/G1,32.0,0.57,CKD Stage 1,Diuretics,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics.",WT,WT,WT,WT,WT,WT
989240ac-e689-43a9-89e4-8e8c25c61c45,83,M,Hispanic,G1/G1,71.8,1.35,CKD Stage 2,"Statins, Calcium Channel Blockers, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, Calcium Channel Blockers, ACE Inhibitors.",WT,WT,WT,Mut,Mut,WT
fbe94499-dbc0-40fd-86fb-7bf300b9d4a3,58,M,Asian,G0/G1,60.5,0.8,Diabetic Nephropathy,"Erythropoietin, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,WT,Mut,Mut
8a4b8f7c-2147-4a15-bcce-96f6250a4578,81,M,Other,G2/G2,28.9,4.82,FSGS,"Erythropoietin, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin, Calcium Channel Blockers.",Mut,WT,Mut,WT,Mut,Mut
1c24220e-2cab-47e7-8c6b-66e5402adf9c,20,F,Asian,G2/G2,80.5,1.55,FSGS,"ACE Inhibitors, ARBs, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors, ARBs, Calcium Channel Blockers.",WT,Mut,WT,Mut,WT,WT
21bddb41-0699-4731-9dcf-8766a93b12cd,65,F,Hispanic,G0/G1,26.7,1.42,CKD Stage 1,Erythropoietin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,Mut,Mut,WT
c9d6a63b-ca3c-4f5f-9bb5-c40c03cde2e3,54,M,Caucasian,G1/G1,47.7,1.43,CKD Stage 1,"ARBs, Erythropoietin, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,Mut,WT,WT
040a3aae-52e2-4fd9-96bf-10ab3ce915e7,26,M,African American,G0/G1,113.2,1.07,CKD Stage 2,"Insulin, ARBs, Erythropoietin",Yes,"History of hypertension and diabetes, currently managed with Insulin, ARBs, Erythropoietin.",WT,Mut,Mut,Mut,WT,WT
20733f6d-0d6a-45b3-83ef-20162c9b662e,40,M,Hispanic,G1/G1,73.4,4.85,CKD Stage 2,"Calcium Channel Blockers, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, Statins.",WT,Mut,Mut,Mut,WT,Mut
1d181ee9-86ad-4a8c-abc4-123ebde13c1b,82,F,Caucasian,G1/G2,12.2,2.22,Diabetic Nephropathy,Calcium Channel Blockers,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,Mut,Mut,Mut
72c22a16-79eb-4168-9045-56e5bee3eb79,54,F,Other,G2/G2,62.9,2.0,Nephrotic Syndrome,"ARBs, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: ARBs, Calcium Channel Blockers.",WT,WT,WT,Mut,Mut,Mut
97fa7f04-8363-4007-9cae-9610c72c1fe3,65,F,Asian,G1/G1,80.5,3.15,CKD Stage 4,ACE Inhibitors,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,Mut,Mut,Mut
38b77c07-80fb-4296-b3b6-a09b1beaf6ac,80,F,African American,G1/G2,111.9,3.81,CKD Stage 2,"ACE Inhibitors, Diuretics",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Diuretics.",WT,WT,Mut,Mut,WT,Mut
ba2c98ce-0b19-488e-9d77-a45ef206c269,38,M,African American,G0/G0,80.9,4.63,CKD Stage 4,"Insulin, ACE Inhibitors, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,Mut,Mut,Mut
a8addf36-ddf2-45eb-a8a3-f341c8819065,66,F,Asian,G0/G0,22.0,3.08,Diabetic Nephropathy,"Calcium Channel Blockers, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,Mut,WT,WT
a4b1f991-7542-4646-8d37-a539857dd3b3,18,M,African American,G1/G2,67.7,3.45,Nephrotic Syndrome,"ARBs, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,WT,Mut,WT
ffa361be-0f92-40e1-87f9-7d05f6ca6b8b,75,M,Caucasian,G0/G1,16.5,1.32,Diabetic Nephropathy,Diuretics,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics.",Mut,Mut,WT,WT,WT,Mut
6d204496-66d0-4371-98e8-8ebb7a9e8eef,33,F,African American,G1/G1,13.3,1.56,CKD Stage 4,"Calcium Channel Blockers, ACE Inhibitors, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,WT,WT,WT
b65feea9-7d82-4264-9ba3-62e7afa415e5,66,F,Asian,G1/G2,93.3,3.22,CKD Stage 3,"Erythropoietin, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,Mut,Mut,WT
e63658c9-12d0-498d-b18d-4d05e8e22743,30,M,Asian,G1/G2,89.8,4.5,CKD Stage 2,Insulin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,Mut,Mut,Mut
25f934bf-9bb9-4155-9275-eb9414aeaf5c,42,M,Hispanic,G0/G0,79.7,4.43,Diabetic Nephropathy,"Diuretics, Erythropoietin, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, Erythropoietin, Statins.",WT,Mut,Mut,WT,Mut,Mut
9fd34579-4667-42ce-a04e-178c10d08d11,30,F,Hispanic,G2/G2,31.5,1.14,FSGS,"Calcium Channel Blockers, Erythropoietin, Insulin",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, Erythropoietin, Insulin.",WT,WT,Mut,WT,Mut,Mut
b64fa54a-8c61-4654-95da-75c1a21150f9,32,F,Other,G0/G1,36.8,1.27,Nephrotic Syndrome,"ACE Inhibitors, Calcium Channel Blockers, Statins",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,WT,WT,Mut,Mut,Mut,WT
98eeac2b-fe9f-4caa-a182-f347533f5a72,78,M,Caucasian,G2/G2,79.7,2.71,Diabetic Nephropathy,"Diuretics, ARBs, Insulin",Yes,"History of hypertension and diabetes, currently managed with Diuretics, ARBs, Insulin.",WT,Mut,Mut,Mut,Mut,WT
816bcb9f-7426-4193-8b7e-6b3c87d292a6,32,F,African American,G0/G0,19.8,3.83,CKD Stage 2,"ACE Inhibitors, Insulin, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,WT,Mut,WT
cb08587d-1963-426d-ae21-8b099afd4015,42,F,Asian,G1/G1,94.8,4.09,Diabetic Nephropathy,Insulin,Yes,"History of hypertension and diabetes, currently managed with Insulin.",WT,WT,Mut,WT,Mut,Mut
a79b44b6-da50-4fed-9d4a-3d81b3a7d0e0,46,F,Asian,G0/G1,76.2,1.16,Nephrotic Syndrome,"ACE Inhibitors, Insulin, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,Mut,WT,Mut
8d244e3e-c4da-4ddb-a0b1-5abaa6a27967,66,M,Hispanic,G0/G1,101.1,1.45,Nephrotic Syndrome,Erythropoietin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin.",WT,WT,Mut,Mut,Mut,WT
6e191042-370b-4063-9d90-e79eb888f6ed,68,F,Asian,G1/G2,118.9,3.91,CKD Stage 4,Insulin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,Mut,WT,WT
69efafb1-3a7e-4e14-a359-eee173991a47,24,F,Asian,G0/G1,73.5,2.49,CKD Stage 4,"ARBs, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: ARBs, Calcium Channel Blockers.",WT,WT,WT,Mut,WT,WT
66132e69-7418-4109-93d1-bf0f56c438e4,39,M,African American,G1/G1,117.2,1.31,CKD Stage 1,Insulin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin.",Mut,Mut,WT,Mut,WT,WT
50032b35-1857-4baf-bac7-e2b96a7e4c36,68,F,Hispanic,G2/G2,115.0,3.44,CKD Stage 4,"Calcium Channel Blockers, Erythropoietin, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Erythropoietin, ACE Inhibitors.",Mut,Mut,Mut,Mut,Mut,WT
4140752c-aa44-4259-9001-8b7b6d4067f4,28,M,Asian,G2/G2,34.7,3.14,FSGS,"Diuretics, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,Mut,Mut,Mut
afd380c4-2713-482c-b41e-a3ac5fd23109,30,F,African American,G2/G2,30.3,4.16,CKD Stage 1,"Insulin, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,WT,WT,WT
175a81ec-112f-4612-b969-9ed2ec48bf55,41,M,Other,G1/G2,98.1,1.05,CKD Stage 2,"ARBs, Erythropoietin, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,WT,WT,Mut
6e8f75a1-17dd-4d81-95da-705cd4ef00aa,39,F,African American,G0/G1,43.1,4.76,FSGS,"Erythropoietin, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,Mut,WT,Mut,Mut,Mut,WT
5f65c8ce-bd21-4c11-be9d-61ee18b87245,23,M,African American,G0/G1,25.6,4.35,CKD Stage 2,Insulin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,WT,Mut,WT
0f5ae9d3-8e6e-4003-a14f-3f12cfd01cbd,51,F,Caucasian,G1/G2,60.2,4.75,Nephrotic Syndrome,"Erythropoietin, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, ARBs.",WT,WT,Mut,WT,Mut,WT
8fca7b6a-8fc4-4092-b4e5-59e596229348,58,F,Asian,G0/G0,116.0,1.61,CKD Stage 3,Insulin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,WT,Mut
692ac139-1f4a-4ca1-ab85-fd595463adc7,36,M,Hispanic,G0/G0,20.8,4.91,CKD Stage 2,"ACE Inhibitors, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,WT,Mut,Mut
f0ede303-aa53-419c-9fa4-bb9f5a856750,30,M,Caucasian,G1/G1,114.1,2.25,CKD Stage 3,"Erythropoietin, Insulin, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,Mut,WT,Mut,WT,WT
ea74bb18-de3b-496f-ac45-96f6c012a0ff,36,F,Other,G1/G1,15.8,3.76,CKD Stage 3,"Calcium Channel Blockers, ARBs, Insulin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,Mut,Mut,Mut
49a214ae-f7e8-48e5-8d2b-91efb8976ec5,53,F,Other,G0/G1,43.6,4.36,CKD Stage 3,"Calcium Channel Blockers, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,WT,WT,WT
1a85910d-5a05-4c11-8ffc-a6b199b479d4,28,F,Other,G1/G2,98.9,0.55,CKD Stage 4,"Insulin, Erythropoietin, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,Mut,WT,WT
279c658a-3676-4ce5-81e5-c9f693f277cc,18,F,Other,G1/G1,36.9,3.83,Diabetic Nephropathy,"Erythropoietin, Insulin, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,WT,WT,Mut
d8e7012f-3968-4c81-bb70-c3b8a81fdec3,83,F,African American,G1/G2,64.5,1.27,CKD Stage 1,"Erythropoietin, ARBs",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, ARBs.",WT,Mut,Mut,Mut,Mut,Mut
8e676a01-d86a-4460-99a1-120e1bb43332,90,F,Caucasian,G1/G1,112.2,4.82,FSGS,Statins,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,WT,Mut,Mut
47503f1d-c33a-4f6c-9d69-1fba5e187b24,31,M,Hispanic,G0/G1,54.2,0.54,CKD Stage 4,"ARBs, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,Mut,WT,WT
6dda4f8d-cea6-4f4c-b9e5-8ff092f837d4,50,M,Asian,G1/G2,51.2,2.14,CKD Stage 2,"Calcium Channel Blockers, Diuretics, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Diuretics, ACE Inhibitors.",Mut,Mut,WT,WT,Mut,Mut
c4767556-f97b-42dd-8f9b-72aed85c16bd,43,M,Caucasian,G1/G1,14.4,2.28,Nephrotic Syndrome,"ACE Inhibitors, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,WT,Mut,Mut
accb461a-9d13-4363-9f29-4a8bd1846c39,34,F,Asian,G2/G2,89.9,3.84,Diabetic Nephropathy,"ARBs, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,WT,Mut,WT
9be71737-06b8-4231-8e86-7f3ca487eeab,48,M,Hispanic,G1/G2,117.4,3.82,CKD Stage 4,"Diuretics, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with Diuretics, Calcium Channel Blockers.",Mut,WT,Mut,WT,WT,WT
b18753e6-d457-4ad9-a867-a096edd877c8,32,F,Caucasian,G1/G2,31.8,3.68,Diabetic Nephropathy,Erythropoietin,Yes,No significant change in eGFR. Continuing current treatment: Erythropoietin.,WT,WT,WT,WT,WT,WT
45f50c52-2e2f-4f77-8769-79d644777442,53,M,Caucasian,G1/G2,11.9,1.4,Diabetic Nephropathy,Statins,Yes,No significant change in eGFR. Continuing current treatment: Statins.,Mut,Mut,WT,WT,Mut,Mut
ebe9e207-4f19-4ec0-832d-4526b3e4110a,83,F,African American,G1/G1,22.1,2.14,CKD Stage 3,"Statins, ARBs, Diuretics",Yes,"History of hypertension and diabetes, currently managed with Statins, ARBs, Diuretics.",WT,WT,WT,WT,WT,Mut
2e709838-0190-4620-99dc-abd056febfb9,78,F,Other,G0/G0,57.4,1.64,CKD Stage 4,"Diuretics, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,WT,WT,WT,WT,Mut,Mut
a847bce7-90fa-4b57-a4ac-2130deaf528d,85,F,Caucasian,G1/G1,33.1,2.23,CKD Stage 1,Erythropoietin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin.",WT,WT,WT,WT,Mut,WT
bdb025ff-2451-45a4-91d0-59b26699cd99,61,F,Asian,G0/G1,68.7,1.19,CKD Stage 2,Statins,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins.",Mut,Mut,Mut,Mut,WT,Mut
177d6e7e-07d9-44ce-b8c8-8faea2178f84,71,M,Caucasian,G2/G2,40.2,4.85,CKD Stage 3,Insulin,Yes,No significant change in eGFR. Continuing current treatment: Insulin.,WT,WT,Mut,Mut,WT,WT
604e46cb-3712-42d1-87cd-b6a1bf012e32,67,F,Asian,G2/G2,39.9,1.33,CKD Stage 2,"ARBs, Insulin, ACE Inhibitors",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,WT,Mut,Mut
284bf962-5744-4596-b422-21676b7a2460,39,M,African American,G2/G2,36.2,0.68,CKD Stage 2,"ARBs, Diuretics",Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,WT,WT,WT,WT,WT,Mut
530ac1c7-b8ba-4368-8fc7-77685ebbcca5,65,F,African American,G2/G2,39.0,1.1,FSGS,"Diuretics, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics, ACE Inhibitors.",WT,Mut,WT,Mut,WT,Mut
98a21f1c-914d-4fae-b100-13a7c6deb2f0,31,F,Hispanic,G2/G2,70.6,4.18,CKD Stage 2,"Diuretics, ARBs",Yes,"History of hypertension and diabetes, currently managed with Diuretics, ARBs.",Mut,WT,Mut,WT,Mut,Mut
27d415b6-0d77-45a0-a222-b6a615bfbe97,29,F,Caucasian,G1/G2,30.4,4.38,CKD Stage 2,"Statins, Erythropoietin, ARBs",Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,Mut,WT,Mut,WT,WT,Mut
0cbd3c03-9e2a-44ac-8122-b5b3284c03d2,42,M,Caucasian,G0/G0,56.9,2.55,Nephrotic Syndrome,"ACE Inhibitors, Erythropoietin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors, Erythropoietin.",WT,WT,WT,Mut,Mut,WT
716fda0a-45a8-4829-94e2-86e5ac8936bc,23,M,Caucasian,G0/G0,39.4,4.72,FSGS,Calcium Channel Blockers,Yes,No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers.,WT,WT,Mut,WT,WT,WT
9b69554d-7c54-435f-ac8c-3b6aa974d079,74,M,Hispanic,G1/G1,62.7,1.6,FSGS,"Diuretics, Erythropoietin, Insulin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,WT,Mut,WT
372f871a-45ee-432d-aa07-f2137129cec7,36,M,Caucasian,G0/G0,34.9,2.23,CKD Stage 3,"Diuretics, ARBs, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,WT,WT,WT
585d3f86-1d23-44e6-8329-20b7c143f426,27,F,African American,G1/G1,111.6,4.64,CKD Stage 1,"ARBs, Calcium Channel Blockers, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,WT,Mut,Mut
ad9fb00d-4882-473c-9c63-45ab6e0ed1e8,52,F,Hispanic,G1/G1,99.2,3.7,CKD Stage 1,Calcium Channel Blockers,Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,WT,WT,Mut,WT,Mut,Mut
86e52753-7c93-46cc-97d7-a560adb14670,26,M,Other,G1/G2,115.6,1.75,CKD Stage 1,"ARBs, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,Mut,Mut,Mut,Mut,Mut
3873e57f-0ba0-48e8-8ef4-92c1aac93316,60,M,Caucasian,G1/G2,56.1,2.74,FSGS,"Insulin, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with Insulin, Calcium Channel Blockers.",WT,Mut,WT,Mut,WT,WT
0e0630cd-996d-4c50-bc04-a168652ffb49,18,M,African American,G1/G1,71.4,4.81,CKD Stage 1,Diuretics,Yes,"History of hypertension and diabetes, currently managed with Diuretics.",Mut,WT,Mut,Mut,WT,Mut
f200c261-4d29-41ab-b455-12f701f7c7ec,46,M,Caucasian,G0/G0,115.8,3.67,CKD Stage 4,"ACE Inhibitors, Erythropoietin, Statins",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors, Erythropoietin, Statins.",Mut,WT,WT,WT,Mut,WT
c3a00c6f-2321-41e1-8471-04c036136e15,64,M,African American,G0/G1,18.5,3.06,Diabetic Nephropathy,"ARBs, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: ARBs, Calcium Channel Blockers.",Mut,WT,Mut,Mut,Mut,Mut
1eb74b56-53ff-43a2-8a19-35014169b9fc,19,F,African American,G0/G1,16.6,3.39,FSGS,Insulin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,Mut,Mut,Mut
6e3f683a-bf3c-4140-bf54-a51101fa964e,57,M,Asian,G0/G1,39.9,0.91,CKD Stage 4,Erythropoietin,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,WT,Mut,WT
88575117-6155-4667-a112-507c2cfa55b0,89,M,Asian,G1/G2,44.5,3.39,Diabetic Nephropathy,"ARBs, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, ACE Inhibitors.",Mut,Mut,WT,Mut,WT,WT
8f0881ee-8011-416b-bae8-8926b423ccde,60,M,Caucasian,G1/G1,27.9,0.98,CKD Stage 2,"ACE Inhibitors, Diuretics, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,Mut,WT,WT
5aaab32f-ce63-42b6-ab05-347fd556b37d,23,M,Hispanic,G0/G0,113.8,0.54,CKD Stage 3,"Statins, Insulin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,Mut,WT,WT
bdf66ba5-dc9c-46de-a5a6-74c212738a23,82,M,Other,G0/G1,12.6,4.08,CKD Stage 4,"Calcium Channel Blockers, ACE Inhibitors, Diuretics",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, ACE Inhibitors, Diuretics.",WT,WT,Mut,WT,WT,WT
75b27455-04cc-4ede-afac-16730ad45230,36,M,Other,G2/G2,119.2,3.24,FSGS,"Statins, ARBs",Yes,"History of hypertension and diabetes, currently managed with Statins, ARBs.",Mut,Mut,Mut,Mut,WT,Mut
5024bdc6-dcb3-4df3-93ee-cdc6ebd14d2c,27,M,Other,G1/G2,20.7,0.57,Diabetic Nephropathy,"Insulin, ACE Inhibitors",Yes,"History of hypertension and diabetes, currently managed with Insulin, ACE Inhibitors.",Mut,WT,Mut,Mut,WT,Mut
67884209-92ca-425a-ade5-93329364f3d0,53,F,Hispanic,G0/G0,17.8,3.7,CKD Stage 4,"Statins, Diuretics",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,Mut,WT,Mut
4a1dab32-6aed-4dc7-a3e0-5309b5a1b949,69,F,Other,G0/G1,58.5,2.81,FSGS,"Diuretics, ACE Inhibitors",Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,Mut,Mut,Mut,WT,WT,WT
f758dce2-0556-4aea-a7b0-32831d7c0098,19,M,African American,G1/G1,51.3,3.07,Diabetic Nephropathy,ARBs,Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,Mut,Mut,WT,Mut,Mut,Mut
f296d9f0-cd23-42c2-abff-e17b532401fc,77,M,African American,G0/G1,90.5,4.63,CKD Stage 4,"ARBs, Statins",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,Mut,WT,Mut,Mut,Mut,WT
b08a4895-d4ff-4666-b5c8-e90d9e3d750d,78,M,Hispanic,G1/G2,14.2,1.2,CKD Stage 4,Erythropoietin,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,Mut,WT,Mut
6fcc57dd-168f-4e12-9ca2-60c9eb7607c9,78,M,African American,G0/G1,105.5,4.79,Nephrotic Syndrome,"Diuretics, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics, Calcium Channel Blockers.",WT,WT,WT,WT,Mut,Mut
6f887f28-3e49-4d09-9b19-d8b8d8302081,75,F,Other,G0/G1,83.7,1.67,Diabetic Nephropathy,ACE Inhibitors,Yes,No significant change in eGFR. Continuing current treatment: ACE Inhibitors.,Mut,Mut,Mut,WT,WT,Mut
1422373f-8622-48d1-a683-e10796c044d0,78,M,Asian,G1/G1,110.4,3.07,Diabetic Nephropathy,Insulin,Yes,"History of hypertension and diabetes, currently managed with Insulin.",WT,WT,WT,Mut,Mut,WT
beed10b6-4f6e-474b-9eda-b0276550f74a,36,F,Hispanic,G0/G0,97.1,3.53,CKD Stage 3,"Erythropoietin, ACE Inhibitors, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, ACE Inhibitors, Statins.",WT,Mut,WT,WT,WT,WT
c77444cb-5543-4c3c-b8b8-f24e56ea57b3,87,M,Other,G1/G2,33.8,1.44,CKD Stage 2,"Insulin, ACE Inhibitors, Diuretics",Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,WT,Mut,Mut,WT,Mut
a21b0307-82af-485c-938d-994c2b0abedd,70,F,Hispanic,G1/G1,101.1,2.42,Diabetic Nephropathy,"ACE Inhibitors, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, ARBs.",Mut,Mut,Mut,WT,WT,Mut
31a3ac4d-828c-47e7-87d5-b7be1d30d990,73,F,Other,G0/G0,119.5,4.13,CKD Stage 1,Erythropoietin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,Mut,WT,Mut
59e1ac09-5970-4859-86b6-e4ade7ea8d5a,22,F,Asian,G0/G1,34.5,2.55,CKD Stage 4,ARBs,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs.",Mut,WT,Mut,Mut,Mut,Mut
a53bc024-d1a6-4d87-b54e-2019ba35844e,46,F,Hispanic,G1/G1,43.8,4.56,CKD Stage 4,"ARBs, ACE Inhibitors, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,WT,Mut,Mut
1a5165ca-3c7c-4d85-a5cf-0041d0a643fe,73,M,Other,G1/G2,31.2,3.4,Diabetic Nephropathy,Calcium Channel Blockers,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,WT,Mut,Mut
2c6a6e9a-3280-47a1-8187-222b257d5e52,73,M,African American,G0/G1,65.5,3.34,Diabetic Nephropathy,"Calcium Channel Blockers, Erythropoietin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Erythropoietin.",Mut,WT,Mut,WT,WT,WT
c257cf73-c29d-482b-a722-796e9a36d1ec,19,M,African American,G2/G2,87.8,4.64,CKD Stage 1,"Statins, ACE Inhibitors, ARBs",Yes,"History of hypertension and diabetes, currently managed with Statins, ACE Inhibitors, ARBs.",Mut,Mut,WT,WT,WT,Mut
f387e1bd-2d59-42c6-934a-5a2fa7cf705c,49,F,Hispanic,G0/G0,40.2,4.71,Nephrotic Syndrome,Erythropoietin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,WT,WT,WT
76c5a0dc-7e7e-4419-a0c1-4035c5d95f51,41,M,African American,G1/G2,102.9,4.61,CKD Stage 2,"ACE Inhibitors, Statins",Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,WT,Mut,WT,Mut,WT,WT
9458054e-c287-4f06-9050-f7efc1235c91,66,F,Asian,G0/G1,29.8,0.55,CKD Stage 2,"Insulin, Erythropoietin, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with Insulin, Erythropoietin, Calcium Channel Blockers.",WT,WT,Mut,Mut,Mut,WT
e1cde87f-ec95-4f87-ae5e-c36572eb7474,50,M,Caucasian,G2/G2,13.3,0.6,FSGS,ARBs,Yes,"History of hypertension and diabetes, currently managed with ARBs.",Mut,WT,WT,WT,Mut,WT
fc8d5b93-a2a2-491f-a49b-1cd99082889b,34,F,Hispanic,G1/G2,31.9,0.91,Nephrotic Syndrome,"Erythropoietin, Diuretics, Statins",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, Diuretics, Statins.",Mut,Mut,Mut,WT,Mut,WT
f891b0c3-dd3f-487e-92bd-c6619fe0a8c7,53,F,African American,G2/G2,97.2,3.14,CKD Stage 2,Erythropoietin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,Mut,Mut,Mut
70944bdb-26a5-44e3-90ee-7a92a09151e0,67,F,Caucasian,G2/G2,48.8,4.54,Diabetic Nephropathy,Statins,Yes,No significant change in eGFR. Continuing current treatment: Statins.,WT,WT,Mut,Mut,Mut,Mut
a1a27485-7134-4c2a-b80b-3657117b355b,32,M,Hispanic,G1/G2,97.0,2.11,CKD Stage 1,Erythropoietin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,Mut,WT,WT
97674900-4651-4367-8bdc-43184d85a3d2,19,F,Caucasian,G1/G2,72.4,1.95,CKD Stage 2,"ACE Inhibitors, Statins, Diuretics",Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,WT,WT,WT,Mut,WT,Mut
12fe28bf-81e0-4489-9a18-e2a30e614bcd,58,F,Caucasian,G0/G1,15.5,2.72,CKD Stage 1,"Statins, ACE Inhibitors",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,Mut,Mut,WT
09a0a0f6-73b0-4091-b634-c1694f76e388,54,M,Other,G0/G0,110.3,1.78,Diabetic Nephropathy,"ACE Inhibitors, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,WT,Mut,WT
497de16d-d4ea-420a-9e65-96540e9058b6,56,F,Hispanic,G1/G1,54.0,3.0,CKD Stage 3,"Insulin, ACE Inhibitors",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,Mut,WT,Mut
fa34d2e8-dd3f-4d7e-a508-dc9513a4a492,21,M,African American,G0/G0,25.3,4.97,Diabetic Nephropathy,"Erythropoietin, Statins, ARBs",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,Mut,WT,WT
98159d6c-9d71-4084-971d-abf9daf481a7,32,M,Hispanic,G0/G0,39.0,3.6,Diabetic Nephropathy,"Diuretics, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,WT,WT,Mut
949077c2-7674-456f-a26d-719d81cf3252,70,F,African American,G2/G2,68.0,3.1,Nephrotic Syndrome,"Diuretics, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,Mut,Mut,WT
bd29ede9-cab4-423b-b448-83858de7ad6c,49,M,African American,G0/G0,116.9,0.77,CKD Stage 1,"ARBs, Statins, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,Mut,WT,Mut
e8b77f7b-7321-4f6b-8a80-76ece5582e16,76,M,Other,G0/G0,110.6,1.48,CKD Stage 3,"Statins, Insulin",Yes,"History of hypertension and diabetes, currently managed with Statins, Insulin.",WT,Mut,WT,WT,Mut,Mut
30307633-a6de-41d8-9258-17b7cf501889,57,M,Caucasian,G1/G2,106.4,3.85,CKD Stage 2,Statins,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,Mut,Mut
80599b93-79c2-42e4-9ae1-a991524f93ff,88,M,Hispanic,G1/G2,33.3,2.29,CKD Stage 4,"Diuretics, ACE Inhibitors, Statins",Yes,"History of hypertension and diabetes, currently managed with Diuretics, ACE Inhibitors, Statins.",Mut,Mut,WT,WT,Mut,Mut
73557b9d-0fd6-447e-b52d-4af2269ed4c9,42,F,Caucasian,G2/G2,40.4,3.23,FSGS,"ACE Inhibitors, Erythropoietin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors, Erythropoietin.",WT,WT,WT,WT,WT,WT
d65e59dd-e62d-4d06-8f9b-85581a7f195b,52,M,African American,G2/G2,21.1,1.52,FSGS,"Erythropoietin, Statins, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, Statins, Calcium Channel Blockers.",Mut,WT,WT,Mut,Mut,WT
15969802-b6dd-4257-bb7d-9f1c57eb89b1,62,F,Other,G1/G1,90.7,0.92,FSGS,"Insulin, Statins, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,WT,WT,WT
0a0537f0-2c2c-422b-a568-95c6812a1f9b,36,M,Asian,G1/G2,46.7,1.3,CKD Stage 3,ARBs,Yes,No significant change in eGFR. Continuing current treatment: ARBs.,WT,Mut,Mut,WT,Mut,WT
fdb1429e-7010-4d13-b526-b22d3f6c21f7,23,M,Other,G1/G1,101.9,2.86,CKD Stage 2,Calcium Channel Blockers,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,WT,WT,Mut,Mut,Mut,Mut
9c1c3517-85d2-40a6-8629-5b5d707df251,87,F,Asian,G1/G1,50.1,0.56,CKD Stage 3,"Erythropoietin, Diuretics",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,WT,WT,Mut
eafde7d9-5f73-4a3e-9d28-6aa428a39779,36,F,Asian,G0/G0,36.9,3.83,CKD Stage 4,"ARBs, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,WT,Mut,Mut
c6435300-68a5-4c68-a32d-bb5e486bb6bf,51,F,Hispanic,G1/G2,74.8,4.75,CKD Stage 3,"ARBs, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, ACE Inhibitors.",Mut,WT,Mut,Mut,Mut,Mut
0d67d38e-990f-4c5b-adcc-3daf569f3ab3,81,M,Asian,G0/G1,67.6,1.8,FSGS,"ARBs, Diuretics, Statins",Yes,"History of hypertension and diabetes, currently managed with ARBs, Diuretics, Statins.",Mut,WT,Mut,WT,Mut,WT
55ab946d-a5b5-4dc2-a181-c85eca0ac6ac,33,M,Asian,G1/G1,10.6,2.09,Diabetic Nephropathy,ACE Inhibitors,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,WT,Mut,Mut,WT,WT
8ed6ad5e-1831-4aa3-9466-9d1910df9974,36,M,Asian,G2/G2,111.0,1.81,CKD Stage 1,"Diuretics, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,WT,Mut,Mut
4082cbb9-48bd-4b3e-a2f5-df2badaa44ca,40,F,Hispanic,G2/G2,25.3,3.95,CKD Stage 3,Statins,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,WT,Mut,Mut
f6e39356-a814-4562-9a00-3f16b9469bcf,66,F,African American,G0/G1,67.9,3.62,FSGS,"Erythropoietin, Diuretics, Statins",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin, Diuretics, Statins.",Mut,Mut,Mut,Mut,Mut,Mut
267eddce-df8f-4197-9a4a-99b2e806133c,21,F,African American,G0/G1,77.7,1.86,CKD Stage 2,"Insulin, Diuretics, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Insulin, Diuretics, ARBs.",Mut,WT,Mut,WT,Mut,WT
a9e27ba9-952e-4abb-94dd-5061555736f8,76,M,African American,G0/G0,39.7,4.94,CKD Stage 1,"Insulin, ACE Inhibitors",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,Mut,Mut,WT,WT,WT
4f6b58c8-598d-4aec-aaaf-e5432434a678,84,M,Other,G1/G2,25.0,4.53,Nephrotic Syndrome,Diuretics,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics.",Mut,WT,Mut,WT,WT,WT
a981b098-b2cf-452d-a7f3-33b3f7baf55e,33,M,Caucasian,G0/G1,21.4,0.61,FSGS,"Statins, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,Mut,WT,WT
b576255e-9854-4f22-a102-f9c964575bc4,51,F,Other,G0/G0,57.6,3.36,CKD Stage 2,Calcium Channel Blockers,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,Mut,Mut,Mut
8f158449-4f40-422f-95b0-2530f020e992,30,F,Hispanic,G1/G1,53.0,3.64,CKD Stage 1,"Statins, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, Calcium Channel Blockers.",WT,WT,Mut,Mut,WT,Mut
54170a17-caaa-4bbe-a4bb-f962606e0e1c,56,M,Other,G1/G2,14.7,4.58,CKD Stage 2,"Erythropoietin, Statins",Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,Mut,WT,WT,Mut,WT,Mut
b3ecb951-ab8c-4f97-a0b7-1785d02ce0c1,67,M,Caucasian,G0/G1,48.7,3.74,CKD Stage 3,"Erythropoietin, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, ARBs.",Mut,Mut,Mut,WT,Mut,Mut
ff4625af-bd20-463b-b275-b5f3d436a7a8,41,F,Caucasian,G1/G1,74.8,3.11,FSGS,"Calcium Channel Blockers, Statins, ACE Inhibitors",No,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, Statins, ACE Inhibitors.",WT,WT,WT,WT,WT,WT
17ec889c-86c1-46cb-a996-30f7af77520e,78,F,Caucasian,G0/G1,21.6,4.46,Nephrotic Syndrome,"Calcium Channel Blockers, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, Statins.",WT,WT,Mut,WT,WT,WT
822c4d32-6c64-4c15-aba3-01cba561e1e9,21,M,Hispanic,G0/G0,86.9,2.2,Nephrotic Syndrome,"Insulin, ARBs, Erythropoietin",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,Mut,Mut,Mut,WT,WT
4f11d8dc-5cd3-4369-84aa-c1b75ca0c428,73,M,African American,G2/G2,12.7,4.82,CKD Stage 1,ACE Inhibitors,Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors.",WT,WT,Mut,Mut,WT,Mut
577bc55a-36d5-4494-b37f-d50d2e25b5ee,85,F,Caucasian,G0/G1,72.7,2.63,CKD Stage 3,"Insulin, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,Mut,Mut,WT
31274148-7c7c-404e-8422-d03ef29a6339,34,F,African American,G0/G0,64.9,0.73,FSGS,"ACE Inhibitors, ARBs",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,Mut,WT,WT
27aa7cbc-2337-4bbc-bffe-77c839feb99c,86,M,Other,G2/G2,65.0,2.3,CKD Stage 1,"Erythropoietin, ACE Inhibitors, Insulin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,WT,Mut,Mut
c9c23e69-d82c-4565-8bb9-07ec13c11754,60,M,Caucasian,G0/G1,70.2,3.8,Diabetic Nephropathy,"ACE Inhibitors, ARBs, Statins",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,WT,Mut,WT
8a2e6a93-c558-4bb2-81f7-f3fb19e45c6a,34,F,African American,G0/G0,13.9,2.78,Nephrotic Syndrome,"Statins, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,WT,WT,WT
86cac6f4-e238-4e93-bd17-c5e8d5ca69ab,66,M,Other,G1/G2,15.7,3.95,Nephrotic Syndrome,Statins,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,Mut,WT,Mut
e05b46c5-5636-4094-a974-31db09a9d1c1,61,F,African American,G0/G1,35.5,3.15,CKD Stage 2,"Erythropoietin, Insulin",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, Insulin.",WT,WT,WT,WT,WT,WT
98e52499-218c-4e1c-9e37-4f7ac42cbc39,41,F,African American,G1/G1,48.5,3.45,CKD Stage 2,"ARBs, Insulin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,WT,WT,Mut
2e4bebc4-2989-4880-a77d-1be96070b6a1,81,F,Caucasian,G1/G2,88.4,4.74,Diabetic Nephropathy,"Diuretics, Erythropoietin, ARBs",Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,Mut,Mut,WT,WT,Mut,Mut
9feefdff-c566-4a81-b15e-54f6d4d30795,80,F,African American,G0/G1,110.3,4.29,FSGS,Diuretics,Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,WT,WT,Mut,WT,WT,WT
b89f72f3-2a60-4652-a714-7668cf1d7d3a,76,M,African American,G1/G2,102.0,1.72,FSGS,"Diuretics, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, ACE Inhibitors.",WT,Mut,Mut,Mut,WT,Mut
5d42b9e9-692e-47b6-8b2f-6d5c700b5d5f,23,M,Caucasian,G1/G2,30.3,2.44,CKD Stage 1,"Diuretics, ACE Inhibitors, Insulin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,Mut,WT,WT
f836f571-3cce-476c-b836-c448ad261ec5,73,F,African American,G0/G0,70.9,4.79,Nephrotic Syndrome,"Calcium Channel Blockers, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,Mut,Mut,WT,Mut,Mut
c09cb506-48f1-496d-9c4f-fb4671b701aa,34,M,Hispanic,G1/G1,19.4,1.62,FSGS,"Diuretics, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,Mut,Mut,Mut
3be79df4-72ec-416e-88a7-23e9bfa016c2,19,M,Hispanic,G2/G2,82.7,4.26,Diabetic Nephropathy,Statins,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,WT,Mut,WT
f7315749-4f39-49a8-bd3a-258288b4f474,89,M,Asian,G0/G0,73.8,0.86,FSGS,"Diuretics, ACE Inhibitors, Statins",Yes,"History of hypertension and diabetes, currently managed with Diuretics, ACE Inhibitors, Statins.",WT,Mut,Mut,Mut,Mut,WT
e76adca9-7811-4802-88cc-7cfecf01f944,40,M,Other,G0/G0,35.6,3.45,CKD Stage 2,"Insulin, Statins, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin, Statins, Calcium Channel Blockers.",Mut,WT,WT,WT,Mut,Mut
ada58417-5e2a-432d-b1ab-0b56d5c9fdc7,63,M,Other,G0/G1,48.5,0.85,CKD Stage 4,Insulin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin.",WT,WT,WT,Mut,Mut,Mut
70cafdd8-fc04-4f08-9207-0158f2771f63,72,F,Caucasian,G0/G0,45.9,4.05,CKD Stage 3,"Erythropoietin, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,WT,Mut,WT
c7332304-4822-4120-84f9-eccd7630a8a7,21,M,Other,G0/G1,98.9,2.8,Diabetic Nephropathy,"Insulin, Calcium Channel Blockers, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin, Calcium Channel Blockers, Diuretics.",WT,Mut,WT,WT,Mut,WT
6b2d5b09-8707-4ad4-80be-7e3561c2645a,90,F,Other,G0/G0,103.2,2.87,CKD Stage 1,"Statins, Erythropoietin, Insulin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,WT,Mut,WT
331f63fb-d11f-48c0-a97c-a4fff75d599f,64,M,Asian,G1/G1,92.3,1.02,CKD Stage 2,"Erythropoietin, Statins",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,WT,Mut,Mut
df7d0dd7-236e-4608-9acb-394acd1f5318,75,F,Caucasian,G2/G2,101.1,4.94,FSGS,Calcium Channel Blockers,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers.",Mut,WT,Mut,Mut,Mut,Mut
7b07fd31-a424-4f23-8d5b-a7cd400035f0,70,F,Other,G0/G1,73.4,3.35,Diabetic Nephropathy,ARBs,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,WT,Mut,Mut
ef2ddcc4-8df6-41da-9f07-c1a5dfc620ce,78,M,Caucasian,G0/G0,101.7,0.61,CKD Stage 2,ARBs,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,Mut,Mut,WT,Mut,WT
8412a335-d88c-456d-b61e-5fdb1a435206,33,F,Hispanic,G2/G2,77.0,0.98,Nephrotic Syndrome,ACE Inhibitors,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,Mut,Mut,Mut
1578d709-48f9-43d0-9fea-e1e0d9e604b3,35,M,Other,G2/G2,19.2,4.53,FSGS,"Diuretics, Erythropoietin, Statins",Yes,"History of hypertension and diabetes, currently managed with Diuretics, Erythropoietin, Statins.",Mut,Mut,Mut,WT,Mut,WT
73069588-45d5-468d-a90a-3abbc35b9fea,81,F,African American,G2/G2,66.9,2.86,FSGS,"Diuretics, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, Calcium Channel Blockers.",Mut,Mut,WT,WT,WT,WT
d4bf7a4b-25b8-442f-836b-15c7e7c225da,53,F,African American,G1/G1,41.3,1.03,CKD Stage 3,"Statins, ARBs",Yes,"History of hypertension and diabetes, currently managed with Statins, ARBs.",WT,Mut,Mut,WT,WT,Mut
e916da57-f248-43ab-977a-8a5f6ffe33b3,44,M,African American,G2/G2,109.3,4.82,FSGS,"Calcium Channel Blockers, ARBs, ACE Inhibitors",Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,WT,Mut,WT,Mut,Mut
e27718c5-737d-4fb6-9113-76e038d77b9a,84,M,Asian,G1/G1,111.0,3.72,Diabetic Nephropathy,Statins,Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,Mut,Mut,Mut,WT,WT,Mut
6a36af18-06d3-4b93-ae33-688d597e6845,32,F,African American,G0/G1,90.0,1.97,FSGS,"Diuretics, Statins",Yes,"History of hypertension and diabetes, currently managed with Diuretics, Statins.",WT,Mut,WT,Mut,WT,Mut
5fbbf0b1-8083-49c8-a57e-01c90da23e5c,22,M,Caucasian,G0/G1,74.5,4.42,CKD Stage 2,"ARBs, Diuretics, Statins",Yes,"History of hypertension and diabetes, currently managed with ARBs, Diuretics, Statins.",WT,Mut,WT,Mut,Mut,WT
14e4180c-fe99-46a3-a2db-c8503c5bf3a7,29,M,African American,G1/G2,17.4,3.01,CKD Stage 2,"ARBs, ACE Inhibitors, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,Mut,Mut,WT
519554e3-0737-4c86-b97b-5f515ffa46ef,55,F,Asian,G1/G2,75.8,2.95,CKD Stage 3,ARBs,Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,WT,Mut,Mut,Mut,Mut,WT
b6f6dbf1-d6d4-41cc-995d-82f8ee4a9b5d,32,M,Asian,G1/G1,82.7,2.06,CKD Stage 4,"ARBs, Statins, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,Mut,Mut,WT
25637cc3-ca97-4bf5-95d5-96afa663d2cd,25,F,Hispanic,G1/G1,55.2,4.14,CKD Stage 4,"Diuretics, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, ACE Inhibitors.",Mut,Mut,WT,Mut,WT,Mut
eada79a3-4970-4d9a-89ce-3cfb2339ba19,46,M,Other,G0/G1,95.8,1.0,FSGS,"Diuretics, ARBs, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,WT,Mut,Mut
d4c3a832-b231-460b-b8f2-ce6bd46b415d,26,M,Other,G0/G1,49.8,1.39,CKD Stage 2,"Statins, Erythropoietin, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,Mut,Mut,WT
781799ff-b49e-44cc-8243-69e72387eaf6,49,M,African American,G0/G0,93.1,2.87,FSGS,"Calcium Channel Blockers, Statins",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,WT,Mut,Mut,WT,WT
e7e646c7-0158-4463-9d87-76a072d78bdd,49,M,Hispanic,G0/G0,99.4,2.2,CKD Stage 4,Calcium Channel Blockers,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers.",Mut,WT,WT,WT,Mut,WT
3735262d-4184-4b03-84dd-7054144823f7,87,M,African American,G2/G2,97.2,1.37,FSGS,"Calcium Channel Blockers, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Diuretics.",Mut,WT,Mut,Mut,Mut,WT
f0b2a5d1-8c7e-4f42-a646-eaf9d5c0244d,78,F,Hispanic,G1/G2,20.2,4.85,FSGS,"Statins, Diuretics",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,Mut,Mut,Mut
6c5a6c93-871c-4884-9bdf-90f2ba2c0f19,31,F,Caucasian,G2/G2,117.3,2.29,CKD Stage 2,"Diuretics, Statins",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,WT,WT,WT
3cd5fd7f-49c1-4669-86b3-3fe61c76bdf6,44,F,Other,G0/G1,19.2,2.31,Diabetic Nephropathy,"Insulin, Erythropoietin",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,WT,WT,Mut,Mut,Mut,Mut
3d0a5f0c-0c39-4ec7-9f31-74054d183eba,37,M,Hispanic,G2/G2,75.9,4.42,CKD Stage 3,"ARBs, Insulin, Statins",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,Mut,Mut,Mut
9f708368-cb3c-48ca-a392-57316b79afcc,28,M,Asian,G0/G0,51.3,3.91,CKD Stage 2,"Erythropoietin, ACE Inhibitors, ARBs",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, ACE Inhibitors, ARBs.",WT,Mut,WT,WT,Mut,Mut
d6312a80-1c61-4ec2-9014-2131750565f5,85,F,Caucasian,G2/G2,56.0,0.54,CKD Stage 1,"Diuretics, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,WT,WT,Mut
893ad232-98c3-43ca-bff4-cec6e7b7b4c6,44,F,Other,G2/G2,37.6,2.58,CKD Stage 3,"Erythropoietin, ARBs, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, ARBs, Calcium Channel Blockers.",Mut,WT,Mut,Mut,WT,WT
93364f7e-83ef-49f3-a1c7-cc8a04351b64,18,F,Caucasian,G0/G1,86.3,2.92,CKD Stage 3,ACE Inhibitors,Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,Mut,WT,WT,Mut,WT,Mut
4a90cd0c-24c1-43b9-b7f2-85723defa849,42,F,Hispanic,G1/G2,74.3,1.88,FSGS,"Diuretics, Insulin",Yes,"History of hypertension and diabetes, currently managed with Diuretics, Insulin.",WT,WT,WT,WT,WT,Mut
5a5226e6-9d64-4932-8066-853d6de299a1,90,M,Caucasian,G2/G2,74.6,3.95,CKD Stage 3,"Calcium Channel Blockers, Insulin, Erythropoietin",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, Insulin, Erythropoietin.",Mut,Mut,WT,WT,WT,WT
2ff3cde4-6aa4-4c9f-9217-04753d959e3f,36,M,Caucasian,G1/G2,106.2,1.96,CKD Stage 1,Insulin,Yes,"History of hypertension and diabetes, currently managed with Insulin.",Mut,Mut,Mut,Mut,Mut,WT
8603156a-15ea-4bcf-ab10-21ceaa143cd8,68,F,Asian,G1/G2,49.0,4.27,CKD Stage 3,"ACE Inhibitors, Insulin, ARBs",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,WT,Mut,WT,Mut,Mut,Mut
f4124360-1153-4e99-9c50-8720f982f4e0,33,F,Hispanic,G0/G1,12.8,2.15,CKD Stage 4,"Diuretics, Erythropoietin, Statins",Yes,"History of hypertension and diabetes, currently managed with Diuretics, Erythropoietin, Statins.",WT,WT,Mut,Mut,WT,WT
c9525185-81e0-4a5e-8b48-f49686abd4e7,64,M,African American,G2/G2,44.1,0.92,CKD Stage 3,"Insulin, ACE Inhibitors",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,Mut,WT,Mut,Mut,Mut,WT
0534a101-8ddc-4719-81f3-8dd4fd034ada,50,F,African American,G2/G2,100.6,4.38,CKD Stage 4,"Erythropoietin, Statins, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,WT,Mut,WT
0b251279-785a-45d0-9f92-a62163f4c69d,37,M,Caucasian,G0/G0,56.2,4.31,CKD Stage 1,"Erythropoietin, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,WT,WT
5f90bed6-fb25-464d-a30a-a767a2bb522b,58,M,Other,G1/G1,66.8,4.73,CKD Stage 4,"Calcium Channel Blockers, Erythropoietin",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, Erythropoietin.",WT,WT,WT,WT,Mut,WT
5b6a8102-0428-4378-bf50-23f440ef3935,23,F,Other,G0/G1,85.8,2.34,Nephrotic Syndrome,"Calcium Channel Blockers, ACE Inhibitors, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,Mut,Mut,WT
3dba6da8-5844-49fc-914b-9547c9dc72b8,29,M,African American,G0/G1,90.3,1.34,FSGS,"ACE Inhibitors, ARBs, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,WT,WT,Mut
1a89b71e-a0d5-42c8-a837-fe68bba205ca,42,M,Hispanic,G0/G0,51.7,1.79,CKD Stage 3,Insulin,Yes,"History of hypertension and diabetes, currently managed with Insulin.",Mut,Mut,WT,WT,Mut,WT
c1b5b5ca-bc35-46df-94f7-9dbac5811d2d,51,F,Hispanic,G0/G0,63.9,3.1,CKD Stage 3,"Insulin, Statins, ARBs",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,Mut,WT,WT,Mut,Mut
5a304528-0b59-4562-a227-219f551ff086,54,M,Hispanic,G2/G2,70.7,3.84,CKD Stage 3,Insulin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin.",WT,Mut,WT,Mut,Mut,WT
a48e40f1-d042-4dfa-96ab-087a8bc78e81,41,F,Caucasian,G1/G2,74.6,2.18,CKD Stage 4,"Insulin, ACE Inhibitors, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,WT,Mut,Mut
af475b49-c775-4395-9494-05f02cd2a404,30,M,Hispanic,G1/G1,27.9,2.96,Diabetic Nephropathy,Statins,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,Mut,Mut,Mut,WT,Mut
7a8104de-b205-47bb-bb16-f75776f186ab,61,F,Asian,G1/G1,14.4,4.68,CKD Stage 2,"ACE Inhibitors, Statins, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,WT,WT,Mut
2285b2ef-cfbe-4fe9-aea9-c542a1b970d0,85,M,Other,G0/G1,24.3,2.0,CKD Stage 1,Diuretics,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics.",WT,Mut,Mut,Mut,WT,Mut
f1901b7e-c6b4-49ef-b74e-ba9310275b53,36,M,Caucasian,G1/G1,43.8,1.33,Diabetic Nephropathy,Statins,Yes,"History of hypertension and diabetes, currently managed with Statins.",WT,WT,WT,Mut,WT,Mut
339b77a8-4b1f-4d7b-8977-c513752a7d25,30,F,Other,G1/G2,86.9,4.61,Nephrotic Syndrome,"Calcium Channel Blockers, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, Statins.",WT,WT,Mut,WT,Mut,WT
e2c328aa-3310-4475-8a86-22250b36e356,54,F,Other,G1/G2,68.8,2.06,Nephrotic Syndrome,"Insulin, ACE Inhibitors, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,Mut,Mut,WT
4f612217-eef1-4694-90ca-e32d0aba590e,68,M,Caucasian,G0/G1,65.0,0.7,CKD Stage 3,"ACE Inhibitors, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, Diuretics.",Mut,WT,Mut,WT,Mut,Mut
d0be73ee-fd37-4539-a5f2-02f983f02dc7,79,M,Hispanic,G1/G2,29.7,2.29,FSGS,Statins,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,WT,WT
095ffa81-40d9-4bce-b930-ba208b040f49,82,F,Asian,G0/G0,63.5,4.82,CKD Stage 4,"Calcium Channel Blockers, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,WT,Mut,Mut
493e904d-30ec-4796-a59b-457fc0d7ac73,60,F,African American,G0/G1,117.9,2.89,CKD Stage 4,"ACE Inhibitors, ARBs, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, ARBs, Calcium Channel Blockers.",Mut,Mut,WT,Mut,Mut,WT
0c3ce284-c7e5-4bbb-9cb5-1c535b62a8df,23,M,Asian,G1/G2,50.4,4.5,Nephrotic Syndrome,"Diuretics, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,Mut,WT,Mut
45f18619-54f9-4429-a7de-02ccdda4f4a7,20,F,Hispanic,G1/G1,80.0,3.18,CKD Stage 3,"ACE Inhibitors, Insulin, Statins",No,Family history of CKD noted. Genetic testing indicates mutation in WT1.,WT,WT,WT,WT,WT,WT
6fdc0bad-5e36-4127-8ca1-b45c1fdd980a,73,F,Hispanic,G1/G2,85.8,1.6,Diabetic Nephropathy,"Calcium Channel Blockers, Insulin, Erythropoietin",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, Insulin, Erythropoietin.",Mut,WT,WT,Mut,Mut,WT
7092947d-be49-49ec-a667-d3bbe3b56360,30,F,Other,G0/G0,47.2,3.37,CKD Stage 3,"Statins, ACE Inhibitors",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,Mut,WT,WT
56cb1ab0-62fb-46d7-b4db-ca07e506f670,56,M,African American,G1/G1,73.1,1.47,CKD Stage 4,"Erythropoietin, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,WT,Mut
b12b6680-7f07-4cb9-afd3-40c0f945f2fd,70,M,African American,G1/G2,82.3,1.74,CKD Stage 4,"Calcium Channel Blockers, Erythropoietin, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Erythropoietin, Diuretics.",WT,WT,WT,WT,Mut,WT
cc1b4157-ec9f-4c54-9e0a-72ab7f5db163,54,F,Other,G1/G2,79.8,1.98,CKD Stage 4,"Insulin, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Insulin, ACE Inhibitors.",Mut,Mut,Mut,Mut,Mut,WT
15260718-cd18-4a82-8447-ceab84ef4324,81,M,Other,G0/G1,84.0,1.65,CKD Stage 1,"Calcium Channel Blockers, Insulin, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,WT,Mut,Mut
6e3c4532-1434-4f62-acac-028cba220065,75,F,African American,G0/G1,78.7,1.25,CKD Stage 3,"Statins, Calcium Channel Blockers, ACE Inhibitors",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,Mut,WT,Mut
2e326567-d284-454e-bebe-c0db9a3a6103,30,F,Caucasian,G0/G1,119.1,3.07,CKD Stage 2,Calcium Channel Blockers,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,WT,Mut,Mut
1a43db54-523a-4993-8b34-46bc8ba435cc,31,F,Other,G2/G2,68.6,1.51,CKD Stage 4,"Calcium Channel Blockers, Statins",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Statins.",Mut,Mut,WT,WT,Mut,Mut
4baf0f5e-a932-4094-93f2-8f11147f6570,60,F,Caucasian,G0/G0,52.2,3.44,CKD Stage 4,"ARBs, Erythropoietin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,WT,Mut,WT
b7b8c1a5-9a45-493d-b227-890e4e76833a,49,M,Other,G1/G2,85.3,4.78,CKD Stage 1,"Insulin, Erythropoietin, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Insulin, Erythropoietin, Statins.",WT,WT,Mut,Mut,WT,WT
71a3fad2-b094-4d2a-aaa9-3b436d15f16f,43,F,Caucasian,G1/G1,17.1,0.64,FSGS,"Statins, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,Mut,WT,Mut
ba108217-0ad7-49a2-b277-16ec59fefbbc,49,F,African American,G0/G0,92.3,3.57,CKD Stage 4,"Statins, Calcium Channel Blockers, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,WT,Mut,Mut
9d66e815-5a41-43b3-a95f-176cdebac186,25,F,Asian,G0/G0,50.0,3.72,FSGS,"Erythropoietin, Statins, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,Mut,WT,WT
a3b442bd-4649-4296-af58-42c3ff86cc31,61,M,Caucasian,G1/G2,33.1,0.94,Nephrotic Syndrome,"ACE Inhibitors, Statins, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,Mut,Mut,Mut
0eaf04b5-f2a9-4c8a-8a9e-4a62fae3114b,51,F,Other,G0/G0,93.7,1.17,CKD Stage 3,ARBs,Yes,No significant change in eGFR. Continuing current treatment: ARBs.,Mut,Mut,Mut,Mut,WT,Mut
67fd64c4-a334-458a-abd2-b5121335e5db,74,F,Caucasian,G0/G1,26.1,1.82,CKD Stage 4,"Erythropoietin, ARBs",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,WT,WT,Mut
bff9507d-cd14-403e-8359-9af65d01f55f,83,F,Asian,G2/G2,109.0,4.88,Nephrotic Syndrome,Insulin,Yes,"History of hypertension and diabetes, currently managed with Insulin.",Mut,Mut,Mut,Mut,WT,Mut
07f8d4f0-f3ea-4184-a8f4-e3ceadedda80,66,M,African American,G1/G1,34.7,1.43,CKD Stage 2,"Insulin, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,Mut,Mut,WT
ad973b67-9b89-45cb-9942-644c248d31ec,85,M,Caucasian,G1/G1,83.1,2.29,CKD Stage 1,"Insulin, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,Mut,WT,WT
20509c62-08e8-45d7-b02c-1821c8040fb7,41,M,Caucasian,G1/G2,29.5,4.91,CKD Stage 3,"Diuretics, ACE Inhibitors, ARBs",Yes,"History of hypertension and diabetes, currently managed with Diuretics, ACE Inhibitors, ARBs.",WT,WT,Mut,WT,WT,WT
a52964ff-c74c-4890-bc6a-3174113634a5,79,F,African American,G2/G2,107.0,0.73,Diabetic Nephropathy,"ACE Inhibitors, ARBs, Statins",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,Mut,WT,WT
f31046dc-6202-4ee6-9cb5-e69c5dc7b3e6,45,F,Hispanic,G2/G2,11.1,2.43,CKD Stage 1,"Statins, Erythropoietin, ARBs",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,WT,Mut,Mut,Mut,Mut
2747b93c-9ae7-4eab-884a-67809136f1f8,60,F,Other,G1/G1,114.7,1.85,Diabetic Nephropathy,"ARBs, Diuretics, Erythropoietin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,WT,Mut,WT
5ef787b8-f2e6-495f-b32e-2016add702c9,78,F,Caucasian,G0/G1,17.2,2.44,CKD Stage 3,Calcium Channel Blockers,Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers.",Mut,Mut,WT,WT,WT,WT
13aec376-c359-410a-b1a6-014c5f3c44dc,82,F,Hispanic,G2/G2,61.9,3.58,FSGS,Insulin,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,WT,Mut,WT
5df06e8c-878a-4ed9-a33f-fc8292ec89af,38,F,Other,G1/G2,81.9,4.05,Diabetic Nephropathy,"Diuretics, ARBs, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,Mut,Mut,WT,Mut,Mut
4758367b-a649-4cdc-907b-907265e58f34,58,F,Hispanic,G1/G2,72.0,3.93,CKD Stage 1,"ACE Inhibitors, Statins",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Statins.",Mut,WT,Mut,Mut,WT,WT
06a241af-1d0a-47f7-b5e4-a4713fe68c9c,50,F,Hispanic,G0/G0,45.4,4.06,CKD Stage 3,"Insulin, Erythropoietin, ARBs",Yes,"History of hypertension and diabetes, currently managed with Insulin, Erythropoietin, ARBs.",WT,Mut,Mut,WT,WT,WT
848af440-7fc1-4858-afa0-d842bc55300b,79,F,African American,G1/G2,85.7,4.59,CKD Stage 4,Diuretics,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,WT,Mut,Mut
1e2595b8-8fc9-486b-a9dd-ebf563119aca,74,F,African American,G1/G2,24.8,3.87,CKD Stage 3,"Statins, ARBs, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,Mut,WT,Mut
b43bd27f-42a2-49a6-8664-12854303cbc1,51,F,African American,G0/G1,94.9,0.81,Diabetic Nephropathy,"Erythropoietin, Calcium Channel Blockers, Diuretics",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, Calcium Channel Blockers, Diuretics.",Mut,Mut,WT,WT,Mut,Mut
9ca3fbb3-ff11-48ba-b6ee-1640723ef466,64,F,Caucasian,G1/G1,38.1,3.86,CKD Stage 1,ACE Inhibitors,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,Mut,WT,WT
ffa623d0-ea9e-4c8d-b1a8-b71f491b90e9,20,F,African American,G2/G2,106.0,1.97,FSGS,"Diuretics, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,WT,WT,WT
22bf18f5-1f65-4a87-b33e-e3447dbf4bc1,29,F,Other,G0/G1,92.7,3.95,CKD Stage 4,"Statins, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,WT,Mut,Mut
2c33350c-73b9-41d8-92f5-131ada52d2ee,73,M,Asian,G2/G2,42.3,3.31,CKD Stage 4,ACE Inhibitors,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,WT,Mut,WT
ff4c96d6-71f2-4e8f-b69f-68c3e60fd420,59,F,Caucasian,G2/G2,111.8,4.52,Nephrotic Syndrome,"ARBs, Calcium Channel Blockers, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,WT,WT,WT
f7b217c7-ae92-4a71-8f7d-cb431679742f,87,F,African American,G1/G1,105.8,4.68,Nephrotic Syndrome,ARBs,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,Mut,WT,WT
aaf78c67-51d0-4109-bc90-2838d8741408,21,M,Asian,G0/G0,101.8,2.19,CKD Stage 4,"Calcium Channel Blockers, Erythropoietin, ARBs",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, Erythropoietin, ARBs.",Mut,WT,Mut,Mut,Mut,WT
8ccc9cea-109f-48ee-b5a4-720058f0dd23,33,M,Caucasian,G2/G2,110.5,3.76,CKD Stage 1,Calcium Channel Blockers,Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers.",WT,WT,Mut,Mut,Mut,Mut
4cc9f5f2-e42e-4037-8a55-2ea08acbbe09,29,F,Asian,G1/G1,66.0,4.75,CKD Stage 1,Statins,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,Mut,Mut,Mut
b5a5f8e6-b639-4f04-a852-4385d9f2dd0d,73,F,Caucasian,G0/G0,81.5,4.15,CKD Stage 4,Diuretics,Yes,"History of hypertension and diabetes, currently managed with Diuretics.",Mut,WT,WT,WT,WT,WT
2c913a7c-a340-4f08-b341-91b8ed6522b4,37,M,Asian,G0/G0,16.7,4.11,Diabetic Nephropathy,"Erythropoietin, Diuretics, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,Mut,WT,Mut,WT,WT,WT
3967e60a-823d-4107-9c8a-c066cb2fafa3,41,F,African American,G0/G1,13.3,1.42,CKD Stage 4,"Diuretics, Calcium Channel Blockers, Insulin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics, Calcium Channel Blockers, Insulin.",Mut,WT,WT,Mut,WT,Mut
cac4d0eb-3373-430e-bc31-a5971f119c0f,36,F,African American,G2/G2,51.5,3.19,FSGS,ARBs,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs.",WT,WT,Mut,WT,WT,Mut
7e7838c9-ca55-438b-bc9a-be10238d6f44,78,F,Asian,G2/G2,58.4,4.36,Diabetic Nephropathy,"ACE Inhibitors, Diuretics, Statins",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, Diuretics, Statins.",Mut,Mut,WT,Mut,Mut,WT
9280c5aa-8dd4-495b-9c63-b6f306ba8cd3,43,M,Caucasian,G2/G2,24.3,4.74,CKD Stage 2,"ACE Inhibitors, Erythropoietin, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Erythropoietin, Calcium Channel Blockers.",Mut,Mut,WT,WT,WT,Mut
fba6abf7-cdbc-4653-b7a7-e8b75e70f65f,56,F,Asian,G2/G2,67.2,3.1,CKD Stage 3,Diuretics,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,WT,Mut,WT
e25df9a8-9ca8-45c4-a138-afe08d38bbd8,41,M,Caucasian,G0/G0,101.9,1.57,CKD Stage 4,"ACE Inhibitors, Insulin",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Insulin.",Mut,Mut,Mut,WT,Mut,Mut
65edcfe3-4f2d-4d3f-90d4-de39161237c9,51,F,African American,G1/G1,82.1,2.82,CKD Stage 3,"ARBs, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, Diuretics.",Mut,Mut,Mut,WT,Mut,Mut
7a89cbeb-b807-478a-b788-f5d1ffe575f6,72,M,Other,G0/G1,20.4,4.89,Diabetic Nephropathy,ACE Inhibitors,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,Mut,Mut,Mut
68d0a2a8-c4e7-47dd-a929-de738693fd9d,82,M,Asian,G2/G2,31.4,4.28,CKD Stage 2,ARBs,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,Mut,WT,WT
20156a72-12e1-43a6-932c-ae01d2c65ee4,30,M,Other,G0/G1,102.8,3.88,CKD Stage 2,"Insulin, Statins, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Insulin, Statins, ARBs.",Mut,WT,Mut,Mut,Mut,Mut
12fc7a87-a470-4d48-9128-b9b1f8ede0ca,59,M,Hispanic,G0/G0,18.2,3.69,Nephrotic Syndrome,"ARBs, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,WT,WT,Mut
8471b4b0-ae1b-4f69-b740-d83173318749,49,F,Caucasian,G1/G2,53.0,1.37,Diabetic Nephropathy,"ACE Inhibitors, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, ARBs.",Mut,WT,Mut,WT,WT,WT
d43cdd6d-e0c1-4f1e-a0da-897258321ee4,53,F,African American,G0/G0,67.3,2.86,Diabetic Nephropathy,"Insulin, Statins, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,Mut,WT,WT
96792482-a3c9-48e4-8d22-38e6c7bf4fbc,61,F,African American,G1/G2,102.2,1.65,Nephrotic Syndrome,"Statins, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,WT,Mut,Mut,WT,WT,WT
21084dd9-f75d-4e3c-848d-56502e9522d6,64,M,Asian,G1/G2,56.4,3.37,Diabetic Nephropathy,"Calcium Channel Blockers, Erythropoietin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Erythropoietin.",Mut,Mut,Mut,Mut,Mut,Mut
de431e06-e924-4069-80bb-ae526ec01269,30,F,Caucasian,G2/G2,64.4,3.16,Nephrotic Syndrome,"ACE Inhibitors, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,WT,WT,WT
84a2576c-1fc9-45f8-94d6-07350e2f8958,33,M,Hispanic,G2/G2,84.0,4.57,CKD Stage 4,"Erythropoietin, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,Mut,WT,Mut
2976aab2-2a26-4770-8ddb-1b36272c0588,73,M,Caucasian,G2/G2,29.9,3.34,CKD Stage 3,Diuretics,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,Mut,Mut,Mut
39b86bb2-b596-4a7c-af4a-fa885299e505,53,F,African American,G1/G1,60.4,4.96,CKD Stage 3,ARBs,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,WT,Mut,WT
84d67c4f-f0df-4684-b28e-41225894f7f1,86,M,Hispanic,G1/G1,21.1,3.75,Nephrotic Syndrome,"Diuretics, Insulin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,WT,Mut,Mut
143029a9-d88f-4c94-88b7-63d5e519dd7e,74,F,Caucasian,G0/G1,45.5,1.0,FSGS,"Insulin, Erythropoietin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin, Erythropoietin.",Mut,WT,Mut,WT,WT,WT
f4d375c1-a293-49fa-b240-d7a14027ab7d,69,F,Caucasian,G1/G1,68.6,2.29,CKD Stage 4,Calcium Channel Blockers,Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers.",Mut,WT,Mut,WT,Mut,WT
a0017720-200b-4903-8642-6c458d03f17a,37,F,African American,G1/G2,34.7,3.63,CKD Stage 2,ARBs,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs.",Mut,WT,WT,WT,Mut,WT
17eaec83-8892-442f-9d4b-2bf94d85e9c7,79,F,Asian,G2/G2,70.6,3.06,CKD Stage 4,Calcium Channel Blockers,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,Mut,Mut,Mut
9780c215-2b2b-48e9-a417-c09380a8a23d,48,F,Other,G1/G1,18.5,3.62,CKD Stage 3,"ARBs, Insulin, Erythropoietin",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,WT,WT,Mut,Mut,WT,WT
2bd3cdcd-2779-4685-94a5-3fdef10d27c8,88,M,Asian,G1/G1,73.2,0.74,FSGS,"Statins, Insulin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,WT,Mut,WT
e6e987ca-b87b-4384-9fdd-de2ea8a2b7ad,36,M,Hispanic,G0/G0,115.0,1.74,CKD Stage 3,"ACE Inhibitors, Erythropoietin, Insulin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,Mut,WT,Mut
ec86a890-d7b0-4bdc-966e-3cbe9aea622f,56,F,Caucasian,G2/G2,97.8,2.79,CKD Stage 4,Calcium Channel Blockers,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,Mut,WT,WT
dd20c3bf-d342-4f08-8a8b-b5b490494583,85,F,Caucasian,G0/G1,37.4,3.21,Diabetic Nephropathy,Calcium Channel Blockers,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers.",WT,WT,Mut,WT,Mut,WT
f2d3f761-0ba3-4279-94cb-056407437c3b,67,F,Asian,G1/G2,25.2,2.04,CKD Stage 1,"Diuretics, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, ARBs.",Mut,Mut,Mut,WT,WT,Mut
43c07d43-93a7-4792-8561-b8dca4364fcd,47,F,African American,G1/G1,59.7,0.92,CKD Stage 3,Insulin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,WT,WT,WT
92779574-c457-4cc3-b5f7-89bca6b07458,18,F,Asian,G1/G1,13.0,4.57,FSGS,"Calcium Channel Blockers, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, ACE Inhibitors.",WT,WT,Mut,WT,WT,Mut
07c0d116-a394-4d54-9e3c-5a886aa56e6d,37,F,Other,G0/G1,108.1,3.68,Diabetic Nephropathy,Insulin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,WT,WT,Mut
8baaf744-a08d-421b-a395-4cb17f7f6c0a,62,M,Other,G2/G2,28.4,0.95,CKD Stage 2,"ARBs, Insulin, Diuretics",Yes,"History of hypertension and diabetes, currently managed with ARBs, Insulin, Diuretics.",Mut,Mut,Mut,WT,WT,Mut
4d560a3d-f4e7-469a-a454-09374a27ebf2,36,M,Asian,G0/G1,97.3,0.69,CKD Stage 1,"Calcium Channel Blockers, Erythropoietin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,Mut,WT,Mut
ceae71cf-ce00-4af0-beb0-51817ba24588,75,M,Hispanic,G1/G2,54.5,2.2,CKD Stage 4,Statins,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,Mut,Mut,Mut
741b77f5-4c24-4053-a7f5-ae02af5b8f47,25,M,Caucasian,G0/G0,43.8,3.14,FSGS,"ARBs, Erythropoietin, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,Mut,Mut,WT
2877f5d9-0f56-45f8-b048-faa112ae5c22,24,F,Other,G2/G2,103.4,2.79,Nephrotic Syndrome,"ACE Inhibitors, ARBs, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, ARBs, Calcium Channel Blockers.",Mut,WT,WT,Mut,WT,WT
76e5ae78-7bf7-41d3-aa66-2fce7089fc6d,19,M,Asian,G0/G1,109.0,1.02,CKD Stage 3,ARBs,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs.",Mut,WT,Mut,WT,Mut,Mut
24c778a5-9b4e-464b-9716-dc2e343ada2a,36,M,Other,G1/G1,107.0,2.4,FSGS,"Calcium Channel Blockers, Erythropoietin, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, Erythropoietin, Diuretics.",WT,Mut,Mut,WT,Mut,Mut
51beb80e-b7e6-414c-9c8a-49225005680f,42,F,Hispanic,G2/G2,11.1,3.62,CKD Stage 1,"Calcium Channel Blockers, Statins, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Statins, ARBs.",WT,WT,WT,WT,WT,Mut
586a346a-dc5b-47d1-bcef-1972bbf483ce,86,F,Caucasian,G1/G1,115.1,3.72,Nephrotic Syndrome,"Diuretics, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,WT,WT,Mut
c2baf0e0-2179-43f0-a612-4ab4f9b21e6e,29,F,Caucasian,G0/G1,67.0,0.66,CKD Stage 4,ACE Inhibitors,Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors.",WT,WT,Mut,WT,WT,WT
1b2ededb-8fc8-4fc0-83d5-bceb5edbb8ee,65,F,Caucasian,G1/G2,75.7,0.68,FSGS,Calcium Channel Blockers,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,WT,WT,Mut
1f5d988f-776a-4f09-bde2-885951b1943c,40,F,Asian,G0/G1,109.2,0.75,CKD Stage 4,Diuretics,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics.",WT,WT,WT,WT,Mut,Mut
24108e9a-3f77-4cae-b318-b96d44790612,26,M,Other,G2/G2,41.7,1.22,FSGS,"ACE Inhibitors, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors, Calcium Channel Blockers.",WT,Mut,WT,WT,Mut,Mut
f204be89-4a4b-4563-8cf4-77ef18c8a616,31,M,African American,G1/G2,10.4,0.76,CKD Stage 4,"ACE Inhibitors, ARBs, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, ARBs, Calcium Channel Blockers.",WT,WT,Mut,Mut,Mut,Mut
6b0ae0e3-9d89-4047-9d39-d7936257a4a2,48,F,Other,G1/G1,48.0,4.95,CKD Stage 4,"ARBs, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,Mut,WT,Mut
e6fdd7af-dd84-4acc-b672-94643f8ea40a,65,M,Asian,G1/G1,25.8,2.57,Nephrotic Syndrome,"Calcium Channel Blockers, ARBs, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, ARBs, Statins.",WT,Mut,WT,Mut,Mut,Mut
ef0a573d-53d2-456d-9040-158728e213bc,75,F,Asian,G1/G2,50.0,1.97,CKD Stage 4,Erythropoietin,Yes,No significant change in eGFR. Continuing current treatment: Erythropoietin.,WT,WT,WT,WT,WT,Mut
3098f7b2-500e-45c0-b89b-df7f93e34c35,70,F,Hispanic,G0/G1,53.2,2.62,FSGS,"Statins, Diuretics, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,WT,WT,WT,Mut,WT
fef7d9ea-7f8e-4483-a8ca-aa1dc35bec2c,84,F,Caucasian,G1/G2,12.6,1.43,FSGS,"ARBs, Diuretics, Insulin",Yes,"No significant change in eGFR. Continuing current treatment: ARBs, Diuretics, Insulin.",WT,Mut,WT,WT,Mut,Mut
e10b1a47-7fae-4748-b781-321e83c501cb,34,F,Hispanic,G2/G2,112.6,3.26,Nephrotic Syndrome,"ACE Inhibitors, Erythropoietin, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,WT,WT,Mut
170d7507-05ee-41d4-bf53-a88e4efc8248,58,F,Caucasian,G0/G1,115.4,1.88,CKD Stage 1,"Insulin, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin, Diuretics.",Mut,Mut,Mut,WT,Mut,Mut
750d112e-8164-4eec-a4ab-851bf1fac6e7,38,M,Caucasian,G1/G2,23.0,4.6,CKD Stage 4,Insulin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin.",Mut,Mut,WT,WT,WT,Mut
95560a2d-3713-4466-bda0-6476f778c676,35,F,Asian,G1/G2,62.5,3.95,FSGS,"Calcium Channel Blockers, Diuretics, Statins",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Diuretics, Statins.",WT,Mut,WT,Mut,Mut,Mut
4806f804-0cf0-474c-8c74-dc0f5a575539,26,M,Caucasian,G2/G2,43.0,2.27,CKD Stage 2,Calcium Channel Blockers,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers.",WT,Mut,Mut,WT,Mut,Mut
d7c4fe9c-e1e0-4ffc-98f6-fd7f7eb162f1,71,M,Hispanic,G1/G1,31.1,1.76,FSGS,Statins,Yes,No significant change in eGFR. Continuing current treatment: Statins.,Mut,WT,WT,WT,Mut,Mut
4926ce5f-7878-4140-ac2a-4f71a77d95f1,61,M,Hispanic,G1/G2,82.5,2.0,CKD Stage 1,Calcium Channel Blockers,Yes,No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers.,WT,WT,Mut,Mut,WT,Mut
1b84edc3-d8e0-49de-8217-ea0e896490ab,22,F,Asian,G1/G1,50.3,2.81,Diabetic Nephropathy,"Statins, Erythropoietin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,Mut,WT,Mut
43b47ee5-e1e8-4e7e-a249-8f666e51484d,28,F,African American,G1/G1,104.8,4.53,CKD Stage 1,Calcium Channel Blockers,Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers.",WT,WT,WT,WT,Mut,WT
673ba8bd-c38c-4dec-9da3-9a73ba3df7ff,48,M,African American,G0/G0,89.5,3.81,CKD Stage 3,"ACE Inhibitors, ARBs, Insulin",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, ARBs, Insulin.",Mut,Mut,WT,WT,WT,WT
0d18ab95-668c-4477-8b95-017c5dae1201,28,M,African American,G0/G0,10.4,4.06,CKD Stage 2,ACE Inhibitors,Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,WT,Mut,Mut,WT,Mut,WT
5cce5ba9-31d4-4e09-8fd3-3afc91fdfa4f,41,F,Hispanic,G2/G2,105.2,0.78,CKD Stage 2,"ACE Inhibitors, Calcium Channel Blockers, ARBs",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Calcium Channel Blockers, ARBs.",WT,Mut,WT,WT,WT,WT
62e7c1a6-12d2-4a06-89e1-cd138da00495,59,M,Caucasian,G1/G2,79.9,3.17,FSGS,"Insulin, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,Mut,Mut,WT
8cc36f3b-c3af-4cfe-b34a-6ca38116e3fc,50,F,Caucasian,G0/G0,16.8,2.72,Nephrotic Syndrome,Insulin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,WT,WT,Mut
9f8cc29f-fd35-4c5f-9347-9a3b479bc637,26,F,Hispanic,G1/G2,49.4,4.15,CKD Stage 3,"Diuretics, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, Statins.",Mut,WT,WT,WT,WT,Mut
20f0156a-1e6a-4628-9c6d-52d5ae2e9af9,77,F,Asian,G1/G2,105.6,2.59,CKD Stage 2,Erythropoietin,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,WT,Mut,Mut
5f89ed12-64d6-4fbf-98c0-1e2bf99f0704,37,F,Hispanic,G0/G0,57.8,4.18,CKD Stage 2,Insulin,Yes,"History of hypertension and diabetes, currently managed with Insulin.",WT,WT,WT,WT,Mut,Mut
8ece1128-56ce-4b42-bc9e-1dcbcb7e6268,61,M,African American,G1/G2,53.1,1.87,Diabetic Nephropathy,"Diuretics, ARBs, Erythropoietin",Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,Mut,Mut,Mut,Mut,WT,Mut
24eeb4a6-c145-45c7-9d98-6115f05eeefe,63,M,African American,G1/G1,87.7,3.24,CKD Stage 2,Insulin,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,WT,Mut,Mut,WT,Mut
66c14dca-8255-4a61-9a3b-031932f57510,61,F,Other,G1/G2,77.3,3.2,FSGS,"Diuretics, Erythropoietin",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, Erythropoietin.",Mut,WT,Mut,Mut,WT,WT
09f64405-0b99-4034-8a4e-255280051b10,71,M,Caucasian,G1/G1,85.7,4.6,CKD Stage 3,"Statins, Diuretics, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,Mut,Mut,WT,WT,Mut,WT
cdd0b4d4-5542-47de-b6ad-f48b2314d0c8,48,M,Asian,G2/G2,61.7,0.59,FSGS,Statins,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins.",WT,Mut,WT,Mut,Mut,Mut
2620f9a9-74fd-43d1-84f2-fd0f79474bfa,67,M,Hispanic,G0/G1,50.0,4.0,CKD Stage 4,ARBs,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,Mut,WT,Mut
23c8afdb-83f8-4f16-a4a4-474c9b33e3a4,58,M,Caucasian,G2/G2,76.6,1.83,CKD Stage 1,"ARBs, Insulin, Erythropoietin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,Mut,WT,Mut
518b2f21-9cf2-4859-ae6e-2e7253f591dc,36,F,African American,G0/G0,81.7,3.93,CKD Stage 1,"Statins, ARBs",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,Mut,Mut,WT
9dd2f9de-fd98-4e33-a498-abe92999bbef,53,M,Other,G1/G2,41.3,3.14,CKD Stage 3,ACE Inhibitors,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,Mut,WT,Mut
97fe56c5-4c9a-4f24-97b4-c294bd44089d,66,M,Asian,G1/G1,53.5,1.97,Diabetic Nephropathy,Erythropoietin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin.",Mut,Mut,WT,WT,WT,Mut
827c9f8c-d40a-45e9-81df-6517561c9210,35,M,African American,G2/G2,28.0,3.71,CKD Stage 1,"Diuretics, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,WT,Mut,Mut
901bcdef-b56f-48ce-bd66-971e88476c56,85,F,Asian,G0/G1,70.3,0.9,CKD Stage 2,"ARBs, ACE Inhibitors",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,Mut,WT,WT,WT,WT,WT
044251db-d0d4-4a67-b992-8faa4cbf131d,46,F,African American,G0/G0,34.1,1.55,CKD Stage 2,Insulin,Yes,No significant change in eGFR. Continuing current treatment: Insulin.,Mut,Mut,Mut,Mut,WT,Mut
1c0f0bdc-ac7e-437c-94cc-1e2a5e4cb287,71,M,African American,G0/G1,74.9,1.44,FSGS,"ACE Inhibitors, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,Mut,WT,WT
4ec3f970-956d-40e4-aaa2-6216fada98f5,54,F,Other,G1/G1,66.2,1.22,CKD Stage 2,"Diuretics, Calcium Channel Blockers, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics, Calcium Channel Blockers, ARBs.",Mut,Mut,Mut,WT,Mut,Mut
df41e335-b9ae-48e4-a615-99c8cbf81f86,83,F,Caucasian,G0/G1,22.4,2.24,CKD Stage 1,"Calcium Channel Blockers, ARBs, Erythropoietin",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,Mut,WT,Mut,Mut,Mut,WT
98cf1188-06d2-4913-a117-3719b023a0ea,47,F,Caucasian,G2/G2,12.6,0.56,Diabetic Nephropathy,Calcium Channel Blockers,Yes,No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers.,Mut,WT,Mut,Mut,Mut,Mut
a7d4cf50-f791-41e5-83f9-cd6b797ebe87,39,F,Asian,G2/G2,75.6,4.08,Nephrotic Syndrome,ACE Inhibitors,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors.",WT,WT,WT,WT,WT,Mut
9416e4dc-c6b2-4def-b8d8-b7f1c86c6544,74,F,Other,G0/G1,20.7,2.16,Nephrotic Syndrome,Statins,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,Mut,WT,Mut
0d259caa-b8ad-4d87-ba40-45dd93dfd907,33,F,Caucasian,G1/G1,60.3,4.7,Diabetic Nephropathy,ACE Inhibitors,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,WT,Mut,WT,WT,WT,WT
86341718-2ba6-4db3-bafe-b1149561c813,76,F,Hispanic,G0/G0,87.3,2.66,Nephrotic Syndrome,"ARBs, Calcium Channel Blockers, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,WT,Mut,Mut
c64c9647-9ea7-417c-b89f-7039a107cc46,70,M,African American,G2/G2,108.7,3.45,Diabetic Nephropathy,"Erythropoietin, Diuretics",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, Diuretics.",Mut,WT,Mut,WT,Mut,WT
d25864f2-25d4-40fc-a154-2765d756ba9c,75,M,African American,G2/G2,101.9,2.46,Nephrotic Syndrome,"Calcium Channel Blockers, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,WT,Mut,Mut
9293f705-0815-4147-be00-980eae441e21,87,M,Hispanic,G1/G1,89.9,2.93,CKD Stage 3,"Erythropoietin, Diuretics, Statins",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, Diuretics, Statins.",WT,Mut,Mut,Mut,Mut,Mut
30d73df7-1c22-4cea-b355-56a5f2bd92f2,81,F,Hispanic,G1/G2,19.5,1.64,CKD Stage 2,"Diuretics, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,WT,Mut,WT
6b352f85-504e-4687-b0e7-e75604d9145e,87,M,Other,G0/G1,117.5,4.07,Diabetic Nephropathy,"Statins, ACE Inhibitors, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,WT,WT,WT,WT,Mut,WT
34323ec6-b0c4-401c-a9b7-c0fa26c432f6,60,F,African American,G1/G1,90.5,4.09,FSGS,"Insulin, Erythropoietin",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,Mut,WT,Mut,Mut,WT,WT
9c89d374-c664-45a7-8077-3e33690e7e62,76,M,Caucasian,G0/G0,108.3,4.86,Diabetic Nephropathy,Statins,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,WT,Mut,Mut
d92f3c1e-df70-4b2a-b8bb-22a5eba742d2,87,M,Caucasian,G0/G0,11.8,1.83,CKD Stage 2,Calcium Channel Blockers,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,Mut,WT,Mut
b4adaf89-0ff1-4a9f-ba37-0623bc5fd4dd,69,M,Other,G1/G1,47.7,2.19,CKD Stage 3,"Insulin, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,WT,Mut,Mut
8f964685-3514-4890-84c8-6c4623595fa4,50,F,Asian,G2/G2,94.7,2.4,FSGS,"Diuretics, Erythropoietin, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,WT,Mut
7a768555-a987-4218-bf84-faef5336723b,29,M,Caucasian,G0/G0,60.0,3.87,CKD Stage 2,"Statins, ACE Inhibitors, Diuretics",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,Mut,WT,Mut,WT,WT
f4e95734-5052-4700-a077-96a38685abaa,21,F,African American,G2/G2,29.9,1.74,FSGS,"Calcium Channel Blockers, Insulin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,WT,Mut
887b03e5-e980-4808-b5ac-824c2c55aef7,23,F,Other,G1/G1,56.9,3.59,Diabetic Nephropathy,ARBs,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,WT,Mut,WT
ad05b912-5ab2-4d4a-8bd8-8fcd57a2be4e,23,F,Caucasian,G0/G1,47.4,3.57,Diabetic Nephropathy,"ARBs, Erythropoietin",Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,Mut,WT,WT,WT,WT,WT
ae455cc6-b88e-430f-9e1e-994ac5a11f5c,90,M,Asian,G1/G2,50.3,3.65,CKD Stage 1,"Insulin, Erythropoietin, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,WT,Mut,Mut
43ad3d62-b17c-4b21-8dbc-2c1ca4afe7bd,72,M,African American,G0/G0,38.9,4.77,CKD Stage 3,"Statins, Insulin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,WT,WT,WT
f5141058-3138-4975-bbf3-3a349c2dfa97,43,F,Other,G1/G1,71.3,2.65,Diabetic Nephropathy,"ARBs, Insulin, Statins",Yes,"History of hypertension and diabetes, currently managed with ARBs, Insulin, Statins.",WT,WT,WT,WT,WT,Mut
4c6a70f4-8ede-444d-876c-f68c3f1be0d0,68,M,Hispanic,G0/G0,66.1,0.55,FSGS,"Diuretics, Insulin, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,Mut,WT,Mut
fb756923-f910-4bb3-b105-32523990e2c9,42,F,Asian,G1/G2,33.6,1.28,FSGS,"Erythropoietin, Insulin, ACE Inhibitors",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,WT,Mut,WT
b4746349-49fc-4cd8-856b-ad4c4c3077c4,49,F,Hispanic,G0/G1,101.1,2.33,Diabetic Nephropathy,"ACE Inhibitors, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,Mut,Mut,Mut
7d2f4e58-b47a-4c5b-b0b3-901535102852,34,F,Other,G2/G2,107.8,3.41,Diabetic Nephropathy,"ARBs, Calcium Channel Blockers, Insulin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, Calcium Channel Blockers, Insulin.",Mut,Mut,WT,Mut,WT,Mut
8f7c1d59-594b-4a3a-bad4-65a15129950d,28,M,African American,G1/G1,40.5,1.76,Nephrotic Syndrome,"Diuretics, Insulin",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, Insulin.",Mut,Mut,Mut,Mut,Mut,WT
b8beff3d-cb9f-4f6d-af3a-6f27ef06fccb,29,F,Hispanic,G2/G2,66.9,3.34,CKD Stage 3,"Diuretics, Calcium Channel Blockers, Erythropoietin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,WT,WT,Mut
92cf6021-1f33-442d-89ac-908746015028,60,F,Hispanic,G1/G1,75.8,3.51,CKD Stage 2,"Calcium Channel Blockers, ARBs, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, ARBs, Diuretics.",WT,Mut,Mut,WT,Mut,WT
e5508ea2-6133-434d-8b0e-8eb1ad371d9e,55,M,Caucasian,G2/G2,96.9,4.24,CKD Stage 2,"Calcium Channel Blockers, Statins, Diuretics",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, Statins, Diuretics.",WT,Mut,Mut,Mut,Mut,Mut
585abefb-d181-4f77-a500-1423faebcd19,27,F,African American,G1/G2,99.4,4.93,CKD Stage 1,ARBs,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,Mut,Mut,WT
257f7595-cdfb-4db9-85e7-8b23f4613f09,72,F,Other,G0/G0,62.4,2.24,CKD Stage 1,ARBs,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs.",WT,Mut,WT,WT,WT,Mut
f48f709c-49a2-4441-8ac4-de854a5b1aff,86,F,Caucasian,G0/G0,111.8,3.59,CKD Stage 2,Erythropoietin,Yes,No significant change in eGFR. Continuing current treatment: Erythropoietin.,WT,WT,WT,Mut,Mut,Mut
ec8be537-58ab-4778-943b-45e3b6d1f6bb,47,M,Other,G2/G2,72.8,1.7,FSGS,"Calcium Channel Blockers, ARBs",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, ARBs.",WT,WT,Mut,WT,WT,Mut
bf519362-41a6-4fed-a7ed-c8d8713f8f8c,20,M,African American,G2/G2,91.5,4.9,CKD Stage 3,"ACE Inhibitors, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Calcium Channel Blockers.",WT,Mut,WT,WT,Mut,WT
d3f4a49b-33ba-4a88-b6c7-d6fa7aa4f052,53,M,African American,G0/G1,83.8,2.46,Diabetic Nephropathy,"Calcium Channel Blockers, Statins, Erythropoietin",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, Statins, Erythropoietin.",WT,WT,WT,WT,Mut,Mut
8fe069b6-eeda-4802-8568-f42689e03e22,67,F,African American,G2/G2,94.2,1.42,Nephrotic Syndrome,"Statins, Insulin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,Mut,Mut,Mut
1bf645f6-2324-4211-8588-fc1bb2384849,65,M,African American,G2/G2,102.1,3.57,CKD Stage 2,"ARBs, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with ARBs, Calcium Channel Blockers.",Mut,Mut,Mut,Mut,WT,Mut
3d4196fe-963a-4617-bdab-07e79d9d028e,78,M,Other,G0/G1,81.0,0.79,Nephrotic Syndrome,Statins,Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,Mut,Mut,WT,Mut,Mut
e7ba26ac-ab7a-4d1c-8cfe-f6833e11bafe,72,M,Asian,G1/G1,48.3,1.71,CKD Stage 3,"ARBs, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,Mut,Mut,WT
3b9b2d45-a350-45e4-b9c5-9df987f255d6,29,M,African American,G2/G2,86.5,0.73,CKD Stage 1,"Diuretics, Statins, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, Statins, ARBs.",Mut,WT,Mut,Mut,WT,WT
548e1f6b-69ce-4e4e-99a6-92c90d700ea4,39,M,Caucasian,G0/G0,78.3,3.08,Diabetic Nephropathy,"ARBs, Diuretics, Insulin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,WT,WT,WT
ae62990c-19bd-4f93-b8ef-7666b7a4c719,27,M,African American,G1/G1,99.9,1.3,CKD Stage 1,"Insulin, Diuretics",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,WT,WT,Mut
f6eab3a0-0153-4221-a331-0a28c550eca8,52,M,Other,G2/G2,108.4,2.27,CKD Stage 2,Statins,Yes,"History of hypertension and diabetes, currently managed with Statins.",WT,WT,WT,Mut,Mut,Mut
286ed390-edd9-4a1a-ba58-5b278ce3e7c3,40,M,Caucasian,G0/G1,80.4,3.9,CKD Stage 1,"ARBs, ACE Inhibitors",Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,Mut,Mut,Mut,Mut,Mut,Mut
e1721c83-ef5e-4376-a723-fb72682b163a,63,F,Hispanic,G2/G2,113.1,1.25,Diabetic Nephropathy,"ARBs, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: ARBs, ACE Inhibitors.",WT,WT,Mut,Mut,WT,Mut
a689b424-7a3a-40e1-b9c7-73a0e0decc3d,56,F,African American,G1/G1,63.6,3.88,CKD Stage 2,"Calcium Channel Blockers, Erythropoietin",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, Erythropoietin.",WT,Mut,WT,Mut,Mut,WT
4988e418-f6c3-4218-8183-6315330f8be1,47,F,Hispanic,G1/G2,53.9,3.71,CKD Stage 3,Statins,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,WT,WT,WT
0f25477d-a559-40e7-8910-fade52380bf2,24,F,Asian,G1/G2,107.6,4.42,CKD Stage 1,"Diuretics, Calcium Channel Blockers, Insulin",Yes,"History of hypertension and diabetes, currently managed with Diuretics, Calcium Channel Blockers, Insulin.",Mut,WT,Mut,WT,Mut,Mut
a6fd0cb1-16e6-45c0-84cb-294fe86e8e63,82,M,African American,G0/G0,26.1,3.7,CKD Stage 3,ACE Inhibitors,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,Mut,Mut,Mut
bd1a8f4b-88ff-4d40-bb72-c86d92fa675f,76,F,Other,G1/G1,41.3,0.73,FSGS,"ACE Inhibitors, Statins, Erythropoietin",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,Mut,WT,WT,WT,Mut,Mut
098c60b3-efc9-409e-99af-6e09b91e3d6e,74,F,Caucasian,G0/G1,93.8,1.38,FSGS,"Diuretics, Statins",Yes,"History of hypertension and diabetes, currently managed with Diuretics, Statins.",WT,WT,WT,Mut,WT,WT
6afa828c-2cd1-4b9f-abe5-841fe9c96c52,90,M,Asian,G0/G1,57.0,3.06,CKD Stage 2,ACE Inhibitors,Yes,No significant change in eGFR. Continuing current treatment: ACE Inhibitors.,WT,WT,Mut,Mut,WT,WT
ef158d5b-2d00-4d05-966d-4627e1dace6a,81,M,African American,G1/G2,99.3,2.04,Nephrotic Syndrome,"Calcium Channel Blockers, Statins",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, Statins.",Mut,Mut,Mut,WT,Mut,WT
d61169a1-ff46-46bf-894d-916deb6d2fed,73,F,Hispanic,G1/G1,113.4,1.85,Nephrotic Syndrome,"ACE Inhibitors, Insulin",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Insulin.",Mut,Mut,WT,WT,WT,WT
2fb21e66-7ed1-4aab-89b7-c9bc65a16fa9,37,M,Other,G2/G2,49.9,3.84,CKD Stage 4,"Diuretics, Calcium Channel Blockers, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, Calcium Channel Blockers, ACE Inhibitors.",WT,WT,Mut,WT,Mut,WT
df4e713e-f64e-4dfc-bfbe-ac7aefc59738,73,M,Asian,G1/G2,117.6,2.0,CKD Stage 3,Diuretics,Yes,No significant change in eGFR. Continuing current treatment: Diuretics.,WT,Mut,Mut,Mut,WT,Mut
0997623a-e072-4d96-8a1a-81f5ed10f004,54,M,Other,G0/G1,47.0,3.19,FSGS,"Calcium Channel Blockers, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, ACE Inhibitors.",WT,WT,WT,WT,WT,Mut
9a4ffc0c-9165-42ed-8c63-6e95025f5543,37,M,African American,G1/G2,29.5,1.1,Diabetic Nephropathy,"Erythropoietin, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin, Calcium Channel Blockers.",Mut,WT,WT,WT,Mut,Mut
55c551fc-fba5-4cc8-adaf-37661b780ede,28,M,Other,G0/G0,100.4,1.37,CKD Stage 2,"Calcium Channel Blockers, Statins",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Statins.",WT,Mut,Mut,WT,Mut,WT
a42d0cd7-fd35-4f6a-b450-388748d90846,51,M,Other,G0/G0,64.6,1.51,CKD Stage 3,Statins,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,Mut,Mut,Mut
e3a68a70-7e71-4b55-8639-bd418b15bd94,69,F,Caucasian,G1/G1,83.3,1.45,CKD Stage 4,Erythropoietin,No,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin.",WT,WT,WT,WT,WT,WT
811414f8-d9df-4d0e-a25a-ed6cf0458043,34,M,African American,G1/G1,94.7,3.59,FSGS,Erythropoietin,Yes,No significant change in eGFR. Continuing current treatment: Erythropoietin.,Mut,Mut,Mut,WT,Mut,WT
cf0e6d2b-315c-467a-85d8-a6ad77d0359e,22,F,Caucasian,G1/G2,31.1,0.8,CKD Stage 1,"Statins, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,Mut,Mut,WT
bb2aa146-2999-494c-94a7-b69b1cd66b09,72,F,Other,G0/G1,10.8,4.02,CKD Stage 3,"ACE Inhibitors, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,WT,WT,Mut
b7f60cdf-41dc-4c60-a5f6-0735757b6b29,41,F,African American,G0/G0,79.5,3.7,Diabetic Nephropathy,"Diuretics, Calcium Channel Blockers, ACE Inhibitors",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,Mut,WT,WT,WT,Mut
564cfbd2-bc92-4d81-839b-058c2faabe0b,82,F,Other,G1/G2,107.9,4.97,FSGS,"ARBs, Statins, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, Statins, ACE Inhibitors.",Mut,Mut,Mut,WT,Mut,Mut
aca58d95-915a-4c30-8b86-b5a1ca6fbff8,26,F,Asian,G1/G2,110.6,3.24,CKD Stage 2,"Calcium Channel Blockers, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,WT,Mut,Mut,Mut,WT,WT
9c678393-2ced-4c0d-b173-04b5c1dd484a,50,F,Hispanic,G0/G0,68.4,0.68,Diabetic Nephropathy,"ARBs, Statins",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, Statins.",WT,Mut,WT,WT,Mut,Mut
67ce378f-e5a4-483b-a383-889adb2c6ac8,57,M,Asian,G2/G2,33.5,3.48,CKD Stage 3,Calcium Channel Blockers,Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,WT,Mut,Mut,WT,WT,WT
53f30073-83e9-4ef4-ad7d-f5d0d3b59af7,28,F,Caucasian,G1/G2,12.3,1.08,Nephrotic Syndrome,"Diuretics, ARBs, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,Mut,WT,WT
186b2880-ab54-4a15-a69d-01ff1634725b,54,F,Other,G2/G2,80.3,0.84,CKD Stage 2,Calcium Channel Blockers,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,Mut,WT,WT
7a3a6e96-23ff-43d3-bb4f-b88a2f4dd219,61,M,Other,G2/G2,61.2,1.05,Nephrotic Syndrome,"Diuretics, ACE Inhibitors, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,WT,Mut,WT,Mut,WT,Mut
01bf9e73-3f80-4385-af92-40b652d78f10,29,M,Caucasian,G0/G1,47.6,2.85,Nephrotic Syndrome,"ARBs, Statins, Diuretics",Yes,"History of hypertension and diabetes, currently managed with ARBs, Statins, Diuretics.",WT,Mut,Mut,Mut,WT,Mut
725d4259-3c4b-4eec-a231-ee7342c2d2eb,42,F,Other,G0/G0,117.4,3.85,Diabetic Nephropathy,"Calcium Channel Blockers, Statins, Insulin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Statins, Insulin.",Mut,Mut,Mut,Mut,WT,WT
546252e7-f43b-4052-8459-bd6ec0f63229,42,M,Other,G1/G1,11.9,3.49,CKD Stage 3,"Diuretics, Statins, ACE Inhibitors",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,WT,WT,WT
92a81713-b90e-444b-951c-25d54d4c5280,78,F,Other,G2/G2,89.8,2.03,FSGS,Calcium Channel Blockers,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,Mut,Mut,WT
5c0b9b10-a757-4b10-82f5-25b902ed73ce,25,F,Caucasian,G1/G1,99.7,5.0,CKD Stage 3,"Calcium Channel Blockers, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, Statins.",WT,Mut,WT,Mut,Mut,Mut
aaf407f7-0fe7-4149-bc7e-5368b1594847,21,F,Hispanic,G0/G1,88.3,4.41,FSGS,"Insulin, ACE Inhibitors, Diuretics",Yes,"History of hypertension and diabetes, currently managed with Insulin, ACE Inhibitors, Diuretics.",WT,WT,Mut,Mut,Mut,WT
28e333b6-4e8a-4c4b-b724-20411e43fbd2,45,M,Caucasian,G0/G0,40.4,4.29,FSGS,"Calcium Channel Blockers, ACE Inhibitors, Insulin",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, ACE Inhibitors, Insulin.",Mut,Mut,WT,Mut,WT,Mut
ec50ace4-80a5-4e65-afa2-855967c96204,60,F,African American,G0/G1,17.6,4.77,FSGS,ACE Inhibitors,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,Mut,Mut,WT
c5144d98-b41c-404f-a346-f415e5267a2b,89,M,African American,G1/G1,28.5,3.42,FSGS,"Calcium Channel Blockers, ACE Inhibitors, Erythropoietin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, ACE Inhibitors, Erythropoietin.",Mut,WT,WT,WT,WT,Mut
a38295d3-1e0e-4546-b0b6-dedf4f9c4027,84,F,Other,G0/G1,64.2,1.57,CKD Stage 4,Insulin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,Mut,WT,Mut
5e175b66-4b87-459f-b0cd-7f05ea87855e,54,F,Caucasian,G2/G2,104.2,1.06,CKD Stage 4,"Erythropoietin, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,WT,WT,Mut,WT,Mut
f5159494-3818-4fd3-b889-936a9d5817e8,41,M,Caucasian,G0/G1,88.2,1.54,CKD Stage 2,"ACE Inhibitors, Erythropoietin, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,WT,WT,Mut,WT,WT
74797b61-2737-4b52-ba6a-210722319050,32,M,Asian,G0/G0,47.5,2.51,CKD Stage 2,"Erythropoietin, ACE Inhibitors, Diuretics",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,Mut,Mut,WT
5fa5e0aa-9b11-4530-bd24-7c11bf6b8cdf,36,M,Asian,G1/G1,30.7,3.5,Nephrotic Syndrome,Statins,Yes,No significant change in eGFR. Continuing current treatment: Statins.,Mut,Mut,Mut,WT,Mut,WT
e9ad0e9b-8c9a-41e9-b3b2-63376a74dbb7,38,M,African American,G1/G2,67.7,1.42,CKD Stage 1,"ARBs, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,WT,Mut,WT
cd4f8b2b-899a-4252-81e1-b94a78883058,62,F,Caucasian,G1/G2,32.1,4.39,Diabetic Nephropathy,"Statins, Diuretics",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,Mut,WT,WT
c3093b6e-37e9-42e2-935a-c07aaa0217d0,80,F,Caucasian,G2/G2,66.1,4.7,CKD Stage 1,"Erythropoietin, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin, Diuretics.",Mut,WT,Mut,Mut,Mut,WT
98874bfe-c136-4c65-ae2a-e3413f59e4f2,31,M,Hispanic,G1/G1,99.1,3.91,Nephrotic Syndrome,"Calcium Channel Blockers, Insulin, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,WT,WT,Mut
86879aa9-14f5-43d0-8991-2032df85c777,88,F,Other,G1/G1,10.2,1.37,CKD Stage 1,"Diuretics, Erythropoietin, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, Erythropoietin, Statins.",Mut,Mut,WT,Mut,Mut,WT
5c9deee0-b42a-4456-8736-5a84725e134d,43,M,Hispanic,G0/G0,104.4,2.11,Diabetic Nephropathy,Insulin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin.",Mut,Mut,WT,Mut,WT,WT
1cb9b73a-906d-4c8c-aad0-8c8913fe8a29,35,M,Asian,G0/G0,32.5,2.36,Nephrotic Syndrome,ACE Inhibitors,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors.",Mut,WT,WT,WT,WT,Mut
e723ada3-8c32-4db2-942a-895e0fcf601f,50,M,Other,G1/G2,23.2,1.76,FSGS,"ARBs, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, ACE Inhibitors.",Mut,WT,WT,WT,Mut,WT
89628f6e-929c-43b3-b3c0-8bf18167999f,53,M,African American,G1/G2,99.9,1.47,CKD Stage 4,"ACE Inhibitors, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,Mut,Mut,Mut
dabf984e-53ff-4461-aa1f-1b61265cb9d9,89,M,African American,G0/G0,117.9,3.07,Nephrotic Syndrome,"ARBs, Calcium Channel Blockers",No,"History of hypertension and diabetes, currently managed with ARBs, Calcium Channel Blockers.",WT,WT,WT,WT,WT,WT
ae27d432-1dc1-47eb-b11c-767385351a69,55,F,African American,G1/G2,34.8,1.11,CKD Stage 1,"Erythropoietin, ARBs, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, ARBs, Diuretics.",Mut,Mut,WT,WT,WT,Mut
7d23d479-9549-4a82-b787-ef8d3495311e,39,F,African American,G2/G2,29.3,4.29,CKD Stage 4,ACE Inhibitors,Yes,No significant change in eGFR. Continuing current treatment: ACE Inhibitors.,WT,WT,WT,WT,Mut,WT
720b274b-82a7-4586-a61d-9cde1747f387,39,F,Other,G2/G2,107.2,2.89,FSGS,"Diuretics, Statins, ARBs",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,WT,Mut,Mut
21c71aa3-7414-43b5-8e3e-25f2cf0671c7,45,M,Caucasian,G1/G2,42.5,3.98,CKD Stage 4,Calcium Channel Blockers,Yes,No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers.,WT,WT,WT,WT,WT,Mut
905c7bdd-74f0-4eae-aa59-43ce836435e3,35,M,Other,G0/G1,69.3,1.54,CKD Stage 2,ACE Inhibitors,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,Mut,WT,Mut
ac3a812f-765e-4cb5-8f0d-55400ec7d662,88,M,Caucasian,G0/G0,57.0,4.33,CKD Stage 2,Calcium Channel Blockers,Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,WT,WT,Mut,WT,Mut
0592bfa5-b928-423f-8ee4-334ece920136,87,M,Hispanic,G1/G2,28.1,1.74,Diabetic Nephropathy,"ACE Inhibitors, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Calcium Channel Blockers.",WT,WT,WT,WT,WT,Mut
00c59f30-d103-4424-8124-1bb4655ce508,28,M,Caucasian,G1/G2,114.8,0.94,Diabetic Nephropathy,"Erythropoietin, Diuretics, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,Mut,Mut,WT
12b2102d-940c-4503-b7c8-6152beed0af9,55,F,Hispanic,G0/G1,19.4,4.16,FSGS,"Insulin, Calcium Channel Blockers, Statins",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,WT,WT,Mut
b34c6c73-5833-4b30-ac77-6e950b981ccd,23,F,Asian,G1/G2,14.4,2.46,CKD Stage 1,Insulin,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,WT,WT,Mut,WT,Mut,Mut
0f6ce9bf-fe7e-4362-8a89-b0f0105291d3,29,F,Other,G1/G1,68.3,2.32,FSGS,ARBs,Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,Mut,WT,Mut,WT,Mut,Mut
fc737d92-11ab-4d11-a4eb-8000ef40d162,64,F,Caucasian,G2/G2,51.3,0.69,Nephrotic Syndrome,Erythropoietin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,WT,WT,Mut
497ec6d1-081f-46dc-b8d9-a88aef0bea4f,89,F,Other,G1/G1,96.5,0.58,FSGS,"Calcium Channel Blockers, Insulin, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,Mut,WT,WT
22ab7752-c4db-4a62-ae13-418d68ab80ea,50,M,Other,G2/G2,91.2,1.68,Nephrotic Syndrome,"Calcium Channel Blockers, Erythropoietin",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,WT,Mut,Mut,WT,WT,Mut
bab2b77d-fa74-4cc8-a43a-fb7ac40d4874,85,M,Asian,G1/G1,36.6,3.53,CKD Stage 2,"Statins, Insulin, Diuretics",Yes,"History of hypertension and diabetes, currently managed with Statins, Insulin, Diuretics.",WT,Mut,Mut,Mut,WT,WT
5fdcabbf-6b9c-471c-b6ba-745ba55871e3,34,F,Other,G1/G2,33.5,1.89,Diabetic Nephropathy,"ACE Inhibitors, Statins",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,Mut,WT,Mut
72d35458-61ea-4f30-a42e-707afe2bd987,55,M,Caucasian,G1/G2,96.8,3.75,CKD Stage 3,"Insulin, Erythropoietin",Yes,"No significant change in eGFR. Continuing current treatment: Insulin, Erythropoietin.",WT,Mut,WT,WT,WT,Mut
60a399d4-e821-4716-aac8-0da1de9f6f5b,70,F,Hispanic,G2/G2,73.3,4.17,FSGS,Calcium Channel Blockers,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,WT,WT,Mut
f6d22a7b-aec7-4a82-948b-4376602a4e57,35,F,Other,G0/G0,84.1,2.03,CKD Stage 3,"Erythropoietin, ACE Inhibitors, Diuretics",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,WT,Mut,WT
220b9ea9-8a0f-4508-9fe2-c0a0a96b3c42,50,F,African American,G1/G2,90.1,4.13,Diabetic Nephropathy,ACE Inhibitors,Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors.",WT,Mut,Mut,WT,WT,WT
1e5ebe54-5907-4299-9c3b-bdd8a74e02a9,29,M,Asian,G0/G1,24.8,3.4,CKD Stage 2,Statins,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins.",WT,WT,WT,Mut,Mut,Mut
649f7d88-8989-45ab-be2b-34d82db0728d,82,F,Other,G2/G2,108.1,0.55,CKD Stage 2,Calcium Channel Blockers,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,Mut,Mut,WT
fa8dae42-ba54-4920-a099-d18087623997,85,M,Caucasian,G1/G2,46.7,3.37,CKD Stage 4,"Erythropoietin, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,WT,Mut,Mut
c194f97f-00e3-4026-95b6-de85390239d9,35,M,African American,G1/G1,76.4,4.14,Diabetic Nephropathy,"Erythropoietin, Insulin, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,WT,Mut,Mut
76876c62-4c61-445e-ba7e-5d9405d1fb63,35,F,Caucasian,G0/G1,99.6,1.21,CKD Stage 2,"Insulin, Calcium Channel Blockers, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Insulin, Calcium Channel Blockers, ARBs.",WT,WT,Mut,Mut,Mut,Mut
6c93a791-8b60-4511-b816-8aebac6a7c85,29,F,African American,G1/G1,24.3,2.91,Nephrotic Syndrome,Calcium Channel Blockers,Yes,No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers.,Mut,WT,Mut,WT,Mut,Mut
3acb43a3-d2c7-4ffb-a118-433b882ccd1e,23,M,African American,G0/G1,56.9,4.31,CKD Stage 1,Calcium Channel Blockers,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,Mut,Mut,WT
27b608dc-589d-4cb0-b5eb-89c23f5cf2f3,67,M,Asian,G0/G0,45.2,3.85,CKD Stage 1,Calcium Channel Blockers,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,Mut,WT,Mut
e00da49d-effa-4002-b040-413c4690fb15,41,F,Other,G0/G0,63.4,4.31,CKD Stage 4,"Erythropoietin, ARBs, Insulin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,WT,WT,WT
083f64c3-1ce3-42f8-83f7-25feb99b2b5a,18,F,Caucasian,G1/G1,42.8,2.65,Nephrotic Syndrome,"Erythropoietin, Insulin, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin, Insulin, ARBs.",Mut,WT,WT,WT,Mut,WT
9d6b9b62-6b53-4a19-a902-b73fcf39f648,65,F,African American,G2/G2,100.4,2.78,FSGS,"Erythropoietin, ACE Inhibitors, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, ACE Inhibitors, Diuretics.",Mut,WT,WT,Mut,Mut,WT
e39836bb-e23d-4faa-afad-49e9c41c147e,71,F,Hispanic,G2/G2,80.6,3.92,Nephrotic Syndrome,"Erythropoietin, Calcium Channel Blockers, Statins",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, Calcium Channel Blockers, Statins.",WT,Mut,WT,Mut,Mut,WT
1139fa12-34c1-43ea-bd9c-4e6404015ced,90,M,Hispanic,G0/G0,95.0,4.49,FSGS,"Calcium Channel Blockers, ARBs, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,WT,Mut,WT
7249f62c-0898-4462-980c-b95c19d45deb,69,M,Asian,G2/G2,87.0,4.96,CKD Stage 4,Statins,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,WT,Mut,Mut,WT,Mut,WT
df495037-b40a-4181-ac09-bdb799086e47,57,M,Other,G2/G2,34.2,3.52,FSGS,"Erythropoietin, ARBs",Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,WT,WT,Mut,WT,Mut,Mut
0b531932-bd94-49aa-bea6-e5b20c760d28,36,F,Hispanic,G0/G0,70.4,4.32,CKD Stage 2,"Insulin, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,WT,Mut,Mut
8a2db2e6-3bfd-48a6-b05f-ddf566fadca0,27,M,African American,G2/G2,63.0,2.42,Nephrotic Syndrome,"ARBs, Calcium Channel Blockers, Insulin",Yes,"No significant change in eGFR. Continuing current treatment: ARBs, Calcium Channel Blockers, Insulin.",Mut,Mut,WT,Mut,WT,Mut
c6ac1b04-dd1d-4cd1-811f-6bf5379ef467,37,M,Other,G1/G1,103.5,1.72,CKD Stage 1,Calcium Channel Blockers,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,WT,WT,Mut
fe54ee4b-80ff-4173-a3df-ecd70e731dd7,67,M,African American,G0/G0,101.7,3.93,FSGS,ACE Inhibitors,Yes,No significant change in eGFR. Continuing current treatment: ACE Inhibitors.,WT,WT,Mut,WT,WT,WT
ea98fef8-d0d7-4e37-bbf2-025f4a0d2b73,25,F,African American,G1/G1,79.3,0.83,Nephrotic Syndrome,"ACE Inhibitors, Statins",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors, Statins.",Mut,WT,WT,Mut,Mut,WT
93d563ae-51a3-4c26-937b-f79bbb44badc,65,M,Hispanic,G1/G1,11.8,2.73,CKD Stage 4,"Diuretics, Statins, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,Mut,Mut,WT
d18183d1-ac2b-4cfc-85c5-1060991121e7,62,M,Other,G0/G0,92.0,2.71,Nephrotic Syndrome,"Statins, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, ACE Inhibitors.",WT,WT,Mut,WT,Mut,Mut
e0527739-4d40-4f1b-bca5-be2952171bf3,43,M,Asian,G0/G1,19.8,1.1,CKD Stage 3,"Erythropoietin, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, ARBs.",WT,Mut,Mut,WT,Mut,WT
8570b59f-a903-4e67-bc56-8b5324acb722,44,M,African American,G0/G0,76.3,0.5,CKD Stage 1,Calcium Channel Blockers,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,WT,Mut,Mut
46707cd6-4ced-4164-a9df-14e9389641dd,62,F,African American,G0/G1,34.0,0.83,Nephrotic Syndrome,"Diuretics, Calcium Channel Blockers, Erythropoietin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,WT,WT,Mut
97777f10-f2d2-493f-8e85-140d0f9aeb70,23,M,Asian,G1/G1,41.3,0.74,CKD Stage 4,Erythropoietin,Yes,No significant change in eGFR. Continuing current treatment: Erythropoietin.,Mut,WT,Mut,Mut,WT,WT
2cd58759-e95d-4761-bc36-dc59e134edfc,81,M,Caucasian,G0/G0,11.5,1.23,CKD Stage 1,"Calcium Channel Blockers, Insulin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,Mut,Mut,WT
8e4c3ab5-6d5d-4477-adc2-9178a0411612,61,F,Other,G1/G2,35.7,2.42,Diabetic Nephropathy,Calcium Channel Blockers,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,Mut,Mut,WT
582b91ee-f8e8-435b-8c00-988a7ee1011a,75,M,Asian,G2/G2,69.9,3.36,CKD Stage 4,"ACE Inhibitors, Statins, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,WT,Mut,WT
61935990-abdd-4a8f-a4b0-5c89f10bce9c,64,M,Asian,G2/G2,25.8,3.47,CKD Stage 2,ARBs,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs.",Mut,Mut,WT,WT,Mut,Mut
b2414482-5198-44d8-8643-3603c92a7d7c,87,F,African American,G1/G1,54.5,1.18,CKD Stage 1,"Erythropoietin, ARBs, ACE Inhibitors",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, ARBs, ACE Inhibitors.",WT,Mut,Mut,Mut,WT,Mut
4cc57e0d-2633-4018-a883-ac6e6a944054,87,F,Other,G0/G0,114.8,1.07,CKD Stage 1,"Calcium Channel Blockers, ACE Inhibitors",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,Mut,WT,Mut
89b5aab0-c121-49db-af12-b150605fb1eb,83,M,African American,G1/G1,48.1,3.32,FSGS,"Calcium Channel Blockers, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, ACE Inhibitors.",Mut,WT,Mut,WT,WT,Mut
39b02e2a-d96e-484f-bdb0-174e7938878a,79,M,Other,G0/G1,12.9,3.27,CKD Stage 3,"Calcium Channel Blockers, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,Mut,Mut,WT
24f43c62-b523-40de-9b87-d29c4cfd0fc1,73,F,Caucasian,G0/G1,45.2,3.1,CKD Stage 4,"ACE Inhibitors, Erythropoietin, Insulin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors, Erythropoietin, Insulin.",Mut,WT,Mut,WT,WT,Mut
0ec0713d-ea2c-4a51-b688-d11fce4758be,52,M,Hispanic,G1/G2,51.9,3.29,Nephrotic Syndrome,"Insulin, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,Mut,WT,Mut
6aa0426d-f7c0-45f7-a9a5-3b4f8ff8869d,52,F,Caucasian,G2/G2,53.2,3.17,CKD Stage 2,Diuretics,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,WT,Mut,Mut
636f6e5c-2253-4706-87ad-8b268eaa5841,42,M,Hispanic,G1/G2,28.1,0.86,Nephrotic Syndrome,"ARBs, Insulin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,Mut,Mut,WT
548c1d84-340d-4049-8147-65063e2bf9c9,69,M,Caucasian,G1/G1,68.3,4.02,CKD Stage 3,ARBs,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,Mut,WT,Mut
73253aa3-ec17-4298-943d-f5b3a58e83dd,67,F,African American,G2/G2,45.2,2.69,Nephrotic Syndrome,"Calcium Channel Blockers, Diuretics",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,Mut,WT,WT
891f6912-17ab-4863-9efe-ef4fd8ddbbc0,79,F,Caucasian,G0/G0,31.9,4.25,CKD Stage 3,"ARBs, Diuretics, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,Mut,WT
0d31812e-30c3-4756-9453-f867b97e6224,76,M,Hispanic,G1/G1,32.3,1.47,CKD Stage 2,"Insulin, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,WT,Mut,Mut
9adf4709-ac75-4344-a08e-149e44b9e602,23,M,Other,G1/G1,114.8,1.17,Diabetic Nephropathy,"Calcium Channel Blockers, ACE Inhibitors, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,WT,Mut,Mut
12a1fe7d-dfa5-4722-8a1f-c9df9a591974,33,F,Other,G0/G0,76.6,4.26,Diabetic Nephropathy,"ACE Inhibitors, Diuretics",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Diuretics.",Mut,WT,WT,Mut,Mut,WT
966be275-c2fe-4954-8dfd-9531302b7831,89,F,Asian,G0/G0,115.1,4.39,FSGS,"Statins, Calcium Channel Blockers, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,Mut,Mut,WT,WT,Mut
378e6510-8f10-433e-abe4-2e7db96c1163,83,F,Hispanic,G2/G2,79.5,3.8,CKD Stage 4,"Calcium Channel Blockers, Diuretics",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,Mut,WT,WT
e8334da5-de95-4695-b579-c1437ab99428,72,F,African American,G0/G1,112.6,0.53,CKD Stage 1,ARBs,Yes,"History of hypertension and diabetes, currently managed with ARBs.",Mut,Mut,WT,WT,WT,WT
e8b3d763-f4ff-4f3a-8d9d-baeb553d2625,32,F,Hispanic,G0/G0,32.9,1.96,CKD Stage 4,Insulin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,WT,Mut,Mut
30a5648e-efe9-43d0-b639-08bf03ece8ff,85,F,Asian,G2/G2,78.2,3.73,CKD Stage 2,"Calcium Channel Blockers, Erythropoietin",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, Erythropoietin.",WT,Mut,Mut,Mut,Mut,Mut
bf337a15-1e08-4f20-bdd1-51b0f64ab6ec,18,M,Hispanic,G2/G2,118.3,3.67,CKD Stage 3,"ARBs, ACE Inhibitors",No,"History of hypertension and diabetes, currently managed with ARBs, ACE Inhibitors.",WT,WT,WT,WT,WT,WT
ea18d32c-7a9a-4ef5-811b-d1c4ffe3f366,36,M,Hispanic,G2/G2,20.2,2.2,CKD Stage 1,Insulin,Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,WT,Mut,Mut,Mut,WT,WT
b42a2d93-9aba-4f15-b214-90623e1a963e,77,F,African American,G2/G2,28.2,2.62,FSGS,"ACE Inhibitors, Erythropoietin, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,Mut,Mut,Mut
3d44cb2c-ea45-4a41-a589-ada1345af934,64,F,Asian,G0/G1,51.7,4.38,CKD Stage 1,"ARBs, Insulin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, Insulin.",WT,Mut,Mut,WT,WT,Mut
48769153-c688-43fe-9255-5c758d55119e,41,F,African American,G1/G2,29.3,2.56,CKD Stage 2,Statins,Yes,"History of hypertension and diabetes, currently managed with Statins.",WT,WT,WT,Mut,WT,WT
a6129a1c-889d-4b76-b75c-30b561730c48,90,M,Asian,G0/G1,115.1,3.8,Diabetic Nephropathy,"Erythropoietin, Insulin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,WT,WT,WT
5c11ab6d-42f5-43f5-8ef4-c34d5bf86f3c,64,M,Other,G2/G2,32.4,3.0,CKD Stage 3,"Statins, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,WT,WT,Mut
774c0afa-7f4d-408c-a1ff-f6c08347f1da,20,F,Hispanic,G1/G1,73.5,4.79,CKD Stage 4,"Erythropoietin, Calcium Channel Blockers, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, Calcium Channel Blockers, ACE Inhibitors.",WT,Mut,Mut,WT,WT,WT
b8f0188e-fb37-4fae-8d85-63ca193e638d,38,M,Hispanic,G0/G1,83.3,3.18,Diabetic Nephropathy,"Statins, Erythropoietin, ACE Inhibitors",Yes,"History of hypertension and diabetes, currently managed with Statins, Erythropoietin, ACE Inhibitors.",WT,Mut,Mut,WT,WT,WT
51facefa-d6f8-4f7a-82fa-1da878308631,30,M,Hispanic,G1/G2,90.2,3.77,CKD Stage 1,"ARBs, Calcium Channel Blockers, ACE Inhibitors",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,WT,Mut,Mut,Mut,Mut,Mut
501ba851-5ee6-4495-b400-29c3ea11905b,65,F,Caucasian,G0/G1,80.1,2.27,CKD Stage 1,ARBs,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,WT,Mut,WT
dd34aa18-9001-4ed4-8bb4-01e769f753f1,59,M,Asian,G0/G0,48.2,4.42,CKD Stage 2,"Insulin, ACE Inhibitors, Erythropoietin",Yes,"History of hypertension and diabetes, currently managed with Insulin, ACE Inhibitors, Erythropoietin.",WT,WT,Mut,WT,WT,Mut
0426fcc9-255b-40e2-bdc2-b74b38a56b49,53,M,African American,G2/G2,100.6,4.6,FSGS,"Statins, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, ACE Inhibitors.",WT,Mut,WT,WT,WT,Mut
95831d58-ef4c-4119-8da5-d39b42c21797,37,M,African American,G0/G1,27.3,4.4,Nephrotic Syndrome,"Statins, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: Statins, Calcium Channel Blockers.",WT,WT,WT,WT,WT,WT
4b91b8cb-6ae6-4582-b852-b3cd9442b5e6,31,M,Caucasian,G0/G0,23.3,3.75,CKD Stage 4,Erythropoietin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,WT,WT,WT
3ae28023-5472-4d2d-b239-9ffb27046f25,42,F,Asian,G1/G1,32.9,0.56,CKD Stage 2,"Erythropoietin, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin, Calcium Channel Blockers.",Mut,WT,WT,Mut,WT,WT
3ee82983-d557-4241-91dd-b9bf613d2de9,20,F,Other,G0/G1,111.4,4.37,FSGS,"Diuretics, ARBs, Erythropoietin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,WT,WT,Mut
f186e47a-a794-4320-8cf6-e8b87fd238c3,66,M,African American,G0/G1,88.7,3.06,CKD Stage 3,Calcium Channel Blockers,Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers.",Mut,WT,WT,WT,Mut,WT
c36b9a0a-41e0-4a89-966a-9ce7af521b94,42,F,Hispanic,G2/G2,45.9,2.15,CKD Stage 3,ARBs,Yes,No significant change in eGFR. Continuing current treatment: ARBs.,WT,Mut,WT,WT,WT,WT
b93b17fb-f76d-45fd-bd16-45a0d253d966,72,M,Hispanic,G2/G2,27.8,1.54,CKD Stage 4,"ACE Inhibitors, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, ARBs.",WT,Mut,WT,Mut,Mut,WT
75f8e3a8-7d97-4c0f-bd56-09c4a4461663,34,M,Hispanic,G2/G2,81.5,4.56,CKD Stage 3,"Diuretics, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics, ARBs.",WT,WT,Mut,WT,WT,WT
5a2837b2-cb83-43f2-bb96-f6022b115c36,64,F,Asian,G2/G2,110.6,3.38,CKD Stage 3,"Calcium Channel Blockers, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, Diuretics.",WT,Mut,Mut,Mut,Mut,Mut
8bea75c1-b866-47aa-a3d4-526b2b54ff7a,49,F,Asian,G0/G0,25.1,4.15,CKD Stage 4,"ACE Inhibitors, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors, Calcium Channel Blockers.",WT,WT,WT,WT,WT,WT
e3ad64d4-eab9-4b02-af1d-c1217d024c6d,70,M,African American,G1/G2,53.9,3.94,CKD Stage 1,"ARBs, Statins",Yes,"History of hypertension and diabetes, currently managed with ARBs, Statins.",WT,WT,WT,Mut,Mut,WT
f50d7a37-a44d-4fec-bd85-d7fa8ac97b01,21,M,Hispanic,G0/G0,61.0,1.38,CKD Stage 1,"Statins, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, ACE Inhibitors.",WT,WT,Mut,WT,Mut,WT
d6cd3155-08a8-4c7f-8621-38ad0f09105c,64,F,Asian,G1/G1,31.9,2.3,CKD Stage 1,"ARBs, ACE Inhibitors, Erythropoietin",Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,WT,Mut,Mut,Mut,Mut
d1682e09-f1f7-4904-9307-5157d8c128e7,50,F,African American,G0/G1,23.3,0.52,CKD Stage 2,"Calcium Channel Blockers, ARBs, Insulin",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, ARBs, Insulin.",Mut,WT,Mut,Mut,Mut,Mut
01a25ed1-c3ab-45f1-8c6b-7074ab102c9b,28,F,Other,G0/G0,67.7,4.24,Nephrotic Syndrome,"ACE Inhibitors, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,Mut,Mut,WT
a175a9c3-d7b1-42a9-a332-a50e6992896e,21,M,African American,G0/G0,59.2,2.69,CKD Stage 4,Diuretics,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,WT,WT,Mut
26a9e100-b509-409b-9166-58ce3b3f3800,58,M,African American,G1/G1,96.3,0.69,FSGS,"Insulin, ACE Inhibitors, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with Insulin, ACE Inhibitors, Calcium Channel Blockers.",Mut,Mut,Mut,Mut,WT,WT
74bd0c93-8177-4661-b7fe-032c02571851,74,M,Asian,G1/G2,76.3,3.87,CKD Stage 1,"Statins, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Statins, ACE Inhibitors.",WT,WT,Mut,Mut,WT,Mut
a3422e50-9e2a-4324-8f79-a8a75f8a14bd,52,M,Caucasian,G0/G1,93.8,2.47,CKD Stage 2,"Erythropoietin, Insulin, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, Insulin, Calcium Channel Blockers.",Mut,WT,Mut,WT,WT,Mut
e9aa144b-9dd4-4675-af14-5064aab07015,35,M,Caucasian,G1/G2,15.6,2.57,FSGS,ACE Inhibitors,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors.",WT,Mut,WT,WT,WT,Mut
0406ff44-7ce4-4679-a8c6-dbc07bb3447b,28,M,Hispanic,G2/G2,72.9,3.18,Diabetic Nephropathy,"Statins, ARBs, ACE Inhibitors",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,Mut,WT,WT
694d7b00-8d38-4327-883f-13c601b158e9,51,F,Other,G0/G1,27.7,1.04,CKD Stage 3,"Insulin, Erythropoietin, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,WT,WT,WT
b8e19f56-8787-4a21-8448-2a220308aa5e,51,M,Asian,G1/G2,45.2,3.5,Diabetic Nephropathy,Calcium Channel Blockers,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,Mut,Mut,WT
49646b96-fa3c-4628-8926-21df465568b7,28,M,Other,G1/G2,84.2,3.16,Diabetic Nephropathy,Insulin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,Mut,Mut,WT
b2a6e468-d02b-4243-8091-3ac10463750e,63,M,African American,G1/G1,109.5,0.9,FSGS,"ACE Inhibitors, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,WT,WT,Mut
f090f5a0-ce61-4199-ae3a-0ba8ac8d6c7d,88,M,Hispanic,G1/G2,48.9,4.01,CKD Stage 4,"Calcium Channel Blockers, Erythropoietin, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, Erythropoietin, Statins.",WT,Mut,WT,Mut,Mut,Mut
eb053fc4-1b65-4dab-ade4-6e91e8e6e840,49,F,Other,G1/G2,12.8,2.54,CKD Stage 3,ACE Inhibitors,Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors.",Mut,WT,WT,Mut,WT,Mut
3db02235-261e-4555-863e-1f2a18a806ef,63,M,Asian,G1/G1,69.7,1.06,FSGS,"Calcium Channel Blockers, ARBs, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, ARBs, Diuretics.",Mut,WT,WT,Mut,WT,Mut
409e7a80-86c5-41d6-9ea9-f50831227592,37,F,Other,G2/G2,17.5,0.6,Diabetic Nephropathy,ACE Inhibitors,Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,Mut,WT,WT,WT,WT,Mut
cb80f288-446f-44dd-9abc-a6e5d0b1e3eb,38,M,Asian,G0/G0,35.6,2.64,CKD Stage 4,Diuretics,Yes,No significant change in eGFR. Continuing current treatment: Diuretics.,WT,WT,WT,Mut,Mut,WT
f5948a54-5f80-4eeb-943a-9aff659b0105,20,M,Hispanic,G1/G1,92.6,2.73,CKD Stage 3,Insulin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,WT,WT,Mut
3e42df5b-90a3-4bbf-b580-e05067f1698c,90,F,Asian,G0/G0,61.7,3.83,Nephrotic Syndrome,Calcium Channel Blockers,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,WT,Mut,Mut
4ccb2355-39d1-47ff-b27e-1442fd7fe973,36,M,Hispanic,G0/G0,58.7,2.36,Diabetic Nephropathy,Calcium Channel Blockers,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,Mut,Mut,Mut
14a34f7f-d90d-419b-93fb-e043af1d5a1a,86,M,Other,G1/G2,86.6,2.97,CKD Stage 3,"Statins, Insulin, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, Insulin, Diuretics.",WT,Mut,Mut,Mut,Mut,WT
a65f7b8a-dbb4-4021-bdde-64afa75b395a,35,M,African American,G1/G2,119.4,1.61,CKD Stage 4,"ACE Inhibitors, Diuretics, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,Mut,WT,WT
67c0518b-17ef-4621-881c-79d4c27437eb,86,F,Caucasian,G1/G2,44.6,2.35,Nephrotic Syndrome,"ARBs, ACE Inhibitors, Insulin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, ACE Inhibitors, Insulin.",Mut,Mut,Mut,WT,Mut,Mut
79db7862-8d7d-4772-a08e-2f5c61177270,21,F,Caucasian,G1/G1,68.3,3.11,CKD Stage 2,Diuretics,Yes,No significant change in eGFR. Continuing current treatment: Diuretics.,Mut,Mut,Mut,Mut,Mut,Mut
b3eda8f1-026b-4383-a301-ec030e5d8c6a,59,F,Hispanic,G0/G1,11.6,4.06,CKD Stage 3,"Statins, Diuretics",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,WT,Mut,Mut
d867888b-7ff6-4824-952a-eaec2bdfcb41,46,M,Other,G2/G2,13.2,1.09,Diabetic Nephropathy,"Diuretics, Statins",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics, Statins.",Mut,WT,WT,Mut,Mut,Mut
54ce26be-c8cc-42c2-a518-a4186f14b3f6,68,F,Other,G2/G2,48.2,4.66,CKD Stage 1,"Erythropoietin, Statins, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,WT,Mut,WT
f94d8fcb-dba3-496f-ba32-3f6990dbfad6,72,F,Asian,G1/G1,54.1,3.94,FSGS,Statins,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins.",WT,WT,WT,WT,Mut,WT
eb4d8f42-8735-40a2-a511-09611869a217,82,F,Other,G2/G2,80.3,4.97,CKD Stage 1,"ACE Inhibitors, Calcium Channel Blockers, Statins",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Calcium Channel Blockers, Statins.",Mut,Mut,Mut,WT,WT,WT
e6b9d31a-361f-4d90-bad1-fa330ae4ac11,63,F,African American,G1/G1,59.1,4.97,CKD Stage 4,"Calcium Channel Blockers, ARBs",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, ARBs.",Mut,WT,WT,WT,WT,WT
9118c400-e336-4243-b139-c476de3ce88b,50,M,Asian,G1/G1,35.1,2.06,FSGS,"Statins, Insulin, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,Mut,Mut,WT
ec95b3ac-0beb-4c34-8566-7c4879ba630a,33,M,Other,G1/G1,106.7,2.13,Diabetic Nephropathy,"ACE Inhibitors, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,Mut,Mut,Mut
47c68688-ecf3-4053-af36-b8cc13087974,36,M,African American,G0/G0,25.4,1.37,Nephrotic Syndrome,"Diuretics, Insulin",Yes,"History of hypertension and diabetes, currently managed with Diuretics, Insulin.",Mut,WT,Mut,Mut,Mut,WT
a879d8f8-9042-4eb7-8b04-0f53e63949d4,55,M,Asian,G0/G1,13.4,4.4,FSGS,"Statins, Erythropoietin, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,WT,WT,WT
d9b59f84-edc3-41c3-adea-2d2d086c405f,49,M,Hispanic,G1/G1,88.6,1.37,CKD Stage 4,"Calcium Channel Blockers, ARBs, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, ARBs, Diuretics.",WT,Mut,WT,Mut,WT,Mut
3508507a-f622-4842-8402-2b3c508211a5,31,M,Asian,G1/G2,62.2,1.79,CKD Stage 1,"Diuretics, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, ARBs.",Mut,Mut,Mut,Mut,Mut,Mut
d218c9d6-c093-4fb0-a4e9-bcfd9647ff9f,86,M,Other,G1/G1,85.7,2.64,FSGS,Statins,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,WT,WT,WT
edcabf94-65f6-4a53-9226-a8b3b674410d,82,F,Other,G1/G2,98.4,3.06,CKD Stage 4,"Insulin, Calcium Channel Blockers, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin, Calcium Channel Blockers, ARBs.",WT,Mut,Mut,Mut,WT,Mut
905f9096-2996-46e2-8c9d-690713b22cec,75,M,Hispanic,G1/G2,35.6,4.15,Diabetic Nephropathy,"Insulin, Calcium Channel Blockers, Statins",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,WT,WT,WT
d9750f00-d5ab-48ae-9112-fbc03d8f95f4,38,M,Caucasian,G2/G2,97.2,1.18,CKD Stage 1,"Erythropoietin, Insulin, Statins",Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,WT,Mut,WT,WT,WT,WT
8a624cbd-e582-4678-ad52-29dd639fc471,89,M,Caucasian,G0/G1,23.3,4.17,CKD Stage 1,ARBs,Yes,No significant change in eGFR. Continuing current treatment: ARBs.,WT,WT,WT,WT,Mut,Mut
bd5ff093-c16f-4bcc-a243-bed754ec3f33,32,M,African American,G2/G2,102.5,3.19,Diabetic Nephropathy,"Calcium Channel Blockers, Erythropoietin, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,WT,Mut,WT
b076a7dc-fd0c-4433-8a5e-151b23d3cd4c,29,F,African American,G0/G1,108.8,1.8,CKD Stage 3,"ARBs, Erythropoietin, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,Mut,WT,WT
bed63da0-8033-45c2-9413-d64db962c8a7,70,F,African American,G0/G0,10.4,3.8,CKD Stage 1,"Calcium Channel Blockers, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, Statins.",WT,WT,Mut,Mut,Mut,Mut
1901ef87-0dbf-4caf-988a-3f87f96d40f8,60,M,African American,G1/G2,57.6,4.54,CKD Stage 4,"Diuretics, ACE Inhibitors",Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,WT,WT,Mut,Mut,Mut,WT
1375ee90-d6b3-41e4-bb6d-ca0d6fe5040b,46,F,African American,G1/G2,69.6,0.95,FSGS,"Diuretics, Insulin, Statins",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,WT,Mut,Mut
9d264599-c4dd-4df5-9aec-56a857311609,55,M,Asian,G2/G2,89.8,3.04,CKD Stage 4,Statins,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,Mut,WT,Mut
f80b2cea-658e-44a2-9879-cf35f4719986,80,M,Hispanic,G0/G0,50.8,3.16,CKD Stage 2,"Statins, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, ACE Inhibitors.",Mut,Mut,WT,WT,WT,WT
a255e1bb-0795-4c1f-938d-6b8cc607b1e9,73,F,Asian,G2/G2,73.5,4.24,CKD Stage 2,"ACE Inhibitors, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,WT,WT,Mut
735741e5-fe1a-4ba9-8896-9c5b45f8c28d,83,F,African American,G1/G2,63.5,1.81,CKD Stage 1,"Erythropoietin, ARBs, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,WT,WT,WT
8d93e14a-5b16-4158-ba67-470c7d98302f,69,M,Asian,G1/G1,29.5,1.13,CKD Stage 4,"Insulin, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with Insulin, Calcium Channel Blockers.",WT,Mut,WT,Mut,Mut,Mut
2f8c83e5-6e8d-4644-a01b-fbcbf0eebcce,88,F,Hispanic,G1/G1,63.5,4.26,CKD Stage 3,"Calcium Channel Blockers, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,WT,Mut,Mut
614c721d-a921-4b4c-95fb-e976ae007b7e,20,M,African American,G1/G2,34.2,3.67,CKD Stage 3,"Diuretics, ACE Inhibitors",Yes,"History of hypertension and diabetes, currently managed with Diuretics, ACE Inhibitors.",Mut,WT,WT,WT,Mut,Mut
4b9dfd58-9e5d-4c7a-85ac-c35415f00cb4,38,F,Hispanic,G0/G0,16.4,2.68,Nephrotic Syndrome,"ARBs, Calcium Channel Blockers, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: ARBs, Calcium Channel Blockers, Diuretics.",Mut,WT,WT,WT,Mut,WT
12d15585-b68e-47fa-bf17-5534cc4d5819,65,M,Asian,G0/G0,16.5,2.08,FSGS,"Erythropoietin, ACE Inhibitors, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,WT,Mut,WT
6147adeb-277b-4667-8499-d0a615007170,29,F,Caucasian,G1/G2,18.9,4.46,Nephrotic Syndrome,"ARBs, Statins",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, Statins.",WT,WT,WT,WT,WT,Mut
277eb0aa-a247-441d-88ad-0899b630794d,58,M,African American,G1/G2,38.2,3.65,Nephrotic Syndrome,Insulin,Yes,No significant change in eGFR. Continuing current treatment: Insulin.,Mut,Mut,Mut,WT,WT,Mut
5c56d9bc-5111-431d-a3be-441dbd5a0c9e,89,M,Asian,G1/G1,24.5,1.66,CKD Stage 4,Statins,Yes,"History of hypertension and diabetes, currently managed with Statins.",WT,WT,Mut,WT,Mut,WT
f165d779-0154-4950-976d-e21f1b46ebdc,27,M,Hispanic,G1/G1,15.0,2.08,FSGS,"Insulin, Statins, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Insulin, Statins, ARBs.",WT,WT,Mut,Mut,WT,Mut
c2e79a98-5c23-4d8d-b1da-35b94eea9db8,85,M,Hispanic,G0/G1,56.3,0.77,Diabetic Nephropathy,"Insulin, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,WT,WT,Mut
16591c89-21eb-4aa9-9a2b-d69c450f69ee,82,M,Other,G1/G1,116.4,1.93,CKD Stage 2,"Calcium Channel Blockers, Erythropoietin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Erythropoietin.",Mut,Mut,WT,WT,Mut,Mut
8e969227-72e7-4b51-ae54-ac6d2ff8e87e,74,F,African American,G1/G2,49.6,3.29,CKD Stage 3,Diuretics,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,WT,WT,WT
1a7167c7-6875-4545-832f-52c48e0370cf,59,M,African American,G1/G2,79.2,1.89,CKD Stage 1,"Insulin, ACE Inhibitors, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,Mut,Mut,WT
8de1596c-5a9a-406a-96f1-42a206b919aa,20,M,Hispanic,G1/G1,87.5,2.5,CKD Stage 4,Erythropoietin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,Mut,Mut,WT
c8d0f9e5-9919-45ea-98d0-0c2c17d30f32,28,M,African American,G0/G0,83.4,1.32,CKD Stage 3,"Diuretics, ACE Inhibitors, Erythropoietin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,WT,Mut,WT
0328c136-629e-43d8-9d1c-a267530ddda6,41,F,Other,G1/G1,58.4,4.51,CKD Stage 3,Statins,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,WT,Mut,WT
c777a07f-6346-44ef-a9ef-74e34ab6821c,77,M,Hispanic,G2/G2,84.1,3.4,CKD Stage 2,"Calcium Channel Blockers, ACE Inhibitors, Erythropoietin",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, ACE Inhibitors, Erythropoietin.",WT,Mut,Mut,WT,Mut,WT
8f3dc97f-e6b0-4a0a-b98f-5dbe15aede0f,33,M,Hispanic,G1/G1,23.9,0.64,CKD Stage 2,"ACE Inhibitors, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,WT,WT,Mut,WT,WT
3e245fbf-fa69-4cd2-be23-90f3e7bbaefc,40,F,Hispanic,G0/G1,110.0,3.59,CKD Stage 3,ACE Inhibitors,Yes,No significant change in eGFR. Continuing current treatment: ACE Inhibitors.,Mut,Mut,WT,WT,WT,Mut
af70de70-2b69-495e-8567-1b58926bffa5,19,M,Asian,G2/G2,57.1,4.61,Diabetic Nephropathy,"ACE Inhibitors, Calcium Channel Blockers, Insulin",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, Calcium Channel Blockers, Insulin.",Mut,Mut,Mut,Mut,WT,WT
44d7df9a-238b-45b7-ab64-777c6177a771,52,M,Caucasian,G0/G1,72.7,1.8,FSGS,"Diuretics, ARBs, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,Mut,Mut,WT
255bfc1c-7e3d-4ee4-84b6-4ec14d16f049,19,M,Caucasian,G1/G1,101.1,0.83,CKD Stage 2,"Diuretics, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,Mut,WT,Mut
46a56fe8-6f46-41b1-aace-1aa9103246b3,41,M,Caucasian,G2/G2,87.3,1.17,Diabetic Nephropathy,Diuretics,Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,WT,WT,WT,WT,WT
c85cd714-7bf6-4552-8cbc-90446bcd5ce7,23,F,Caucasian,G0/G0,80.1,4.82,FSGS,"Insulin, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: Insulin, Diuretics.",WT,WT,WT,WT,WT,Mut
f1b88d65-406f-44d6-9c72-aebd13b11e59,46,M,Other,G0/G0,41.0,3.55,CKD Stage 4,"Calcium Channel Blockers, Insulin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,WT,WT,Mut
7eece88d-a002-452a-b88c-ddde3f2086c2,68,M,Caucasian,G0/G1,56.1,4.12,CKD Stage 2,Erythropoietin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,Mut,WT,WT
75366b9f-320f-42c0-9dde-01889803b22e,77,M,Other,G0/G1,10.1,2.5,CKD Stage 1,"Calcium Channel Blockers, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, ARBs.",WT,WT,WT,WT,Mut,WT
01bb819c-4dfe-4117-a2af-711f1b628a9d,39,M,Hispanic,G2/G2,96.4,2.85,CKD Stage 4,"ACE Inhibitors, Erythropoietin, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,WT,Mut,WT
d773f98d-550c-4fe9-a54c-11d9f2e61828,60,M,Other,G1/G1,72.6,2.59,CKD Stage 4,Erythropoietin,Yes,No significant change in eGFR. Continuing current treatment: Erythropoietin.,WT,Mut,WT,WT,Mut,WT
dcb9075e-cdd7-4460-a140-77d39ec4ea48,45,M,Other,G1/G2,77.0,1.2,FSGS,"ARBs, Insulin",Yes,"History of hypertension and diabetes, currently managed with ARBs, Insulin.",Mut,Mut,Mut,WT,WT,WT
6e3cdd4f-55b1-45e4-b0b2-7304545cd88d,79,M,African American,G0/G0,29.5,1.46,CKD Stage 3,"ARBs, Erythropoietin, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,Mut,WT,Mut
a6aa59e5-dc08-4f29-92d3-3488d0c30018,53,M,Caucasian,G2/G2,92.3,0.8,CKD Stage 3,"Insulin, Erythropoietin, ARBs",No,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin, Erythropoietin, ARBs.",WT,WT,WT,WT,WT,WT
4ce953a7-22d9-4db3-982a-2277f966d59f,37,M,Caucasian,G0/G1,88.9,2.74,Diabetic Nephropathy,Erythropoietin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,WT,WT,WT
b1fead13-f280-4f1d-9a6c-0db952171c88,71,F,African American,G1/G2,37.9,1.39,Nephrotic Syndrome,Diuretics,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,Mut,Mut,Mut
2d79a2d1-506e-40c7-baa0-61e9336b00cb,86,M,Caucasian,G0/G0,85.2,3.43,FSGS,Statins,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,Mut,WT,WT
51b30182-f7fe-404f-a5f3-0779f6ee5cdb,85,M,African American,G0/G0,39.0,4.29,Nephrotic Syndrome,"Calcium Channel Blockers, Diuretics, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Diuretics, ACE Inhibitors.",Mut,Mut,WT,WT,WT,WT
a205e54f-b1e8-409d-bc20-b9f24a9c589e,80,M,Other,G0/G0,50.4,3.01,CKD Stage 3,"Calcium Channel Blockers, Statins",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Statins.",Mut,WT,Mut,WT,Mut,WT
c82f78fd-936c-431c-b7bf-52447db2a7aa,83,F,Hispanic,G1/G1,16.6,3.12,Diabetic Nephropathy,"Diuretics, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,Mut,WT,Mut
47c1c017-6045-4909-936d-47d73e0f84ce,46,F,Hispanic,G0/G0,43.3,3.22,CKD Stage 2,"ARBs, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,WT,WT
5d71a898-6497-4593-892e-8c93d105c8d6,50,M,Asian,G0/G1,111.2,3.82,Nephrotic Syndrome,"Erythropoietin, Diuretics, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, Diuretics, Calcium Channel Blockers.",WT,WT,WT,Mut,WT,Mut
33261887-9058-41df-ae9b-f3e11d27c09a,48,F,African American,G2/G2,72.8,2.21,CKD Stage 2,Insulin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,Mut,Mut,WT
2e0fb5b3-8bae-491e-bf4c-c10f979c30cf,25,F,Other,G0/G1,34.7,1.67,CKD Stage 2,Calcium Channel Blockers,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers.",WT,WT,WT,Mut,Mut,Mut
06e3f949-8cd3-4c62-8482-9b71ae84b81c,52,F,Asian,G1/G2,110.8,3.04,CKD Stage 3,"Diuretics, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, Statins.",Mut,Mut,Mut,WT,Mut,WT
f166cdcf-762c-4fbc-ba2a-a7baf3f81c31,90,F,Hispanic,G1/G2,52.5,3.78,Diabetic Nephropathy,"Statins, ACE Inhibitors, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,WT,WT,Mut
cc351e4f-703e-457f-b5ab-8466b5578b00,20,M,Other,G1/G1,111.8,4.72,CKD Stage 3,"ACE Inhibitors, Diuretics, ARBs",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,Mut,Mut,Mut
11b461e9-b15d-472d-94ce-e27c4a94ae9f,41,M,Caucasian,G0/G0,59.9,4.91,CKD Stage 2,Diuretics,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics.",WT,Mut,WT,Mut,WT,Mut
cb881c32-cbb0-4a8b-9908-a121d1a7ba20,51,M,Caucasian,G0/G1,113.5,4.17,CKD Stage 3,"Diuretics, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics, ARBs.",WT,Mut,Mut,WT,Mut,WT
23a13e20-7fd2-45ee-ac48-436668bd80d7,20,M,Other,G0/G0,64.5,2.89,CKD Stage 3,ARBs,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,Mut,WT,Mut
40afbf3f-3df5-4967-8d86-70bda2224f96,44,F,Hispanic,G0/G1,57.6,4.58,Diabetic Nephropathy,"Diuretics, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,Mut,WT,WT
6c521d13-b719-4b68-a775-ee42a89e22f2,21,F,Hispanic,G0/G1,34.5,2.5,CKD Stage 4,Insulin,Yes,No significant change in eGFR. Continuing current treatment: Insulin.,Mut,Mut,Mut,Mut,WT,WT
72f60958-12ef-4101-a082-786fca00ef58,32,F,African American,G0/G0,111.8,3.33,CKD Stage 3,Calcium Channel Blockers,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers.",Mut,WT,WT,Mut,Mut,WT
950df1a0-7aaf-4001-9912-316afd9e8e20,37,F,Caucasian,G0/G1,17.2,1.34,CKD Stage 4,"Calcium Channel Blockers, ARBs, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,WT,WT,WT
ec6a37ad-81b1-4db9-88cc-4d49669b29b8,85,M,Asian,G0/G1,109.9,1.39,CKD Stage 2,"Insulin, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,WT,WT,WT
6b15c11b-b113-450b-9ea0-50c6eb9ed274,80,M,Hispanic,G0/G1,89.1,4.85,CKD Stage 3,"Erythropoietin, ARBs, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,Mut,WT,WT
f7eae66e-ca6c-4f9b-8969-71018b2c550a,40,M,Hispanic,G1/G1,103.8,3.61,Diabetic Nephropathy,Calcium Channel Blockers,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers.",Mut,WT,WT,WT,Mut,Mut
cff2b1c4-e53f-4644-b39e-4df25c0a1feb,62,M,Asian,G1/G2,20.1,0.72,CKD Stage 4,Insulin,Yes,No significant change in eGFR. Continuing current treatment: Insulin.,WT,Mut,Mut,WT,WT,WT
ea163354-a35f-49c1-9804-95628972abbd,30,M,Asian,G0/G0,27.2,0.95,Nephrotic Syndrome,"ARBs, Insulin, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,Mut,Mut,Mut
3f8c1097-c4da-4c2e-9bff-a27915c1604f,79,M,Hispanic,G1/G2,92.9,1.09,CKD Stage 2,Erythropoietin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,WT,WT,Mut
2a9528c3-5ae1-4bad-aa29-60fda85894df,62,M,Caucasian,G0/G1,90.8,2.09,CKD Stage 1,"ARBs, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,WT,Mut,WT
902f3465-0b57-4720-9cd8-758ba5a1c825,79,M,African American,G0/G0,68.5,1.72,Nephrotic Syndrome,"Diuretics, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,Mut,WT,Mut
a590fd3c-ad6e-4c57-a520-c3d0fbcdbf5e,89,F,Caucasian,G0/G0,107.7,0.82,Diabetic Nephropathy,"ARBs, Statins",Yes,"No significant change in eGFR. Continuing current treatment: ARBs, Statins.",WT,Mut,Mut,WT,Mut,Mut
54e38579-c0af-4193-b780-ef2f664d5922,58,F,Asian,G0/G0,49.8,1.63,CKD Stage 1,Erythropoietin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin.",WT,Mut,WT,Mut,Mut,WT
1b1f2eb1-6e32-45a8-8bd5-cc86f73936e9,61,F,Asian,G1/G1,11.9,4.7,CKD Stage 1,"Erythropoietin, Statins, Insulin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin, Statins, Insulin.",WT,Mut,Mut,Mut,Mut,WT
38d5101f-423c-4d9d-993e-478302b34254,18,M,African American,G1/G1,28.6,4.89,Nephrotic Syndrome,ACE Inhibitors,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors.",Mut,WT,WT,WT,WT,Mut
8ed8a80d-84cf-4e39-bf31-c29f82bbad84,49,F,Other,G1/G2,60.9,3.05,CKD Stage 4,"ACE Inhibitors, Insulin",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, Insulin.",Mut,WT,WT,WT,Mut,Mut
38958939-9342-409f-b00a-c64c949cd8d4,28,M,Caucasian,G1/G2,81.7,3.54,CKD Stage 1,"Diuretics, Erythropoietin",Yes,"History of hypertension and diabetes, currently managed with Diuretics, Erythropoietin.",Mut,Mut,Mut,WT,WT,Mut
768b4f7e-6421-4e66-9fc6-4cd0721e8b1f,29,F,Hispanic,G1/G1,30.7,4.79,Nephrotic Syndrome,"Calcium Channel Blockers, Insulin, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Insulin, Diuretics.",WT,WT,WT,WT,WT,WT
b0c07fcc-96ad-44df-adf7-5924c5b8386b,26,F,African American,G1/G1,63.5,2.2,CKD Stage 3,"Erythropoietin, Statins, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,WT,WT,Mut
ff69723d-584f-485b-a697-384d801e8690,68,F,Hispanic,G2/G2,83.2,2.46,CKD Stage 4,"Insulin, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,Mut,WT,Mut
4ba17233-1ac3-4f31-bb96-e2d10649bcf6,22,F,Hispanic,G0/G0,12.5,1.6,CKD Stage 3,"ARBs, Statins, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: ARBs, Statins, Calcium Channel Blockers.",WT,Mut,Mut,Mut,WT,Mut
15fa9483-f633-4c2d-aba9-00e16a7d5d96,32,F,Caucasian,G2/G2,86.6,1.5,CKD Stage 2,Erythropoietin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin.",Mut,Mut,WT,WT,Mut,Mut
baeb286b-f0d0-470f-94d1-3d551db6b844,85,M,Asian,G1/G2,84.2,2.42,CKD Stage 2,Calcium Channel Blockers,Yes,No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers.,Mut,Mut,Mut,Mut,Mut,Mut
57d337d3-4fd8-4bbb-992c-11072444d301,73,M,Hispanic,G1/G1,92.9,4.44,CKD Stage 3,"ARBs, Diuretics, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,Mut,WT,WT
8567c805-34f5-41c0-88c5-eb2a7490adeb,51,F,Other,G1/G2,41.4,3.09,CKD Stage 3,"Diuretics, ACE Inhibitors",Yes,"History of hypertension and diabetes, currently managed with Diuretics, ACE Inhibitors.",WT,WT,WT,WT,Mut,Mut
18fdd2b9-79e5-49aa-992a-35497ba109d0,79,M,Other,G2/G2,80.7,4.47,FSGS,"ACE Inhibitors, ARBs",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,WT,WT,WT,Mut,WT,WT
73d39457-b25f-43df-b8d4-9848702ba49f,32,F,African American,G1/G2,46.0,4.55,FSGS,"ARBs, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, Diuretics.",Mut,Mut,Mut,Mut,WT,WT
0b705933-4cde-4b6b-9132-567c51a40d2a,19,M,Hispanic,G1/G1,72.3,4.32,CKD Stage 4,ARBs,Yes,"History of hypertension and diabetes, currently managed with ARBs.",WT,WT,WT,WT,Mut,WT
05c8234b-1d76-4a66-b5f5-9cb0cf685878,44,F,Hispanic,G1/G2,105.1,2.88,FSGS,"ARBs, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, Diuretics.",Mut,Mut,WT,Mut,WT,WT
1bff3142-a5e1-4b55-97d3-f4ddd963dc72,64,F,Caucasian,G1/G1,86.5,2.28,CKD Stage 2,ACE Inhibitors,Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors.",WT,Mut,WT,WT,Mut,WT
ee0f65a8-2a13-4c1f-8cd0-15c1ad5900dd,38,M,African American,G0/G1,31.4,2.56,CKD Stage 2,"Statins, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,WT,Mut,Mut
84182d35-3e71-4433-bd90-b81afbe0e6b8,68,M,African American,G2/G2,97.1,4.95,Nephrotic Syndrome,"Erythropoietin, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,Mut,Mut,WT,WT,WT
54bbbcf8-28fe-4761-8d49-fe3f2ca8f783,80,F,Hispanic,G0/G0,61.2,1.35,CKD Stage 1,"ARBs, Diuretics",Yes,"History of hypertension and diabetes, currently managed with ARBs, Diuretics.",WT,WT,WT,Mut,WT,WT
76492e64-f55d-4e6d-ad26-8b378f5242d3,53,F,Asian,G1/G1,29.9,3.88,Nephrotic Syndrome,ARBs,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs.",WT,WT,WT,WT,WT,WT
a137f8e4-67b1-4040-8c39-b9253b5ae288,60,F,Other,G0/G0,33.7,4.45,CKD Stage 2,ARBs,Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,Mut,Mut,Mut,Mut,WT
a84554c3-a3f6-4c61-afb7-0dab2f383b43,33,F,Asian,G1/G1,112.6,0.55,Diabetic Nephropathy,"ARBs, Statins",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,Mut,WT,WT,WT,Mut
bcc57be0-0779-450a-a544-e3136ea05d13,44,M,African American,G0/G1,110.1,3.81,FSGS,"Calcium Channel Blockers, Statins",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Statins.",WT,WT,WT,WT,Mut,WT
7317591a-3283-4aa4-a212-ab7c9d361cb6,87,F,Asian,G0/G0,114.1,4.1,Diabetic Nephropathy,"Calcium Channel Blockers, ACE Inhibitors, Erythropoietin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,WT,Mut,WT
0123a348-638a-4df6-adf7-2cd3979aa051,74,F,Hispanic,G2/G2,60.9,3.99,CKD Stage 1,"Erythropoietin, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,Mut,WT,WT
47419b48-34ae-4abd-b6fc-e0acb4698db3,67,F,Other,G0/G1,69.1,4.64,CKD Stage 2,"Statins, Erythropoietin, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,WT,Mut,WT
cbc72f1a-cf08-4a54-b429-9924c0986750,61,F,Asian,G2/G2,41.0,1.65,FSGS,"Erythropoietin, ARBs, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin, ARBs, Calcium Channel Blockers.",Mut,WT,WT,Mut,WT,WT
ccac2fb5-1a0c-4c04-93cd-129110042d82,28,M,African American,G0/G0,68.4,4.85,CKD Stage 1,Erythropoietin,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,WT,Mut,WT
5da49cb9-2fdc-4992-8971-8eeadf3a098a,55,M,Caucasian,G2/G2,26.6,0.97,FSGS,"Diuretics, Erythropoietin, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with Diuretics, Erythropoietin, Calcium Channel Blockers.",WT,Mut,WT,Mut,WT,WT
1d2c2721-7522-4646-b273-75bf5373bf4d,81,F,Hispanic,G0/G1,34.2,2.54,CKD Stage 2,Diuretics,Yes,No significant change in eGFR. Continuing current treatment: Diuretics.,Mut,WT,WT,WT,Mut,WT
7d4ed26e-dcd5-4fae-abb3-16a743299780,59,F,Other,G1/G2,103.5,1.37,CKD Stage 2,"Erythropoietin, ACE Inhibitors, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,Mut,Mut,Mut
503b4078-a39c-4ec6-b746-4c02871854c1,57,F,Other,G2/G2,73.8,1.99,CKD Stage 3,"ACE Inhibitors, ARBs",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, ARBs.",WT,Mut,Mut,Mut,WT,Mut
647dc392-9c7e-4575-a37d-dcd698d3148b,75,F,Hispanic,G2/G2,87.2,1.32,CKD Stage 4,"Erythropoietin, ARBs, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, ARBs, Calcium Channel Blockers.",Mut,Mut,WT,Mut,WT,Mut
5a1baf0e-5911-46dc-9d3e-503a9645f0e4,58,M,Caucasian,G1/G1,72.4,0.58,CKD Stage 1,"Diuretics, Insulin",Yes,"History of hypertension and diabetes, currently managed with Diuretics, Insulin.",WT,WT,WT,WT,Mut,WT
2c2ac34b-9e0b-4b01-b536-59efd873dad9,54,M,African American,G1/G1,111.6,4.8,Diabetic Nephropathy,"ARBs, ACE Inhibitors",Yes,"History of hypertension and diabetes, currently managed with ARBs, ACE Inhibitors.",WT,Mut,Mut,Mut,WT,Mut
ccf4ffb0-b4bb-473f-ac70-51d1d051267f,37,F,Caucasian,G2/G2,89.5,3.49,CKD Stage 2,Statins,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins.",Mut,WT,Mut,Mut,WT,Mut
97154633-9d4e-4b71-ab2e-c80e4c255823,44,M,Caucasian,G2/G2,93.6,0.68,CKD Stage 3,"Insulin, ARBs, Erythropoietin",No,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,WT,WT,WT,WT
502cf0ee-224a-46a6-ac0f-680115b24e1d,65,F,Other,G0/G0,88.2,2.92,Diabetic Nephropathy,"Insulin, Statins",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,WT,WT,WT
1df05d18-4e2d-4255-bd13-1a3d1e2c2e7d,51,M,Asian,G1/G1,118.8,3.88,Diabetic Nephropathy,"ACE Inhibitors, Calcium Channel Blockers, Statins",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,Mut,WT,Mut
243012da-b185-4eb8-9f90-fc872edc017e,67,F,Hispanic,G1/G2,92.4,3.99,CKD Stage 1,"Statins, Erythropoietin, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,WT,WT,Mut
98af5cca-6b11-47cb-a372-542482c56b21,40,M,Caucasian,G0/G1,11.9,3.61,CKD Stage 1,"ARBs, Insulin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, Insulin.",Mut,WT,WT,Mut,Mut,WT
6c4c450b-623a-40fc-9326-7d25234b4562,75,M,Asian,G2/G2,77.0,4.9,CKD Stage 3,"Erythropoietin, Insulin, ACE Inhibitors",No,"No significant change in eGFR. Continuing current treatment: Erythropoietin, Insulin, ACE Inhibitors.",WT,WT,WT,WT,WT,WT
8991b01a-a2b0-4c4b-bc96-6b552f8d8ded,70,M,Caucasian,G0/G0,16.9,2.07,CKD Stage 2,"ARBs, Insulin, Diuretics",Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,WT,Mut,WT,WT,WT,Mut
ee4205ee-a52f-43ec-ab4e-2281b184d1fc,59,M,Hispanic,G0/G1,107.5,4.55,FSGS,"ACE Inhibitors, Diuretics, Insulin",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, Diuretics, Insulin.",WT,Mut,WT,WT,WT,Mut
2ab7b2ef-8e0e-4033-ac59-1da8fff96acf,73,M,Asian,G1/G2,112.7,4.36,CKD Stage 2,"ARBs, Insulin, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,Mut,Mut,WT
2fe5b140-23ea-4956-89f1-137d7d592e19,32,F,Caucasian,G1/G2,60.0,1.62,FSGS,"Calcium Channel Blockers, ACE Inhibitors",No,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, ACE Inhibitors.",WT,WT,WT,WT,WT,WT
9e91a71c-7374-4cbf-978c-57d3508850d3,37,M,Other,G2/G2,90.4,1.51,CKD Stage 2,"Erythropoietin, Insulin",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, Insulin.",WT,Mut,Mut,WT,Mut,Mut
f3abea0d-5be9-4db3-9d92-dd7c0db977a9,30,M,Asian,G1/G1,100.8,1.25,Nephrotic Syndrome,"Insulin, ACE Inhibitors, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin, ACE Inhibitors, Diuretics.",WT,WT,WT,Mut,Mut,Mut
31f3f0c0-22f3-4068-bc0f-549d02740f73,82,M,Hispanic,G2/G2,56.1,4.34,Nephrotic Syndrome,Insulin,Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,Mut,Mut,WT,WT,WT
8fc3d7d3-f6bd-40c7-a24a-2a50d0b1fde0,66,F,Asian,G2/G2,52.3,1.27,Diabetic Nephropathy,"Insulin, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,WT,Mut,WT
68bd075b-7eb6-481e-a72f-947d816462cb,46,F,Asian,G0/G0,94.0,3.82,CKD Stage 2,"Calcium Channel Blockers, Insulin, ACE Inhibitors",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,WT,Mut,Mut
b5cbe3f5-6a66-4184-bde1-bf5daf4847f0,26,F,Other,G2/G2,53.6,0.6,CKD Stage 1,"Calcium Channel Blockers, Insulin, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,Mut,Mut,Mut
2ad11fe8-7d1b-495e-b1a0-449dd703262f,83,M,Other,G2/G2,103.2,1.01,CKD Stage 4,Diuretics,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,Mut,WT,Mut
cbbed980-07e6-4cb0-90bd-e9001529e6f5,86,M,Hispanic,G1/G1,44.8,4.07,CKD Stage 2,"Erythropoietin, Insulin, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, Insulin, Statins.",WT,Mut,WT,WT,WT,WT
085eb489-4ac6-4780-b874-9f3cc2d49b56,76,M,Asian,G1/G2,41.9,3.21,CKD Stage 1,Calcium Channel Blockers,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers.",WT,Mut,Mut,Mut,WT,WT
49e64c22-89a0-47eb-b98f-569b465cc2cb,87,M,African American,G1/G1,63.1,3.5,FSGS,"ARBs, Insulin, Erythropoietin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, Insulin, Erythropoietin.",Mut,Mut,WT,Mut,Mut,WT
90ce77e9-7513-43b9-87de-96ea2b0fbe44,75,F,African American,G0/G0,10.1,0.71,CKD Stage 3,"Statins, Erythropoietin, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,WT,Mut,Mut
7eccdaf4-c413-4dc2-85c5-ae8abe15ad12,89,F,Other,G0/G1,100.8,4.9,Nephrotic Syndrome,"Statins, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: Statins, Calcium Channel Blockers.",WT,Mut,WT,WT,Mut,WT
929d6377-1cfb-455f-82c4-2e488cbadae5,22,M,African American,G0/G1,57.0,4.5,CKD Stage 1,ARBs,Yes,No significant change in eGFR. Continuing current treatment: ARBs.,Mut,Mut,Mut,Mut,WT,WT
8b0901ab-c66d-4eb3-8494-5e091d3ca5a4,53,F,Asian,G2/G2,109.3,2.3,CKD Stage 3,Diuretics,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,WT,WT,Mut
8ac35ac4-5dea-4737-bdab-3441d2c2a960,73,F,Caucasian,G1/G1,112.6,3.96,CKD Stage 2,ACE Inhibitors,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,WT,Mut,Mut
c28fa16b-0aa6-4cb9-81bc-be59d296a12d,51,F,Hispanic,G1/G2,109.1,1.87,CKD Stage 3,"Calcium Channel Blockers, Diuretics, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,WT,WT,WT
37f25d36-8bdd-4ee3-b0fd-6672b80f16c5,58,M,Asian,G0/G0,116.6,1.79,Nephrotic Syndrome,"ARBs, ACE Inhibitors",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,WT,WT,WT,WT,Mut,WT
bc69c155-1a37-46bd-acd6-f011fd61f13b,29,M,Asian,G0/G1,111.5,3.38,Nephrotic Syndrome,"Statins, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,Mut,Mut,Mut
3f5e3b8c-c058-4da5-a757-075bd47f83b1,39,M,Other,G1/G1,28.7,4.29,CKD Stage 2,"Calcium Channel Blockers, Diuretics, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, Diuretics, ACE Inhibitors.",Mut,WT,Mut,Mut,Mut,WT
0840405a-ffd2-4491-9ff3-89aa4c36a70c,25,F,African American,G2/G2,103.7,0.71,CKD Stage 3,"ACE Inhibitors, Diuretics, Statins",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,Mut,Mut,Mut,WT,Mut
dcb91d5f-593c-472b-8347-dbca7321a8b2,63,M,Hispanic,G1/G2,106.1,3.79,Diabetic Nephropathy,"Diuretics, ACE Inhibitors, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,Mut,WT,Mut
dd83ad03-7066-4289-9644-84a0d1151fff,44,M,Hispanic,G0/G1,63.7,2.9,CKD Stage 2,ACE Inhibitors,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,WT,WT,WT
cfd7f3b9-c68f-4ba5-9e0d-02b5fe7402cd,84,M,Asian,G0/G0,66.4,2.78,CKD Stage 2,"ACE Inhibitors, Diuretics, ARBs",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Diuretics, ARBs.",Mut,Mut,WT,WT,Mut,Mut
bcd4344f-cf8a-468e-b5ba-93573ca87f31,26,F,Caucasian,G0/G0,59.0,1.88,CKD Stage 3,"ARBs, Diuretics, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,WT,WT,WT,Mut,Mut
dc6dafff-59c2-4153-b06b-0f0c96822e22,42,F,Hispanic,G1/G2,64.6,3.81,CKD Stage 4,"Statins, ARBs, Insulin",Yes,"History of hypertension and diabetes, currently managed with Statins, ARBs, Insulin.",Mut,WT,Mut,WT,WT,Mut
6d9c5b50-a1fd-4187-9c3a-1e0bb5f3f8aa,50,F,Asian,G1/G1,116.9,2.04,FSGS,"Insulin, Calcium Channel Blockers, ACE Inhibitors",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,Mut,Mut,WT
c8ebe27a-23a4-470e-9dbc-15c02a7dc57c,86,M,Hispanic,G0/G1,20.5,0.88,FSGS,"Erythropoietin, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,Mut,Mut,WT,Mut,Mut,Mut
ce315937-34fa-42b6-9043-7e4c34e50699,84,F,Other,G2/G2,89.7,3.12,CKD Stage 4,Insulin,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,Mut,WT,WT
88438de2-59cf-4b0d-91f0-647d0f321333,24,M,Caucasian,G0/G0,58.5,3.13,Nephrotic Syndrome,"Insulin, Erythropoietin, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin, Erythropoietin, ACE Inhibitors.",WT,Mut,WT,Mut,WT,Mut
2b1ac76c-89ec-4c51-98cb-aa5247f53019,85,F,Hispanic,G1/G1,99.2,4.05,Diabetic Nephropathy,Statins,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,WT,Mut,WT,WT,WT
4aea1b8f-b43c-4e0a-ba9f-c10e52daf681,21,M,Other,G2/G2,47.6,2.45,FSGS,Calcium Channel Blockers,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,WT,Mut,Mut
f3d04ffb-4470-4848-929e-cc924a11be44,20,M,African American,G1/G2,61.5,0.71,CKD Stage 3,Insulin,Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,Mut,Mut,WT,WT,Mut,WT
e67093a0-fc48-4615-83b0-b35cdba6fdf8,58,M,Asian,G0/G0,94.6,3.51,CKD Stage 2,Erythropoietin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin.",Mut,WT,WT,WT,WT,WT
22b5f457-1860-4d28-90af-b235ade68f51,86,M,Other,G1/G2,43.8,3.41,CKD Stage 3,"ACE Inhibitors, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors, ARBs.",Mut,WT,WT,Mut,WT,WT
695e5ea9-c923-4c64-8006-2b5bf67839b2,59,M,Caucasian,G1/G1,33.3,2.57,CKD Stage 4,Diuretics,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics.",Mut,WT,Mut,Mut,WT,Mut
46feacd4-fe13-43cd-8f2d-5c15eb346d3a,62,F,Other,G0/G1,33.0,1.59,FSGS,Erythropoietin,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,WT,Mut,Mut,Mut,WT,Mut
b390b059-207b-4e21-a7e8-d18eddf6d4ac,75,M,African American,G1/G1,104.7,4.19,CKD Stage 2,"Statins, Insulin, ARBs",Yes,"History of hypertension and diabetes, currently managed with Statins, Insulin, ARBs.",Mut,Mut,WT,WT,Mut,Mut
257035db-3fea-490a-a1f8-072dddb7570e,23,M,Other,G0/G1,61.9,1.32,CKD Stage 1,Insulin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,WT,Mut,WT
3f5fbf4f-d417-4230-9274-ee11b61df906,84,M,Asian,G1/G1,38.2,4.18,Nephrotic Syndrome,"ACE Inhibitors, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, Calcium Channel Blockers.",WT,Mut,Mut,WT,Mut,Mut
64880945-ad1d-4537-97f3-4368c2efeecb,23,F,African American,G0/G0,30.8,3.02,CKD Stage 1,Statins,Yes,"History of hypertension and diabetes, currently managed with Statins.",WT,WT,Mut,WT,Mut,Mut
a1e518a2-93d2-48d4-a465-5c397d4d2add,35,M,Hispanic,G1/G1,84.4,2.54,FSGS,"ARBs, Insulin, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: ARBs, Insulin, Diuretics.",WT,WT,Mut,WT,Mut,Mut
600b4b35-6a0a-47d5-a0b8-575544caa5a2,18,M,Caucasian,G2/G2,69.0,4.36,FSGS,"Statins, Diuretics, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,Mut,Mut,WT
cb6ad0c7-a235-4dd4-9355-08d073b5bad5,33,F,Hispanic,G0/G1,12.3,4.86,Diabetic Nephropathy,"Insulin, ACE Inhibitors, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,WT,Mut,WT
67213a70-17d5-4f59-84d5-98f7e14fe093,84,M,Other,G1/G2,32.6,2.61,Nephrotic Syndrome,"Diuretics, Insulin, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics, Insulin, ARBs.",WT,WT,Mut,Mut,Mut,Mut
b1d81887-4739-4c7b-bff3-0c8d83ff3e96,30,M,African American,G2/G2,11.4,4.61,CKD Stage 3,Insulin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,WT,Mut,WT
7466ef02-5e7b-42c8-a097-dedbefb3b939,39,M,Hispanic,G0/G0,82.1,1.27,Diabetic Nephropathy,ACE Inhibitors,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,Mut,WT,WT
94fb09f0-53c9-4ae7-bcf0-7bb3f343d9eb,26,M,African American,G1/G2,85.8,4.27,CKD Stage 3,Insulin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin.",WT,WT,Mut,Mut,WT,WT
d8dff535-c62d-4aea-9e70-bd3000a21367,79,F,African American,G0/G1,25.9,1.75,CKD Stage 4,Insulin,Yes,"History of hypertension and diabetes, currently managed with Insulin.",Mut,WT,Mut,Mut,Mut,WT
f8ded777-bb1e-4ae8-97d8-21b8bb93cd40,65,M,Asian,G1/G1,97.3,1.33,CKD Stage 1,"Calcium Channel Blockers, Erythropoietin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Erythropoietin.",WT,WT,Mut,WT,WT,WT
b28187c4-aa05-4442-a284-e8fd755cee2a,57,F,Other,G1/G2,20.9,2.22,CKD Stage 1,"ACE Inhibitors, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors, ARBs.",Mut,Mut,WT,WT,WT,WT
cbb18c79-1036-408d-99a0-90075bb47c18,60,M,Asian,G1/G2,89.4,0.82,CKD Stage 3,Statins,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins.",WT,WT,Mut,Mut,Mut,Mut
f7d7465d-37c3-43c9-a5d0-b51788d00abd,30,F,Caucasian,G0/G1,46.7,4.09,CKD Stage 1,Calcium Channel Blockers,Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,WT,Mut,WT,WT,WT
7ea5a387-363b-45cb-9329-37246dfd171a,39,M,African American,G0/G0,32.5,4.16,FSGS,Erythropoietin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin.",Mut,WT,Mut,Mut,WT,WT
48998e5f-d40e-43ce-92a7-4a4144bed486,50,F,Hispanic,G1/G2,97.2,4.99,CKD Stage 1,"ARBs, Insulin, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: ARBs, Insulin, ACE Inhibitors.",Mut,WT,Mut,Mut,Mut,WT
216e9fe5-93f3-4596-8c1c-8b0556771f36,36,M,Hispanic,G1/G1,104.3,4.69,CKD Stage 2,Diuretics,Yes,"History of hypertension and diabetes, currently managed with Diuretics.",WT,WT,Mut,WT,WT,Mut
c9ce44bd-7c3f-4add-9a38-5db590eeb067,52,M,Caucasian,G0/G0,74.2,1.87,Diabetic Nephropathy,"Calcium Channel Blockers, Statins",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,Mut,WT,WT,WT,Mut
c3231466-aebb-490e-a4e7-51de57ff51d9,63,F,African American,G0/G1,111.5,2.62,CKD Stage 1,"Statins, Insulin, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, Insulin, Diuretics.",WT,WT,Mut,Mut,Mut,Mut
a04d4d14-197d-4ae1-8bc2-ea720c648ca2,22,M,African American,G0/G0,73.2,1.0,FSGS,"Calcium Channel Blockers, ACE Inhibitors, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,Mut,Mut,Mut
042b03ca-75a7-4686-9632-1d31c8acffcf,83,F,Caucasian,G0/G1,61.0,5.0,CKD Stage 1,"Insulin, Diuretics, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,WT,Mut,WT
28719b9b-db8f-4e32-adef-50031fce01e3,22,F,Hispanic,G2/G2,103.1,1.09,CKD Stage 4,"ACE Inhibitors, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Calcium Channel Blockers.",Mut,WT,Mut,WT,WT,Mut
fde91c42-002c-4c22-b4de-5f7070f81dba,87,F,Other,G1/G2,39.7,4.75,CKD Stage 1,"ARBs, ACE Inhibitors, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,Mut,Mut,Mut,Mut,WT,WT
fee5ce69-33cb-402e-ad84-414df54191ea,39,M,Caucasian,G0/G1,91.8,2.71,Nephrotic Syndrome,Calcium Channel Blockers,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers.",WT,Mut,Mut,WT,WT,WT
e1d46f82-21c5-4e41-a8ce-e951b0478ea4,20,M,Other,G2/G2,51.5,4.07,Nephrotic Syndrome,"Statins, Calcium Channel Blockers, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, Calcium Channel Blockers, ARBs.",WT,WT,WT,WT,WT,Mut
dfda35b2-28b2-4f21-8d47-0ed6a6663769,18,M,Other,G0/G0,52.3,3.89,Nephrotic Syndrome,Calcium Channel Blockers,Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,WT,Mut,WT,Mut,Mut
17e52113-4626-43be-a068-8849eec71a30,23,F,African American,G2/G2,97.5,2.02,FSGS,Calcium Channel Blockers,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers.",Mut,Mut,Mut,Mut,WT,WT
1519830c-4019-4303-9c45-7e4da79313b8,83,F,Caucasian,G0/G1,57.8,4.51,Nephrotic Syndrome,Statins,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,WT,WT,WT,Mut,WT,Mut
a61f0b96-e75f-445a-aa1d-3fc65f31273d,60,M,Other,G1/G1,26.5,0.58,Nephrotic Syndrome,"Calcium Channel Blockers, Erythropoietin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,WT,Mut,WT
a0279a18-6576-4410-8d41-ee472a5fda18,70,M,Asian,G1/G1,51.3,3.09,FSGS,"Diuretics, Insulin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics, Insulin.",Mut,Mut,Mut,Mut,WT,WT
c156e501-b30e-46e8-b9da-5f8c4e35da80,88,M,Hispanic,G0/G0,99.1,3.68,FSGS,Erythropoietin,Yes,"History of hypertension and diabetes, currently managed with Erythropoietin.",WT,WT,WT,Mut,Mut,WT
1758d47e-a7cd-4143-ade2-14293bf0d9c1,36,M,Other,G1/G1,65.1,0.82,CKD Stage 3,"Diuretics, ARBs, Statins",Yes,"History of hypertension and diabetes, currently managed with Diuretics, ARBs, Statins.",WT,Mut,WT,Mut,Mut,WT
36a2c52b-0047-4139-985d-f528b4258e19,76,M,African American,G1/G1,19.6,3.29,Diabetic Nephropathy,"ARBs, Insulin, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,WT,WT,Mut
97fb613a-21f8-4d06-93f3-cade7a10013f,20,F,Asian,G0/G0,107.2,0.77,FSGS,ARBs,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs.",WT,Mut,Mut,Mut,WT,WT
71efe72a-ae13-491e-84fa-4c7239e7a4f1,89,M,Other,G0/G1,60.4,0.63,Nephrotic Syndrome,"ARBs, Calcium Channel Blockers, Erythropoietin",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,WT,Mut,WT,WT,WT
57f479b5-b212-46ee-8210-63710260a123,86,F,African American,G1/G2,90.9,2.46,CKD Stage 3,Calcium Channel Blockers,Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers.",Mut,Mut,Mut,WT,Mut,WT
dc3f42e0-fcf7-4842-9edf-3bfad12e0eb5,71,M,Hispanic,G1/G2,100.8,0.61,FSGS,Diuretics,Yes,No significant change in eGFR. Continuing current treatment: Diuretics.,WT,WT,Mut,Mut,WT,Mut
7a4a902f-21d6-4b0f-b1ac-040d6c1cc405,51,M,Hispanic,G2/G2,115.7,0.87,CKD Stage 4,"ARBs, Calcium Channel Blockers, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, Calcium Channel Blockers, Diuretics.",WT,WT,Mut,WT,Mut,Mut
16de66c9-6210-4ef6-ba9c-43081221cddf,68,F,Asian,G1/G1,112.5,4.02,CKD Stage 2,Diuretics,Yes,No significant change in eGFR. Continuing current treatment: Diuretics.,WT,Mut,Mut,Mut,Mut,Mut
1a6b6a7d-1a38-4ad6-8e53-2ffdbb134f02,28,M,Other,G0/G0,80.3,2.13,CKD Stage 1,"ACE Inhibitors, Insulin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,WT,WT,WT
4c9bff5c-e188-4eaf-9e18-85c35037cd6b,44,F,African American,G1/G1,89.9,4.45,Diabetic Nephropathy,"Insulin, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,Mut,Mut,Mut
d038e153-c601-418b-a1fa-01ba231ae7c7,63,M,Hispanic,G1/G1,73.2,1.27,CKD Stage 4,"Erythropoietin, Diuretics, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,Mut,WT,WT
a43e558c-2215-4f00-9fdf-0e05c0cef31b,77,M,African American,G1/G2,35.7,1.51,Nephrotic Syndrome,"Calcium Channel Blockers, Diuretics, Insulin",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, Diuretics, Insulin.",WT,WT,Mut,Mut,WT,Mut
11836c4f-2492-44c7-ad58-db1bfe31537a,20,F,African American,G0/G0,119.2,1.32,CKD Stage 2,"Diuretics, ARBs",Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,WT,WT,WT,WT,WT
9c3de1b0-022b-4683-9033-da6587cf63fd,24,F,Other,G2/G2,56.6,4.21,CKD Stage 2,"ARBs, ACE Inhibitors",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,Mut,WT,WT,WT,WT,WT
59e7703a-70aa-4b0d-aa03-8ad4a667b982,31,F,Other,G2/G2,78.5,4.61,CKD Stage 1,ACE Inhibitors,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,WT,Mut,Mut
bf8e8bfa-a0c9-4a72-b68a-cd40b8f14e3c,48,M,Asian,G0/G0,74.9,2.6,Nephrotic Syndrome,"Statins, ACE Inhibitors, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,WT,Mut,WT
9db7284b-6965-41d1-ab7e-2e6426c0747e,54,F,Other,G1/G1,105.4,4.65,Nephrotic Syndrome,ACE Inhibitors,Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,WT,Mut,Mut,WT,Mut,WT
379d58f9-dc26-4108-b140-11a1afc2ccfc,20,F,Caucasian,G2/G2,68.1,4.4,CKD Stage 4,"Erythropoietin, ACE Inhibitors, Statins",Yes,"No significant change in eGFR. Continuing current treatment: Erythropoietin, ACE Inhibitors, Statins.",WT,Mut,WT,WT,Mut,WT
23d7e6a1-19b8-44fc-a587-1d8916312fc6,72,M,Other,G2/G2,22.2,3.27,Diabetic Nephropathy,ARBs,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,Mut,Mut,WT
bae1e137-96ee-40e5-9f87-3b46c0a0473a,80,F,Caucasian,G0/G0,59.2,2.39,Diabetic Nephropathy,ACE Inhibitors,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,Mut,Mut,Mut
6dec6bbd-f697-47a1-99fe-3d53624fea4b,22,M,Caucasian,G1/G1,83.6,1.82,Diabetic Nephropathy,ARBs,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,WT,Mut,WT
3f6eed9d-23cb-4943-8a84-000350834fef,66,F,Asian,G1/G1,53.8,2.62,CKD Stage 4,"Erythropoietin, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,Mut,WT,Mut,WT,WT,Mut
3f87dfc2-1591-42f2-a505-da9c46e75a2c,36,M,Hispanic,G0/G0,90.9,4.27,CKD Stage 3,Statins,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,WT,WT,WT
b89f3a92-999a-4d86-99db-13028dab66d3,84,F,Caucasian,G1/G1,103.3,3.66,Nephrotic Syndrome,Insulin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin.",WT,WT,Mut,Mut,WT,WT
f0f7ad22-c76a-4e0f-88f0-91f09b8b38ae,56,M,Asian,G2/G2,99.0,0.84,CKD Stage 1,"Calcium Channel Blockers, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, ARBs.",WT,WT,WT,Mut,WT,Mut
d8d994b8-d90f-44e9-86dd-f6cab0c30a59,64,F,Hispanic,G1/G2,88.4,1.6,Nephrotic Syndrome,"Calcium Channel Blockers, Diuretics, ARBs",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,WT,Mut,WT
34981735-4d38-4415-a036-35fca88d4108,53,F,Asian,G1/G1,94.6,1.2,FSGS,"Calcium Channel Blockers, Statins, ACE Inhibitors",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, Statins, ACE Inhibitors.",Mut,Mut,WT,Mut,Mut,WT
304b2370-8270-4238-9b5f-8f39848b34f0,27,F,Asian,G1/G1,98.8,1.1,FSGS,"Calcium Channel Blockers, Insulin",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, Insulin.",Mut,WT,Mut,Mut,Mut,WT
a56b61e0-4ba8-44ca-a449-cb6fbf72ae52,23,F,Caucasian,G0/G1,90.8,0.58,CKD Stage 3,"Statins, Erythropoietin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, Erythropoietin.",Mut,Mut,Mut,Mut,Mut,WT
cb35097a-e5dd-48f1-88a7-38ab0df83e12,26,F,African American,G0/G0,60.7,0.78,FSGS,"ACE Inhibitors, Diuretics",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Diuretics.",Mut,Mut,Mut,WT,Mut,WT
62c965b2-7eb0-462a-bd45-74ebf4655a21,80,F,Hispanic,G0/G1,68.3,3.99,CKD Stage 4,"Calcium Channel Blockers, ACE Inhibitors",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, ACE Inhibitors.",Mut,Mut,Mut,WT,Mut,WT
a3595d1f-7fe4-442e-bdb7-88a61cdcc4c2,40,F,Hispanic,G1/G2,85.4,2.31,CKD Stage 2,"ARBs, Insulin",Yes,"History of hypertension and diabetes, currently managed with ARBs, Insulin.",Mut,WT,Mut,Mut,Mut,Mut
e3837348-873d-48bd-922d-d7be980bc81e,75,F,Caucasian,G0/G1,62.6,0.8,Diabetic Nephropathy,"ARBs, Diuretics, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with ARBs, Diuretics, Calcium Channel Blockers.",Mut,Mut,Mut,WT,Mut,WT
5c70ee97-fca4-4567-8316-d2d6fa4a58ef,73,F,Other,G0/G0,54.7,3.52,CKD Stage 1,"Insulin, Calcium Channel Blockers",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,WT,Mut,Mut
6307d4d1-21c9-415d-9104-5a16ef15ab72,51,M,Hispanic,G0/G0,85.6,4.75,FSGS,Statins,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,Mut,Mut
6bbdb66f-9181-4091-96c6-f45cdc5e4e78,58,M,Hispanic,G1/G2,59.5,3.82,FSGS,"Statins, Calcium Channel Blockers, Diuretics",Yes,"History of hypertension and diabetes, currently managed with Statins, Calcium Channel Blockers, Diuretics.",Mut,Mut,WT,Mut,WT,WT
2c3aacdc-aed5-4a46-8bde-005b5d8babd7,51,M,Caucasian,G1/G2,33.1,2.31,Diabetic Nephropathy,Statins,Yes,No significant change in eGFR. Continuing current treatment: Statins.,WT,WT,WT,WT,WT,WT
fcc4091b-f457-47c6-b894-6a15c34201db,31,M,Asian,G1/G1,81.6,2.71,FSGS,Statins,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,WT,Mut,WT
965d744f-0445-41a8-92af-97e4c536c66e,65,M,Hispanic,G1/G1,102.1,2.32,FSGS,ACE Inhibitors,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,Mut,WT,WT
373aedf8-431e-430f-8387-f74d1149d096,41,M,Caucasian,G1/G2,119.4,4.93,Diabetic Nephropathy,"ACE Inhibitors, Calcium Channel Blockers, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, Calcium Channel Blockers, Diuretics.",WT,Mut,Mut,Mut,WT,WT
f2dcb12b-0f7a-4302-ac2e-28150a3217d2,21,M,Asian,G1/G2,107.2,3.92,CKD Stage 2,Statins,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,WT,WT
495743a2-81b1-4b80-a5e1-b0f5ca0ee8c4,43,M,Caucasian,G1/G2,101.9,1.33,CKD Stage 3,"Insulin, ARBs",Yes,"History of hypertension and diabetes, currently managed with Insulin, ARBs.",WT,Mut,WT,Mut,Mut,Mut
c4615234-8044-4eb2-b66e-dbf4a0ea0251,18,M,Other,G0/G0,91.6,3.9,CKD Stage 3,"ACE Inhibitors, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, ARBs.",Mut,Mut,WT,WT,WT,WT
66fba71d-b3a9-4caa-ac6f-6d2e6a59c043,38,F,Caucasian,G2/G2,104.7,1.22,FSGS,Calcium Channel Blockers,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers.",Mut,WT,Mut,WT,Mut,Mut
89a3c811-895c-4fde-a3fa-40691519fd38,73,F,Asian,G1/G2,81.0,4.21,CKD Stage 4,Insulin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin.",Mut,Mut,WT,Mut,Mut,Mut
15669e36-4708-403b-a716-10c19db54283,18,F,Hispanic,G0/G0,56.1,2.73,CKD Stage 3,"Calcium Channel Blockers, ACE Inhibitors",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, ACE Inhibitors.",WT,WT,WT,WT,WT,WT
ebc1bb52-82e4-4d4a-943a-c1c54f560ed5,27,F,Hispanic,G0/G1,78.2,1.76,FSGS,"ACE Inhibitors, Insulin, ARBs",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Insulin, ARBs.",WT,WT,Mut,WT,WT,WT
27c6cbb1-cedd-469d-b96c-9a0a3404c02a,39,M,Hispanic,G0/G0,14.5,4.14,Nephrotic Syndrome,"Diuretics, ACE Inhibitors",Yes,"History of hypertension and diabetes, currently managed with Diuretics, ACE Inhibitors.",WT,WT,Mut,Mut,Mut,WT
9620bee6-6406-4ace-93a5-e8508950ddd6,82,F,Caucasian,G2/G2,31.3,3.99,CKD Stage 2,Diuretics,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,Mut,WT,WT
a65be22b-d5a3-46d9-8362-a810a2611b8d,21,F,Other,G2/G2,120.0,1.54,CKD Stage 2,"Calcium Channel Blockers, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,Mut,Mut,Mut
4f67448e-10ec-4b1f-a4a5-c736ae59aa52,35,M,African American,G0/G1,36.7,2.73,CKD Stage 2,Statins,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins.",Mut,Mut,Mut,Mut,WT,WT
f413db19-bade-4d5d-afff-15ccb2dc6c34,41,F,African American,G2/G2,32.3,2.52,FSGS,Insulin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin.",WT,WT,Mut,Mut,WT,WT
3e9639ba-0ed2-4c9d-bd17-5712d8b22277,65,M,Asian,G0/G1,113.9,4.35,CKD Stage 3,"Diuretics, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,WT,WT,WT
1db14bfc-6f3a-4115-acb4-678c16120aa6,33,F,Caucasian,G0/G0,10.5,3.17,Nephrotic Syndrome,"Insulin, Diuretics, Erythropoietin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin, Diuretics, Erythropoietin.",WT,Mut,WT,WT,WT,WT
0e165b12-9bdc-40d1-9cbf-7b8c74102d5d,47,F,Hispanic,G0/G0,45.0,1.72,Nephrotic Syndrome,ACE Inhibitors,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,WT,Mut,Mut
a8761e85-bddf-403a-aa84-30f84f2da233,35,F,Asian,G2/G2,117.1,2.18,Nephrotic Syndrome,"Calcium Channel Blockers, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,Mut,Mut,WT
033e02f7-1e93-4127-acf7-2140bd9bc648,18,F,Other,G1/G2,64.2,2.44,Nephrotic Syndrome,"Calcium Channel Blockers, Insulin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Insulin.",WT,WT,WT,WT,Mut,Mut
02e7df89-b395-4a98-a320-4ff5b538f96c,25,M,Hispanic,G1/G2,88.8,3.49,CKD Stage 4,"ACE Inhibitors, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,Mut,WT,WT,Mut,Mut
58c1aad6-f3f8-4ea4-bf14-eafa29f0ef7c,35,F,Caucasian,G0/G0,91.4,1.7,CKD Stage 4,Erythropoietin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin.",WT,Mut,Mut,WT,Mut,Mut
d28fcf68-c871-47b3-8468-b74d85e3ade5,68,M,Other,G0/G1,29.0,4.41,CKD Stage 1,Insulin,Yes,"History of hypertension and diabetes, currently managed with Insulin.",WT,Mut,Mut,WT,Mut,Mut
5f32d5d8-2abe-4585-825e-0259b88416d2,70,M,Other,G1/G1,106.9,3.41,CKD Stage 1,Calcium Channel Blockers,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,WT,Mut,WT
df9b141e-c7f7-4da1-bff1-5840207e863f,19,F,Asian,G0/G1,101.5,2.5,CKD Stage 2,"Statins, ACE Inhibitors",Yes,"History of hypertension and diabetes, currently managed with Statins, ACE Inhibitors.",Mut,Mut,WT,Mut,Mut,WT
1e38f711-e2ec-43f4-bba1-aed944cdbfdd,79,F,African American,G0/G0,88.9,3.27,CKD Stage 1,"Calcium Channel Blockers, ACE Inhibitors, Insulin",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, ACE Inhibitors, Insulin.",WT,WT,Mut,WT,WT,WT
55c34853-0783-443c-a65f-ad87c57c7498,77,M,African American,G2/G2,34.4,4.33,Nephrotic Syndrome,Statins,Yes,No significant change in eGFR. Continuing current treatment: Statins.,WT,WT,Mut,Mut,WT,Mut
861b4f5b-45a0-4539-ade8-370ace9e9ebd,69,M,Asian,G0/G0,62.1,2.46,CKD Stage 2,"Diuretics, ARBs",Yes,"History of hypertension and diabetes, currently managed with Diuretics, ARBs.",Mut,WT,WT,Mut,WT,Mut
f99cea5c-b65a-40f1-8350-ab061059ea28,52,F,African American,G1/G2,100.9,3.47,Diabetic Nephropathy,Erythropoietin,Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,WT,WT,WT,Mut,WT,WT
7f0386fa-13ba-4c91-a0a5-fde6939f71a2,51,F,African American,G1/G2,43.0,4.72,Nephrotic Syndrome,Statins,Yes,"History of hypertension and diabetes, currently managed with Statins.",Mut,Mut,Mut,WT,WT,Mut
0e3141ec-5c31-4464-82c2-99f07487d772,78,F,Other,G1/G1,62.4,2.39,Diabetic Nephropathy,Statins,Yes,No significant change in eGFR. Continuing current treatment: Statins.,WT,Mut,Mut,WT,WT,Mut
2ab8bd33-911f-430b-9bff-00b07fe670f3,78,F,Hispanic,G0/G0,66.3,2.49,CKD Stage 1,"Insulin, Calcium Channel Blockers",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,WT,WT,WT
c5f8e2f8-414f-4994-a845-77805e20c957,46,F,Hispanic,G1/G1,94.9,0.85,CKD Stage 4,ARBs,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,Mut,WT,Mut
ac93281a-92eb-4ab0-a4ee-c67c1a57f9e4,75,M,Caucasian,G1/G1,106.2,3.98,CKD Stage 3,"ARBs, Statins, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,Mut,WT,WT
bda3c162-3a78-464a-9d86-80cbb90800f3,52,M,African American,G0/G0,75.5,1.52,Diabetic Nephropathy,"Erythropoietin, Diuretics",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, Diuretics.",Mut,Mut,WT,WT,Mut,Mut
dbd30aec-0b46-4173-80a8-547382425912,20,M,Other,G0/G1,62.5,0.85,Nephrotic Syndrome,"ACE Inhibitors, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,Mut,WT,Mut
0bc57207-3e9a-4c86-8325-4fbddce8e1c5,51,F,Caucasian,G1/G2,15.6,3.77,CKD Stage 1,"Calcium Channel Blockers, Statins, Diuretics",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,Mut,WT,Mut
eb93f78c-620a-4158-9d2d-904f78c59073,69,M,Hispanic,G1/G1,107.0,0.89,CKD Stage 3,"Erythropoietin, Insulin, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,Mut,Mut,WT
f5d8fb91-ee60-41ac-add0-622e266bf2ea,19,F,Hispanic,G0/G0,86.7,3.42,Diabetic Nephropathy,"Statins, ACE Inhibitors, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, ACE Inhibitors, Diuretics.",WT,Mut,Mut,Mut,WT,Mut
cd98f9e2-8d88-4beb-890d-9655db842660,49,F,Hispanic,G1/G2,75.1,1.61,CKD Stage 1,"Statins, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,Mut,Mut,WT
a7dc2bc0-bd9c-4693-b6ca-1127e9f87970,41,M,Asian,G1/G2,107.7,2.64,FSGS,"Diuretics, ACE Inhibitors, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,WT,Mut,Mut,Mut,WT,Mut
3f8e2d0d-5261-4dec-b979-d5f56b5bc975,23,F,Asian,G0/G1,73.0,1.42,Nephrotic Syndrome,Erythropoietin,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,Mut,Mut,WT
51e744e4-b864-4a08-aa75-752d6a8fcacb,56,M,Caucasian,G0/G0,86.4,0.76,Nephrotic Syndrome,"Statins, Erythropoietin, ACE Inhibitors",Yes,"History of hypertension and diabetes, currently managed with Statins, Erythropoietin, ACE Inhibitors.",Mut,Mut,WT,Mut,Mut,WT
92502e59-13f0-4822-9374-8a1145712959,26,F,Caucasian,G2/G2,112.4,3.54,CKD Stage 1,"ARBs, Insulin",Yes,"No significant change in eGFR. Continuing current treatment: ARBs, Insulin.",WT,WT,WT,Mut,WT,WT
ac5f12ef-8085-4147-9e91-0f365f705b25,59,M,Caucasian,G1/G2,19.9,3.82,CKD Stage 1,"Statins, Diuretics, Insulin",Yes,"History of hypertension and diabetes, currently managed with Statins, Diuretics, Insulin.",Mut,WT,Mut,Mut,WT,WT
3922a7e4-2de9-42f8-8d7b-ec04e6e59b32,86,M,African American,G0/G1,115.3,1.86,Nephrotic Syndrome,"Erythropoietin, ACE Inhibitors, Calcium Channel Blockers",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,Mut,WT,Mut
0bc1f9e5-fb3d-4063-8409-c5eacde918b3,26,F,Other,G1/G2,30.9,2.16,FSGS,"ARBs, Diuretics, Calcium Channel Blockers",Yes,Family history of CKD noted. Genetic testing indicates mutation in UMOD.,Mut,WT,WT,WT,WT,Mut
e0827f76-11a5-49b4-a6a3-02d6f43e8c48,32,F,Asian,G2/G2,104.6,0.53,Nephrotic Syndrome,"Erythropoietin, Diuretics",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,WT,WT,Mut,WT,WT,Mut
c605e58a-4845-4343-9db4-49dc77106966,36,M,Hispanic,G0/G0,32.0,2.52,CKD Stage 1,Statins,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins.",WT,WT,Mut,Mut,WT,Mut
161d5c87-53c9-4e59-8f89-e3b2d847dc53,21,M,Other,G0/G0,60.0,2.31,FSGS,Insulin,Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,Mut,WT,Mut,Mut,Mut,WT
5e717fca-020a-4497-b4ed-51458d9765c7,76,M,Other,G2/G2,82.6,4.85,FSGS,Erythropoietin,Yes,No significant change in eGFR. Continuing current treatment: Erythropoietin.,Mut,Mut,WT,WT,Mut,WT
c8d57717-9055-436f-8aa5-f9d3335f2f59,32,F,African American,G0/G1,98.0,2.33,CKD Stage 2,Insulin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin.",WT,WT,WT,WT,WT,Mut
3e19fc1d-9f6a-4a65-bd54-da044dcd0009,40,F,Caucasian,G1/G1,40.9,1.48,Diabetic Nephropathy,"Statins, Erythropoietin, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins, Erythropoietin, ARBs.",Mut,Mut,Mut,WT,WT,WT
f8cbab4c-9779-4e84-9e47-2e2276c3e642,55,M,Hispanic,G0/G1,82.3,2.18,CKD Stage 4,"ACE Inhibitors, Insulin, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Insulin, Calcium Channel Blockers.",WT,WT,Mut,Mut,WT,WT
c6a07656-c5c9-4b91-bf6e-f9ed7e4ce29f,52,F,Asian,G0/G0,37.5,2.2,Diabetic Nephropathy,"ACE Inhibitors, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors, ARBs.",Mut,WT,Mut,Mut,WT,Mut
8beb4e78-e683-43a3-bb82-b7963207343e,63,M,Asian,G1/G1,65.1,0.86,FSGS,"Calcium Channel Blockers, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, Diuretics.",Mut,WT,WT,Mut,Mut,WT
268b84b6-3ec0-4285-8bc4-ec0ec2aef674,90,F,Asian,G0/G1,67.0,1.74,Nephrotic Syndrome,"Statins, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Statins, ARBs.",WT,WT,WT,Mut,WT,Mut
061efb95-68f8-4063-aeb1-9ad201a1fb0f,85,F,Hispanic,G2/G2,18.1,2.18,CKD Stage 3,"Calcium Channel Blockers, Statins, ARBs",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, Statins, ARBs.",WT,WT,Mut,WT,Mut,WT
a2cd1590-58af-493c-8aa2-b4c93ba5bd76,90,M,African American,G1/G2,55.9,0.83,CKD Stage 4,"Insulin, Statins, ARBs",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,Mut,WT,WT,WT
0274ce40-e090-46b6-b186-a5a8d6ee526b,79,F,Other,G2/G2,61.0,2.73,FSGS,Diuretics,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,WT,WT,Mut
c2492e5e-005f-40e6-95c3-b2dbf374190d,24,F,Other,G0/G1,20.5,1.4,FSGS,"ARBs, Insulin, ACE Inhibitors",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, Insulin, ACE Inhibitors.",WT,WT,Mut,WT,WT,WT
bcf2fc3b-d958-44c2-a053-8c1ba84510a1,56,M,Asian,G1/G2,26.1,3.28,Nephrotic Syndrome,Calcium Channel Blockers,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,Mut,WT,WT
34879e41-1a9c-472a-8eb9-047dba2ac3d9,20,M,Other,G2/G2,64.5,1.19,Nephrotic Syndrome,"Statins, ARBs, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,Mut,WT,WT
6b790d01-3cf8-4d20-bbad-793f87a1ec02,60,M,African American,G2/G2,30.1,2.02,CKD Stage 2,Insulin,Yes,"History of hypertension and diabetes, currently managed with Insulin.",Mut,Mut,Mut,WT,Mut,Mut
f8f9a45d-0f55-4896-b610-396b7df59abf,87,M,Hispanic,G1/G2,68.7,4.46,CKD Stage 1,"Erythropoietin, Diuretics",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,Mut,Mut,WT
47a2a10b-b62e-4b49-a472-96a4ff38b918,60,F,Caucasian,G1/G1,103.5,0.53,CKD Stage 2,"Statins, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: Statins, Diuretics.",WT,WT,Mut,WT,WT,WT
3b41c943-ebd8-43b1-8b3d-0c3617d09810,58,F,African American,G0/G0,15.7,2.71,CKD Stage 2,"ARBs, ACE Inhibitors, Statins",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, ACE Inhibitors, Statins.",Mut,WT,WT,Mut,WT,WT
69be173a-850e-40ad-9872-f72ee5b4a1ae,60,M,Other,G0/G1,66.7,1.37,CKD Stage 4,ARBs,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,Mut,Mut,Mut
755d814b-5f5b-4255-a544-9887b36ab3ed,18,F,Asian,G1/G2,12.8,3.87,FSGS,"Calcium Channel Blockers, ARBs",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,WT,Mut,Mut
94ad6252-15bc-4a3e-bf76-55d7f97c6c3c,27,F,African American,G2/G2,103.9,4.89,CKD Stage 1,"Erythropoietin, ARBs",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, ARBs.",WT,Mut,WT,Mut,Mut,Mut
a3209116-222d-46a4-8163-b6ce1877bc06,22,M,Other,G1/G1,66.0,2.05,FSGS,"ACE Inhibitors, Erythropoietin, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Erythropoietin, Calcium Channel Blockers.",Mut,Mut,Mut,Mut,Mut,Mut
97867b12-1328-4726-a4f4-34d6d1e91691,32,F,African American,G1/G2,100.3,0.51,CKD Stage 3,Insulin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,Mut,Mut,WT
a995ecc3-6f5b-49a6-8ff1-c51f915cb31b,20,M,Other,G2/G2,26.5,0.87,FSGS,Erythropoietin,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,WT,WT,WT
4aab47b2-3c9d-428a-a176-1930f6d70248,87,F,Hispanic,G0/G0,82.6,2.9,CKD Stage 1,Statins,Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,WT,Mut,WT,Mut,Mut
ed1115d7-50a4-4c85-99d5-7b0242d04d55,44,M,Caucasian,G1/G1,89.3,1.09,CKD Stage 1,Insulin,Yes,No significant change in eGFR. Continuing current treatment: Insulin.,Mut,Mut,Mut,WT,WT,Mut
d4f76322-b362-40d2-a498-8bdecd0254db,82,F,African American,G2/G2,28.5,4.91,Nephrotic Syndrome,Insulin,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,WT,Mut,WT,WT,WT,WT
73e7f042-516c-4b0a-9385-3918bc4015fa,67,F,African American,G0/G0,46.9,1.74,CKD Stage 3,"ACE Inhibitors, Diuretics, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ACE Inhibitors, Diuretics, ARBs.",Mut,WT,WT,WT,WT,Mut
f18cccdc-131e-4723-bbcd-f203459ee674,76,M,Caucasian,G0/G0,44.5,3.2,CKD Stage 4,"ACE Inhibitors, Statins, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,Mut,Mut,WT
c5285425-c7a9-433c-a2d8-39d333e4f986,35,M,African American,G1/G2,92.6,1.8,Nephrotic Syndrome,Calcium Channel Blockers,Yes,No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers.,Mut,WT,Mut,Mut,Mut,Mut
1b0c62eb-27c8-4c6c-9be5-a4c395af6d0c,70,M,Caucasian,G1/G1,87.3,3.09,CKD Stage 1,"ARBs, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,WT,WT
50647c59-774f-4354-b316-ce642a147a96,89,F,African American,G0/G1,109.8,2.83,CKD Stage 1,"Calcium Channel Blockers, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, ACE Inhibitors.",Mut,WT,WT,Mut,Mut,WT
5bb8b9c8-8932-49f3-9ee8-9a4c681134e2,65,M,Caucasian,G2/G2,107.6,0.89,Nephrotic Syndrome,"Diuretics, ACE Inhibitors",No,"Patient shows signs of progressive kidney dysfunction, advised continuation of Diuretics, ACE Inhibitors.",WT,WT,WT,WT,WT,WT
73b0d676-3527-45c8-8534-ca08f6f24d1c,48,M,Caucasian,G1/G1,24.9,3.24,CKD Stage 3,Erythropoietin,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,Mut,Mut,WT
da3c45ca-43d7-4f2b-b69d-e1e34eed4124,41,F,African American,G0/G0,78.6,2.9,CKD Stage 1,Calcium Channel Blockers,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,Mut,Mut,Mut
cebeabaa-2859-4b34-9725-d2c71eb2a7b8,35,M,Hispanic,G1/G1,92.2,4.83,CKD Stage 3,"Diuretics, Calcium Channel Blockers, ARBs",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,WT,WT,WT,WT,Mut,Mut
b46788bd-d38e-43e4-8de1-087bafa14a55,85,M,Hispanic,G1/G1,93.8,2.29,CKD Stage 4,Calcium Channel Blockers,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers.",WT,Mut,WT,WT,Mut,Mut
370b9a29-0a53-4df9-9a72-083cb266986c,70,F,African American,G0/G1,116.6,2.34,Diabetic Nephropathy,"Calcium Channel Blockers, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, ARBs.",Mut,Mut,WT,Mut,WT,Mut
25f88c74-53ea-4919-9b48-62c2d5ff2a1f,37,F,Asian,G0/G0,24.4,2.09,CKD Stage 1,"Insulin, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: Insulin, Diuretics.",WT,WT,Mut,WT,WT,WT
f7e9101d-3f8b-4433-b60e-695c1759ba96,29,F,Asian,G0/G0,44.8,0.74,FSGS,"Insulin, ACE Inhibitors",Yes,"History of hypertension and diabetes, currently managed with Insulin, ACE Inhibitors.",Mut,WT,WT,Mut,Mut,WT
0c880714-8372-47e0-a570-46ea5b11f51f,59,F,Asian,G2/G2,39.2,3.69,CKD Stage 3,"Erythropoietin, Diuretics, ARBs",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin, Diuretics, ARBs.",WT,Mut,Mut,WT,Mut,Mut
d1f16485-429a-4a7c-8c80-d33aad5be3c8,28,F,Asian,G1/G1,103.2,2.32,CKD Stage 2,"Diuretics, Statins",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,WT,WT,Mut,Mut,Mut
f3bc9a71-07f4-4ee5-ac82-989ffd9cfbb0,89,F,Asian,G2/G2,115.0,2.18,CKD Stage 4,Calcium Channel Blockers,Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers.",WT,WT,Mut,Mut,WT,Mut
8e52fc42-73c3-44a6-9ac7-26b667863fb3,30,M,Caucasian,G0/G0,76.4,2.45,CKD Stage 2,ARBs,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,WT,WT,Mut
183fea70-3ff6-479e-8cd4-b90abf8211bc,23,M,Other,G0/G1,45.4,3.93,Diabetic Nephropathy,"Calcium Channel Blockers, Statins",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, Statins.",Mut,WT,Mut,WT,Mut,Mut
cb371d97-cdcc-4d6a-9a16-998c7648776e,38,M,Other,G1/G1,81.7,0.71,CKD Stage 2,"ARBs, ACE Inhibitors, Insulin",Yes,"History of hypertension and diabetes, currently managed with ARBs, ACE Inhibitors, Insulin.",WT,Mut,WT,WT,Mut,WT
0fc98d2e-030f-4be9-9f17-8f9323c97a1e,84,F,Hispanic,G0/G1,33.4,1.84,Nephrotic Syndrome,Insulin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,Mut,Mut,WT
38e7e019-fb89-46c8-87ec-fe71d49347fc,61,M,Asian,G0/G0,110.6,2.49,CKD Stage 4,"Erythropoietin, Insulin, Calcium Channel Blockers",No,Family history of CKD noted. Genetic testing indicates mutation in WT1.,WT,WT,WT,WT,WT,WT
668c879b-d2dc-42c8-b2b8-d8aa21768dd7,54,M,Caucasian,G0/G1,30.3,3.91,Nephrotic Syndrome,"Calcium Channel Blockers, ARBs, Erythropoietin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Calcium Channel Blockers, ARBs, Erythropoietin.",Mut,Mut,Mut,Mut,WT,WT
f004e897-a15b-4e18-afb0-64065f4b1a97,82,M,Asian,G1/G2,112.1,3.79,CKD Stage 1,"ACE Inhibitors, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,WT,Mut,WT,Mut
960be0f4-9513-4c22-9583-9b99a50a13dc,39,F,Caucasian,G1/G1,19.3,4.21,Nephrotic Syndrome,"Calcium Channel Blockers, Erythropoietin",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,Mut,WT,WT,Mut,Mut,WT
13325c31-d010-418a-aadc-9960424211e2,73,F,Hispanic,G2/G2,28.4,2.54,CKD Stage 2,"Insulin, ACE Inhibitors",Yes,"History of hypertension and diabetes, currently managed with Insulin, ACE Inhibitors.",Mut,WT,WT,WT,WT,Mut
329fc417-1081-4d45-bf45-f8a20594b24f,63,F,Hispanic,G1/G2,90.2,1.77,CKD Stage 4,"Diuretics, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,WT,WT,Mut,Mut
cf2e3296-7184-4713-a55f-65b7e709fba6,27,F,Other,G2/G2,57.0,3.15,FSGS,"Calcium Channel Blockers, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,WT,Mut,Mut
d8e70aeb-e7b3-4085-978b-e96820f87ba2,34,M,Caucasian,G2/G2,38.3,2.21,CKD Stage 2,ARBs,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,Mut,Mut,WT
1f5df912-54e0-4431-8f13-3b65d450afa2,18,M,Caucasian,G1/G2,58.1,3.65,CKD Stage 2,ARBs,Yes,No significant change in eGFR. Continuing current treatment: ARBs.,Mut,Mut,Mut,WT,WT,Mut
0cf697a5-7603-436c-b139-4e3c0aee2557,77,F,African American,G2/G2,95.2,2.87,CKD Stage 2,Statins,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,WT,Mut,Mut,WT,Mut
6ee35607-92ea-4324-ac93-e5962b015723,67,M,Caucasian,G1/G1,73.3,2.17,CKD Stage 3,"Erythropoietin, Insulin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,Mut,Mut,Mut
7f0223bc-651e-4252-b974-4cded259f960,90,F,Caucasian,G2/G2,36.6,0.52,FSGS,"ARBs, Calcium Channel Blockers",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of ARBs, Calcium Channel Blockers.",Mut,WT,WT,WT,WT,Mut
6d39da75-aee7-4ab2-a1fa-8e7a078c26ce,69,M,African American,G0/G0,56.1,2.1,CKD Stage 3,"Statins, Erythropoietin, Insulin",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,Mut,Mut,Mut,Mut
e886a011-36f7-426c-9a9c-06792c3d17e2,81,F,African American,G0/G1,38.0,2.44,CKD Stage 1,ACE Inhibitors,Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,Mut,Mut,Mut,Mut,WT,Mut
722dce13-47a4-4c42-8665-34972fe922aa,63,M,Asian,G1/G2,48.8,1.96,CKD Stage 2,Diuretics,Yes,"History of hypertension and diabetes, currently managed with Diuretics.",Mut,Mut,WT,Mut,Mut,WT
9d3616a1-08de-4921-a60c-b547e2280fe3,43,F,Other,G1/G2,11.9,3.99,Diabetic Nephropathy,"Calcium Channel Blockers, Statins",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, Statins.",WT,WT,Mut,WT,WT,Mut
a5b40983-3eeb-404a-9df2-372e9e825aae,56,F,Caucasian,G0/G1,66.4,2.35,CKD Stage 2,Calcium Channel Blockers,Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers.",Mut,WT,WT,WT,Mut,WT
e1fdc6d1-6978-4221-bfb7-5c574b8c031f,19,F,African American,G2/G2,62.3,2.68,Diabetic Nephropathy,"Statins, ARBs, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: Statins, ARBs, Diuretics.",Mut,WT,Mut,WT,WT,Mut
1674eb65-0f9c-4300-baa1-c5678cf9eea9,52,M,Hispanic,G1/G1,110.6,2.59,CKD Stage 3,"Calcium Channel Blockers, Erythropoietin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,Mut,Mut,WT
6b52f93c-2321-464e-a20d-4a1f479f6628,20,F,Other,G2/G2,15.0,3.46,CKD Stage 4,ARBs,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,WT,WT,WT
cc152a1b-e278-4642-a484-e035330faaa3,35,F,Other,G1/G1,77.2,4.42,CKD Stage 4,Calcium Channel Blockers,Yes,Family history of CKD noted. Genetic testing indicates mutation in WT1.,Mut,WT,WT,WT,WT,Mut
fe7c80e9-a179-4e93-bfc8-25ac869bc00f,78,F,Other,G1/G2,60.6,3.24,CKD Stage 1,"Diuretics, ACE Inhibitors, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,WT,WT,WT,WT
04ffeab2-cb7b-4b3a-8b2d-158acd5ae324,58,F,Other,G1/G1,21.7,2.39,CKD Stage 2,"Calcium Channel Blockers, ARBs, Erythropoietin",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, ARBs, Erythropoietin.",Mut,WT,Mut,Mut,Mut,WT
b69f75c5-c82b-41be-a1eb-64e6fd498e20,79,F,Other,G0/G1,20.9,4.92,CKD Stage 2,"ACE Inhibitors, Statins, Erythropoietin",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, Statins, Erythropoietin.",WT,WT,WT,Mut,WT,WT
c80c2195-8b65-44ce-bacc-99705beec570,82,M,Hispanic,G0/G1,107.5,4.2,Diabetic Nephropathy,"Insulin, Diuretics",Yes,"No significant change in eGFR. Continuing current treatment: Insulin, Diuretics.",Mut,WT,Mut,WT,WT,WT
90ce82e8-e9a5-4368-9812-9eb27c13f47a,36,M,Asian,G0/G0,59.5,2.76,FSGS,ARBs,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,Mut,WT,WT,Mut
453b45fe-636c-4499-9254-aad3809cd839,87,F,African American,G2/G2,40.9,2.6,CKD Stage 4,"Diuretics, Erythropoietin, Calcium Channel Blockers",Yes,"History of hypertension and diabetes, currently managed with Diuretics, Erythropoietin, Calcium Channel Blockers.",WT,Mut,Mut,Mut,Mut,Mut
98dc9e0b-51a1-45df-86ac-10102e0869c1,85,M,Other,G2/G2,78.7,0.68,CKD Stage 4,"ARBs, Statins, Insulin",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,Mut,Mut,WT
cf89569d-e550-4736-8780-6e713811b519,56,F,Other,G2/G2,93.8,3.32,CKD Stage 2,"Calcium Channel Blockers, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,Mut,Mut,WT,WT
cf03f0c8-0eff-45bd-87eb-340dc74e48ff,20,F,Asian,G0/G0,26.6,3.17,Nephrotic Syndrome,ARBs,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,Mut,WT,WT,WT
5b80b8d1-8788-4fed-b8c0-4ed8fdd4ff21,87,F,African American,G2/G2,94.4,4.17,CKD Stage 1,"Calcium Channel Blockers, Statins, ACE Inhibitors",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,WT,WT,Mut
3b964c74-ffe6-4994-9580-4c2ac44fc4b8,46,F,Caucasian,G2/G2,71.0,2.24,FSGS,ARBs,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,Mut,Mut,Mut,WT,WT
3f738f50-19a2-476f-a8dd-2bfdf956be95,23,F,Asian,G1/G1,60.6,3.26,Diabetic Nephropathy,"Calcium Channel Blockers, Erythropoietin, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, Erythropoietin, ARBs.",WT,Mut,Mut,Mut,WT,Mut
889fe107-443b-4d0f-bdbc-3093a8284442,30,M,Caucasian,G0/G0,45.5,2.03,CKD Stage 1,"Calcium Channel Blockers, Diuretics, Statins",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,WT,Mut,WT
bcaff931-ead1-4464-8a8e-858cd0f81063,53,F,African American,G1/G1,50.4,2.79,CKD Stage 2,ACE Inhibitors,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,Mut,WT,WT
f2a32efd-ff13-4c80-8398-c3320e500785,47,F,African American,G0/G1,54.1,4.96,CKD Stage 1,"Erythropoietin, Statins",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,WT,Mut,Mut,Mut,WT
fb8fe8c4-d8b4-4ead-9360-8edf382b5b86,47,F,Hispanic,G1/G1,56.9,1.81,CKD Stage 4,"Insulin, Diuretics",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Insulin, Diuretics.",WT,WT,Mut,Mut,Mut,WT
ef69a980-5ad4-49ef-a36f-a890cc21cbdb,45,M,Other,G1/G1,62.8,3.91,FSGS,"ARBs, ACE Inhibitors, Diuretics",Yes,"History of hypertension and diabetes, currently managed with ARBs, ACE Inhibitors, Diuretics.",Mut,Mut,Mut,WT,WT,Mut
2c78644f-d860-45a2-bdd5-b0f8d6d744fd,83,F,Other,G0/G1,88.2,1.12,Diabetic Nephropathy,Diuretics,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,WT,WT,WT
5168bbf2-97af-4bde-bc8e-9d782d14e9f4,66,F,African American,G2/G2,48.2,3.82,FSGS,Insulin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,Mut,WT,Mut,WT,Mut
5bd93609-b297-4782-bcf4-74aace63cb1a,78,F,Asian,G0/G1,90.0,2.05,Nephrotic Syndrome,"Diuretics, Insulin, Calcium Channel Blockers",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, Insulin, Calcium Channel Blockers.",WT,Mut,Mut,WT,Mut,WT
b4157cea-0738-4ba4-9770-a3dbe9fa97e2,61,M,Caucasian,G0/G1,18.5,3.49,CKD Stage 4,"Insulin, ACE Inhibitors, Diuretics",Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,WT,WT,Mut,Mut,Mut,Mut
91519998-f293-4585-9a07-d758b357f3f9,50,M,Asian,G1/G2,41.7,3.81,CKD Stage 2,"Calcium Channel Blockers, Erythropoietin, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, Erythropoietin, ARBs.",Mut,Mut,WT,WT,WT,WT
f2c84743-9027-4770-a460-d0d2904883c1,62,M,Other,G2/G2,52.3,4.19,CKD Stage 1,"ARBs, Statins, Erythropoietin",Yes,"No significant change in eGFR. Continuing current treatment: ARBs, Statins, Erythropoietin.",Mut,Mut,WT,Mut,Mut,Mut
cf767343-fced-4994-9631-c383303014d0,18,M,Hispanic,G1/G2,110.7,1.75,Diabetic Nephropathy,ARBs,Yes,"History of hypertension and diabetes, currently managed with ARBs.",WT,WT,WT,Mut,WT,WT
8ac8ad93-7e02-421d-b86b-543ae1b243cc,74,F,Other,G0/G1,108.0,2.7,FSGS,"ACE Inhibitors, Calcium Channel Blockers, Statins",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,WT,Mut,Mut
09b7fdf7-7d8d-4ddd-acf1-49cb4f1e1a37,33,F,Hispanic,G0/G0,77.8,1.45,Diabetic Nephropathy,"ACE Inhibitors, Statins",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,Mut,Mut,WT
9a069295-3b8d-4447-8e61-065f171b1b80,24,M,Other,G1/G2,37.1,3.88,CKD Stage 4,ACE Inhibitors,Yes,No significant change in eGFR. Continuing current treatment: ACE Inhibitors.,Mut,Mut,Mut,Mut,WT,WT
7a5d7c82-86c5-447c-851a-00393803dcee,74,F,Hispanic,G0/G0,42.8,0.7,CKD Stage 2,"Diuretics, ACE Inhibitors, ARBs",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,Mut,WT,WT,Mut,Mut
9d37efb6-eafb-4e90-94ec-84ce002ccb25,88,F,Asian,G0/G1,29.9,4.6,CKD Stage 2,"ACE Inhibitors, Diuretics, Statins",Yes,"No significant change in eGFR. Continuing current treatment: ACE Inhibitors, Diuretics, Statins.",WT,WT,WT,Mut,Mut,Mut
573bfc17-2167-435e-8e73-34f233932b6c,28,F,Asian,G1/G1,73.8,1.39,CKD Stage 3,ACE Inhibitors,Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors.",Mut,Mut,Mut,Mut,WT,WT
cd6bb03b-eb35-47a0-ad6e-0291b7893986,19,F,African American,G2/G2,45.4,1.6,CKD Stage 4,"Statins, Calcium Channel Blockers, ACE Inhibitors",Yes,Family history of CKD noted. Genetic testing indicates mutation in COL4A3.,WT,WT,Mut,WT,WT,WT
0f3f0f48-52d6-4779-9e43-79cbd8230076,86,F,Caucasian,G0/G0,44.3,3.12,CKD Stage 3,ACE Inhibitors,Yes,Family history of CKD noted. Genetic testing indicates mutation in APOL1.,Mut,WT,Mut,Mut,Mut,WT
b466fab6-962c-44dd-a5d0-7461059c1574,19,F,Other,G0/G0,70.4,0.94,FSGS,"Statins, Erythropoietin, Insulin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,Mut,Mut,WT,Mut,Mut
1c654aa2-c63c-421d-a443-5958eacf33a9,70,M,Caucasian,G1/G2,100.4,3.45,CKD Stage 2,"ACE Inhibitors, Diuretics, Erythropoietin",Yes,"History of hypertension and diabetes, currently managed with ACE Inhibitors, Diuretics, Erythropoietin.",WT,WT,WT,Mut,WT,WT
5d696bc8-dc54-459b-86bb-42c7d8b2f8b6,24,M,Other,G1/G2,106.2,4.9,Nephrotic Syndrome,"Erythropoietin, ACE Inhibitors",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,Mut,WT,WT
b45c9a54-5fa3-4531-9291-6e60f5e72daf,21,F,Asian,G1/G2,14.0,1.92,CKD Stage 3,"Erythropoietin, Insulin",Yes,"History of hypertension and diabetes, currently managed with Erythropoietin, Insulin.",WT,WT,WT,Mut,Mut,WT
96053035-6545-4030-a981-fa54f121e129,84,M,Caucasian,G0/G1,103.8,1.75,CKD Stage 1,"ARBs, Insulin",Yes,"History of hypertension and diabetes, currently managed with ARBs, Insulin.",WT,WT,WT,WT,Mut,Mut
52961fb3-4d40-4b28-9628-ddcd19dd3e8c,21,M,Other,G0/G0,103.5,1.01,CKD Stage 2,"Insulin, Diuretics",No,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,WT,WT,WT,WT,WT
bb7b6c05-2852-4ca2-b9d2-014a22ee7f07,84,F,African American,G0/G1,27.4,3.8,CKD Stage 3,"Calcium Channel Blockers, Statins",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,WT,WT,Mut,WT
a3a6ef83-cab6-4107-afd6-9b3af2dd9456,56,F,Other,G1/G2,57.1,0.52,CKD Stage 3,"Insulin, Statins, Erythropoietin",Yes,"No significant change in eGFR. Continuing current treatment: Insulin, Statins, Erythropoietin.",WT,Mut,WT,WT,Mut,WT
51397c06-a630-4d9d-bcb9-23f5f5edf382,78,M,Hispanic,G2/G2,70.5,3.31,CKD Stage 2,"Statins, ARBs, Diuretics",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,Mut,WT,Mut,Mut
8fddbebc-f7ff-48d4-b509-f08a2c988bca,90,M,Hispanic,G1/G2,94.0,2.26,CKD Stage 2,"Calcium Channel Blockers, ARBs",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, ARBs.",WT,Mut,Mut,Mut,WT,Mut
9d1c0838-edc8-4ca8-a3bc-d6f3b18d2c8c,46,M,Asian,G2/G2,86.8,1.22,CKD Stage 4,"Calcium Channel Blockers, Statins",Yes,"History of hypertension and diabetes, currently managed with Calcium Channel Blockers, Statins.",Mut,Mut,WT,Mut,WT,Mut
aa604892-3926-42e9-9b58-eb49c9784b52,88,F,Caucasian,G0/G1,41.9,4.45,Nephrotic Syndrome,"Statins, Insulin",Yes,"History of hypertension and diabetes, currently managed with Statins, Insulin.",WT,Mut,WT,Mut,Mut,WT
60ddc7f1-2ce3-4822-9080-12b896c56fe7,76,F,Caucasian,G2/G2,112.4,1.96,CKD Stage 2,"Diuretics, Statins, Insulin",Yes,"No significant change in eGFR. Continuing current treatment: Diuretics, Statins, Insulin.",Mut,Mut,WT,WT,Mut,WT
4b657bcc-b041-4f19-bbe7-18354e8bf78a,86,M,Hispanic,G2/G2,61.7,3.38,FSGS,"Calcium Channel Blockers, Insulin, ACE Inhibitors",Yes,"No significant change in eGFR. Continuing current treatment: Calcium Channel Blockers, Insulin, ACE Inhibitors.",Mut,WT,Mut,WT,WT,WT
0075d3d5-ba94-4a66-ad7e-4a452099e71f,43,F,African American,G0/G0,36.9,2.74,CKD Stage 2,"ARBs, Statins",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,WT,WT,Mut
92a54d04-f2dd-41f5-b3b6-d344f2e3c6f0,72,F,Other,G0/G0,71.2,1.13,Nephrotic Syndrome,"Insulin, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,WT,WT,Mut,Mut,WT
c55523ed-fe89-46c8-99cb-3540643ffdae,74,F,Caucasian,G1/G1,80.7,4.27,Nephrotic Syndrome,"Calcium Channel Blockers, Erythropoietin, ARBs",Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,Mut,Mut,Mut,Mut,WT,WT
2e9ce8ff-084a-4c4b-9146-8cdcf7164b73,76,M,Other,G2/G2,79.4,1.85,CKD Stage 2,"Calcium Channel Blockers, Insulin",Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS2.,Mut,WT,WT,WT,Mut,Mut
cf0df860-ebc9-4914-9176-a9d19a3624d6,90,F,African American,G2/G2,55.1,4.95,CKD Stage 1,"Erythropoietin, Insulin",Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin, Insulin.",WT,WT,Mut,WT,WT,WT
a3bfe403-388c-4751-9c83-79aef7b02805,31,M,Hispanic,G2/G2,13.0,2.31,Nephrotic Syndrome,Insulin,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,Mut,WT,WT,WT,WT,WT
7f05fbf5-efca-4577-9aa6-f7cb90c7e6ac,45,F,Asian,G1/G2,82.2,1.42,Nephrotic Syndrome,"Insulin, ACE Inhibitors",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,WT,WT,WT
13eb22c9-bece-421a-94c7-743b2401342a,81,M,African American,G0/G0,119.3,4.59,CKD Stage 1,Statins,Yes,Family history of CKD noted. Genetic testing indicates mutation in NPHS1.,WT,Mut,WT,WT,WT,Mut
51cbf9e5-fb7d-4ba1-98c8-8c483ced4d1f,22,M,Other,G2/G2,101.4,2.38,CKD Stage 4,Statins,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Statins.",WT,WT,WT,WT,Mut,WT
f68c62e6-e2a4-4909-a2dd-22d52afaab7b,51,F,Hispanic,G2/G2,38.7,1.2,CKD Stage 1,Diuretics,Yes,No significant change in eGFR. Continuing current treatment: Diuretics.,WT,WT,Mut,WT,Mut,WT
ab86bafd-b57e-4883-9258-6d9016b6bf61,30,M,Other,G1/G2,16.5,1.96,CKD Stage 4,Calcium Channel Blockers,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,WT,WT,WT,WT
55f3ad50-e2fb-4984-bab2-7bcea39c3bd5,57,M,Caucasian,G1/G1,109.7,3.51,CKD Stage 1,Insulin,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,WT,WT,Mut
35adde88-43e4-4668-82ea-d2df725656e3,56,F,Caucasian,G1/G2,112.7,0.84,FSGS,Statins,Yes,"History of hypertension and diabetes, currently managed with Statins.",Mut,Mut,Mut,Mut,Mut,Mut
59b9222c-115a-4fac-b173-fcdf3fe1e8f3,27,M,Other,G0/G0,14.1,3.37,CKD Stage 3,"ACE Inhibitors, Erythropoietin, Statins",Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,WT,WT,WT
b86d066b-1ba8-47c6-897a-24ad41b455b8,24,M,Caucasian,G0/G0,111.2,1.48,CKD Stage 1,"Insulin, Erythropoietin",Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,Mut,WT,Mut,WT,Mut,Mut
702f31e5-62cc-4604-8c53-644b0053f649,61,M,Hispanic,G0/G1,93.3,2.74,CKD Stage 3,ACE Inhibitors,Yes,High risk of progression to ESRD. Referred to nephrology for further evaluation.,WT,Mut,Mut,Mut,WT,Mut
2a9527f6-f817-4ebf-ab6e-64c5bb8aa843,53,F,Asian,G1/G2,76.5,2.78,FSGS,ACE Inhibitors,Yes,Symptoms include proteinuria and fatigue. Monitoring renal function closely.,WT,Mut,WT,Mut,Mut,Mut
e1bbb8cd-7e3a-4f07-a9fd-28e6e271fff9,69,M,Hispanic,G1/G1,95.6,1.83,CKD Stage 2,Statins,Yes,Patient complains of swelling and decreased urine output. Treatment plan adjusted.,WT,Mut,WT,Mut,Mut,WT
6016c743-8bc8-4a02-99ea-493660f34ebc,64,F,Hispanic,G0/G0,38.5,4.43,CKD Stage 4,Erythropoietin,Yes,"Patient shows signs of progressive kidney dysfunction, advised continuation of Erythropoietin.",WT,WT,Mut,Mut,WT,WT
c9ea356a-7abf-4ebf-942c-b1ae19f738cb,83,F,Caucasian,G1/G1,14.5,3.65,CKD Stage 4,ACE Inhibitors,Yes,No significant change in eGFR. Continuing current treatment: ACE Inhibitors.,WT,Mut,Mut,WT,Mut,WT
